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ABSTRACT 
Chronic schistosomiasis presents with either a moderate or a severe form, termed 
intestinal (INT) or hepatosplenic (HS) schistosomiasis, respectively. The Schistosoma 
mansoni-associated hepatomegaly is estimated in 8.5 million people and ultimately results 
from liver granulomas induced by trapped parasitic eggs. The CBA/J mouse model 
replicates these two human disease forms and was used to understand the progressive 
pathology that leads to HS and to identify potential biomarkers. In this model 20% of 
infected mice spontaneously develop hypersplenomegaly syndrome (HSS) by 20 weeks of 
infection while the remaining 80% develop moderate splenomegaly syndrome (MSS). 
Using this model, we compared the liver protein patterns of control mice and mice 
infected for 6, 8, 12, or 20 (MSS and HSS) weeks. Two-dimensional differential in gel 
electrophoresis (2D-DIGE) was used to identify protein pattern variations and protein 
spots were identified using matrix adsorption laser desorption ionisation-time of flight 
(MALDI-TOF) mass spectrometry. In the first experiment, we found 124 protein spot 
unique changes for MSS and HSS compared to control mice of which 80 were identified 
and 35 changes were specific for HSS. In the second experiment, comparison between 
various time points with control mice revealed 76 significant protein spot changes of 
which 44 were identified using MALDI-TOF mass spectrometry. Importantly, we found 
that the abundance of liver keratin D, transferrin isoforms, collagen isoforms, 
hydroxyproline and Schistosoma mansoni-phosphoenolpyruvate carboxykinase increased 
while epoxide hydrolase isoforms, peroxiredoxin 6 and major urinary protein (MUP) 
isoforms decreased significantly with infection. To verify the changes in the liver 2D-
DIGE analysis, candidate liver protein markers were measured in mouse serum using 
targeted biochemical assays. The mouse serum analysis showed MUP levels were 
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decreased, while transferrin, connective tissue growth factor (CTGF), keratin D, 
hydroxyproline were increased in HSS mice compared to control mice or MSS mice 
supporting the liver 2D-DIGE analysis. Using targeted assays, serum samples from INT 
and HS patients were tested for the candidate liver protein markers: keratin D, CTGF, 
hydroxyproline and transferrin. The human serum analysis showed keratin D levels 
increased for HS compared to INT and normal sera. The CTGF levels were high in INT 
compared to HS and normal sera, while transferrin remained unchanged in INT and HS 
similar to normal sera. Additionally, in severe HS disease, serum hydroxyproline emerged 
as a strong indicator of fibrosis. We believe that these findings will have direct value in 
the development of diagnostic tools for early detection of hepatosplenic schistosomiasis in 
humans. 
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CHAPTER1: INTRODUCTION 
 
1.1 Background 
In 1851, Theodor Bilharz first identified the cause of urinary schistosomiasis and thus 
schistosomiasis is known as bilharzia or bilharziosis in many countries. Endemic in Africa, 
South America and Asia, the spread of schistosomiasis is due to the freshwater snails that 
carry the parasite. Also known as snail fever, human schistosomiasis is caused by five 
helminth species: Schistosoma mansoni, Schistosoma haematobium, Schistosoma 
japonicum, Schistosoma intercalatum, and Schistosoma mekongi and of these 5 species, S. 
mansoni is the focus of this thesis. The worms are called blood flukes because they live in 
the vascular system of humans and other vertebrates like dogs, pigs, cows, water 
buffaloes, horses. The life cycle of the worms involves two hosts: fresh water snails, 
which are the intermediate hosts, carrying the asexual stage and humans (and other 
vertebrates) which are the definitive hosts carrying the sexual stage (Figure 1.1). Different 
genera of snails act as intermediate hosts for each of the five Schistosoma spp. and are 
listed in Table 1.1. 
 
TABLE 1.1 Fresh water snails act as intermediate hosts for different species of 
schistosomes. 
No. Schistosoma spp. Snail gen. 
1. Schistosoma mansoni Biomphalaria spp. 
2. Schistosoma haematobium Bulinus spp. 
3. Schistosoma japonicum Oncomelania spp. 
4. Schistosoma intercalatum Bulinus spp. 
5. Schistosoma mekongi Neotricula spp. 
 
     2 
 
FIGURE 1.1 Life cycle of Schistosoma mansoni. In the human vascular system, adult 
worms mate and lay eggs. Parasite eggs exit the host through feces and urine.  On sensing 
fresh water, the miracidia are released from the eggs and penetrate the snail. Within 3-5 
weeks, they asexually multiply into hundreds of fork-tailed cercariae. The cercariae leave 
the snail and swim to a human, where they penetrate the skin. Inside the definitive host, 
cercariae transform into schistosomulae and travel to the heart, lungs and portal veins, 
where they develop into adult worms. (Picture drawn is based on my microscopic 
observations and readings.) 
 
1.2 Geographic distribution 
Schistosomiasis is endemic in 74 countries, mostly African, Asian, Eastern Mediterranean, 
Caribbean and South American countries (Figure 1.2) and is the second most devastating 
parasitic disease after malaria in terms of the world health budget. Currently, 200 million 
people have schistosomiasis and 600 million people are at the risk of infection (Chitsulo et 
al., 2000). In particular, Schistosoma mansoni infects almost 83 million people causing 
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intestinal or hepatic schistosomiasis (Crompton, 1999). It is estimated that approximately 
40% of the 200 million people affected with schistosomiasis worldwide remain 
asymptomatic (80 million) and 60% become symptomatic (120 million). Of the 
symptomatic patients approximately 10% develop severe hepatosplenic disease (20 
million) (Chitsulo et al., 2000) with 8.5 million people suffering from life threatening S. 
mansoni hepatosplenic disease alone (Van der Werf et al., 2003). 
 
 
FIGURE 1.2 Global distribution of schistosomiasis, 2007 (Map courtesy: Centers for 
Disease Control and Prevention, USA). 
 
In addition to the infection of persons living in endemic areas, travellers are at risk of 
schistosomiasis due to bathing, wading or swimming in fresh waters in these endemic 
areas. A report by GeoSentinel Surveillance Network 1997-2008, USA on Schistosome-
endemic area travellers shows that, of 828 travellers evaluated for schistosomiasis 49% 
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were diagnosed with schistosomiasis (Nicolls et al., 2008). The data questions the 
effectiveness of pre-travel
 
intensive schistosomiasis education
 
programs and emphasises 
the importance of research programs for biomarkers, vaccine and drug development. Thus, 
tourism and immigration from endemic areas results in cases of schistosomiasis even in 
the developed world. Finally, researchers warn that global warming will lead to the 
shifting of isotherms, lines that connect areas with the same temperature, and this shifting 
may ultimately facilitate spread of infectious diseases to new places and novel habitats. 
Current records indicate that intestinal schistosomiasis which previously occurred only at 
altitudes below 1,400 metres above sea level, now occurs at 1,682 metres above sea level 
(Githeko, 2009), suggesting the shift has already begun. 
 
1.3 Schistosomiasis mortality and morbidity 
Schistosomiasis-associated mortality is about 280,000 people per year (0.08% of the 
deaths worldwide). The majority of these mortalities due to S. mansoni infections 
occurring in 52 countries (Pearce and MacDonald, 2002) include both intestinal 
schistosomiasis and hepatosplenic schistosomiasis.  Figure 1.3 shows the cartogram for 
deaths due to schistosomiasis in the year 2002 (approximately seven deaths per million 
people). However, this information does not include estimates of deaths that may be due to 
schistosomiasis-associated pathologies such as bladder cancer, cirrhosis of the liver, or 
colon cancer (www.worldmapper.org/images/largepng/393.png) and so underestimates the 
true number of deaths due to schistosomiasis.  
 
In general, the morbidity related to schistosomiasis is classified into overt or end-organ 
morbidity (direct) or subtle systemic morbidity (indirect). Consequence of egg deposition 
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is the most severe and accounts for the overt or end-organ morbidity characterised by 
hepatic fibrosis, portal hypertension and their clinical complications. In S. mansoni 
infections end-organ morbidity includes bleeding oesophageal varices, haematemesis and 
S. mansoni-associated hepatomegaly that is estimated in 8.5 million people (Van der Werf 
et al., 2003). 
 
Subtle morbidity includes stunted growth, decreased cognitive performance and anaemia 
observed in intestinal and hepatosplenic schistosomiasis. These subtle forms of morbidity 
are a consequence of chronic infection with either malnutrition and/or iron deficiency 
occurring simultaneously. Pregnant women, young children, growing adolescent children 
and persons with co-morbid diseases are most susceptible to subtle forms of morbidity 
(Olds and Dasarathy, 2001). Details of the clinical features of these morbidities are 
described in subsequent sections. Epidemiological data shows that although chemotherapy 
provides protection for schistosomiasis there is a high risk of re-infection (Magnussen, 
2003). Additionally, the use of anti-schistosomal drugs influences development, physical 
fitness and working ability in adults and in children (Olds and Dasarathy, 2001) thus 
contributing to schistosomiasis associated morbidity.  
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FIGURE 1.3 Cartogram shows schistosomiasis deaths in 2002, highest being in the sub-
Saharan Africa (yellow, orange and red), followed by South Americas (blue) and lowest in 
Asian countries mainly China (green) (Map courtesy: www.worldmapper.org). 
 
1.4 Clinical features of schistosomiasis 
1.4.1 Acute toxaemic schistosomiasis  
The acute phase of schistosomiasis occurs at 6-8 weeks after infection coincides with the 
onset of egg laying by the adult worms and is mostly seen in travellers, army personnel 
and peace workers. Acute schistosomiasis is characterised by “katayama fever”, cough, 
headache, rash, diarrhoea, weight loss and eosinophilia, diffuse abdominal pain and 
toxaemia especially upon first exposure to the parasite egg antigen. Katayama fever is 
believed to be due to the high worm and egg antigen stimuli that result from egg-specific 
immune response and is rare in chronically exposed people. Although the eggs are 
excreted through urine and faeces, half are lodged in the liver microvasculature inducing a 
strong immune response that directs granulomatous lesion development. Additionally, 
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peripheral-blood mononuclear cells produce large quantities of tumour-necrosis factor 
(TNF), interleukin-1 (IL-1) and IL-6 (Pearce and MacDonald, 2002) during acute 
schistosomiasis. Abdominal ultrasound shows hepatosplenomegaly and periportal and 
peripancreatic lymphadenomegaly (lymph nodes enlarge temporarily). These changes are 
transient and non-specific and may resolve (Corachan, 2002). While, most clinical 
manifestations are benign; some are severe and can result in severe morbidity or death. 
However, the exact mechanism by which acute toxaemic schistosomiasis causes death is 
not fully understood. 
 
1.4.2 Chronic clinical features of schistosomiasis  
The chronic phase occurs at approximately 4-5 years or more post-infection presenting 
with severe granulomatous lesions in the liver, intestine, spleen, lungs, brain and male and 
female pelvic organs. Liver fibrosis and hepatosplenomegaly due to granulomatous lesions 
are the most important features of chronic schistosomiasis. The chronic disease may also 
cause blood in stool, abdominal pain, oesophageal varices and haematemesis and if 
untreated and lead to death (King and Dangerfield-Cha, 2008, Strauss, 2002). The 
common features (granulomas, fibrosis and hepatosplenomegaly) are detailed in the 
subsequent sections.  
 
1.4.2.1 Granulomas 
Granulomatous lesions result from schistosome eggs that get trapped in tissues. In S. 
mansoni infection, the major sites of egg deposition are the liver and intestine. Egg 
induced granuloma formation is a delayed type hypersensitivity (type IV hypersensitivity) 
reaction towards hepatotoxic components secreted by the entrapped egg (Doughty et al., 
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1984). The granuloma that forms around the egg consists of a number of different types of 
cells: T and B lymphocytes, macrophages, epitheloid cells, mast cells, fibroblasts and 
eosinophils (Figure 1.4). The immune cells contribute to the formation of the granuloma 
and interactions with surrounding hepatocytes and in particular CD4 cells have been 
shown to be essential in granuloma formation (Jankovic et al., 1998). The interactions are 
highly complex, and occur both by direct cell to cell interactions and a wide variety of 
cytokines, resulting in severe pathology (Rumbley et al., 1998). Many studies have 
contributed to the understanding of granulomatous immune responses and modulation in 
schistosomiasis with varying results. Previous studies have demonstrated a pivotal role for 
IFN-gamma in the early granulomatous response to schistosoma eggs (Rezende et al., 
1997). In S. mansoni-infected gene knockout mice deficient in either CD8 lymphocytes or 
IFN-gamma demonstrated that neither of these immunologic components plays roles in 
granuloma formation and or immune responses during the acute or chronic stage of 
infection (Yap et al., 1997). A study in mice demonstrated that S. mansoni infection 
induced IL-2 and IFN-gamma (Th1 cytokines) just before parasite egg laying and initiated 
liver granuloma formation during the acute disease. Whereas after egg laying and during 
the chronic disease the embedded parasite eggs induced IL-4 and IL-5 (Th2 cytokines) 
(Cheever et al., 1992) thus illustrating the importance of immune responses in the 
pathogenesis of liver granulomas during schistosomiasis.  
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FIGURE 1.4 Haematoxylin and eosin (H&E) stained section of liver parenchymal 
granuloma with S. mansoni egg at its centre. The granuloma around the egg consists of 
different types of immune cells like macrophages, eosinophils, T cells. (Image courtesy of 
Dr. Anne La Flamme)  
 
1.4.2.2 Intestinal schistosomiasis 
In 90% of infected individuals, the disease symptoms and egg-associated inflammation 
recede resulting in intestinal schistosomiasis (INT) with potential gastrointestinal 
haemorrhage. Nearly 80 million people have INT (Rowland, 1971) caused by S. mansoni 
endemic in 52 countries (Kogulan and Lucey, 2007). INT remains asymptomatic most of 
the time with subtle morbidity either due to nutrient deficient food (anaemia, impaired 
cognitive development and growth retardation) and/ or due to functional difficulties 
(educational impairment and productivity loss). Importantly, patients with INT have lower 
titres of IgM, IgG and IgA antibodies to S. mansoni carbohydrate antigens than those with 
hepatosplenic disease (Nyame et al., 2003). Moreover, intestinal granulomas are smaller 
and contain less collagen fibres when compared to hepatic granulomas (Santos et al., 
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1992). Yet, despite these known differences, it is not known what factor(s) drive the 
development of intestinal versus the more severe hepatosplenic disease. 
 
1.4.2.3 Hepatic fibrosis 
S. mansoni infection is an important cause of hepatic fibrosis. Hepatic fibrosis is a wound 
healing process in the liver, triggered by chronic injury due to inflammatory responses and 
accumulation of extracellular matrix proteins (especially collagen) being overproduced, 
not degraded, or both. Advanced hepatic fibrosis is asymptomatic but can lead to portal 
hypertension or cirrhosis and ultimately failure to build and replace destroyed liver cells 
resulting in liver dysfunction and liver failure. Schistosomiasis research has been directed 
on identifying biomarkers for hepatic fibrosis and determining the underlying mechanisms 
that lead to hepatic fibrosis. Studies have characterised collagen isoforms in liver biopsies 
indicating increased deposition of collagen I, III and B forms in portal triads and fibrotic 
septa  (Biempica et al., 1983). Another study demonstrated increased levels of serum 
procollagen peptides and collagen type VI suggesting their importance for the assessment 
of degree of hepatic fibrosis in schistosomiasis (Shahin et al., 1992). Increase in other 
cytoskeletal proteins like actin in schistosome infections show the intensity of liver 
damage caused by the parasite during pathogenesis of schistosomiasis (Andrade et al., 
1992, Harvie et al., 2007). 
Measurement of liver hydroxyproline in liver fibrosis and cirrhosis requires needle liver 
biopsies which is an invasive technique and has shown sampling variability (Lee et al., 
2005). Alternatively, serum hydroxyproline content has been measured in liver fibrosis 
associated with chronic HCV infections (Attallah et al., 2007) and therefore proves to be 
promising for schistosomiasis hepatic fibrosis. Additionally, recent studies have focussed 
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on connective tissue growth factor (CTGF) and transforming growth factor - (TGF-) in 
fibrosis. Studies show increased CTGF and TGF- in HCV fibrosis (Kovalenko et al., 
2009) and increased CTGF in idiopathic portal hypertension (Morikawa et al., 2007). 
Another study associates CTGF variants with schistosomiasis fibrosis (Dessein et al., 
2009). During acute S. mansoni infection, hepatic inflammation is controlled by TGF- 
and IL-10 (Herbert et al., 2008),  while in the chronic stage IL-13 and TGF- appear to be 
most important in the fibrotic process (Kaviratne et al., 2004).  
 
Many schistosomiasis studies have also focussed on the intermediate filament proteins that 
support the liver infrastructure and are hepatoprotective. Intermediate filament protein 
keratin 18 (cytokeratin 18 ) fragments have been studied extensively in liver fibrosis 
related to non-alcoholic steatohepatitis in children (Vos et al., 2008) and adults (Yilmaz, 
2009) but not in human schistosomiasis fibrosis. These studies indicate a definitive role of 
hepatic inflammation and hepatocellular apoptosis in inducing liver fibrosis. Additionally, 
studies indicate mutations in keratin 18 predisposes the liver to fibrosis during 
hepatocellular diseases (Ku et al., 2003). Studies have demonstrated increased abundance 
of vimentin in hepatosplenic schistosomiasis (Andrade et al., 1992) and in acute 
schistosomiasis (Harvie et al., 2007). Laminin, another intermediate filament protein is 
increased in human hepatosplenic schistosomiasis compared to hepatointestinal 
schistosomiasis (Andrade et al., 1992, Parise and Rosa, 1992) indicating a definitive role 
of these proteins in severe disease.  
 
Imaging techniques are used commonly for assessing schistosomiasis morbidity. 
Ultrasound is one such technique which is cheap, non-invasive and easily portable; some 
     12 
studies have established hepatic fibrosis grading system based on the ultrasound image 
pattern (IP) analysis, viz. A, B, C, D, E, F. Image patterns A, B represent normal livers 
and C, D, E, F represent increasing levels of fibrosis (Mohamed-Ali et al., 1999).  Mwinzi 
and co-workers assessed the ultrasound image patterns for degree of liver fibrosis in 
schistosomiasis patients. The authors‟ assigned patients with a normal liver texture as IPA, 
IPB was indicative of patients with a small degree of fibrosis, but no definitive pathology. 
IPC showed “ring echoes” that appeared as pipe stems in a perpendicular scan. IPD 
characterised by a “ruff” around the main portal vein and bifurcation. IPE showed a “ruff” 
extending into the liver parenchyma with patches of fibrosis (Mwinzi et al., 2004). This 
same image pattern assessment was used in our study for human serum analysis.  
 
1.4.2.4 Hepatosplenic schistosomiasis 
Hepatosplenic disease caused by S. mansoni is characterised by hepatosplenomegaly, 
Symmers‟ or “clay pipestem” fibrosis, portal hypertension, and oesophageal varices, 
which may lead to haematemesis and death. The marked features of hepatosplenic 
schistosomiasis are renal failure with anaemia, abdominal distension, hepatosplenomegaly, 
pedal oedema, and ascites seen in adults and children. In 10% infected individuals, the 
disease presents with severe hepatic and Symmers' fibrosis, portal hypertension and 
portal-systemic venous shunts due to hepatic granulomas and gastrointestinal bleeding; 
these contribute to life-threatening severe hepatosplenic schistosomiasis (HS). Patients, 
both adults and children (Figure 1.5) with HS present relatively normal liver function, but 
increased hydroxyproline levels and collagen synthesis (Warren 1978). Hepatosplenic 
schistosomiasis associated morbidity is a consequence of egg deposition in other tissues in 
addition to the liver and intestine, aggravating disease pathology. Morbidities due to egg 
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deposition in three most common tissues (reproductive organs, central nervous system, 
lungs) are discussed below. 
 
a)  b)  
FIGURE 1.5 a) Magnetic resonance imaging and surgery of a 21-year-old patient with 
hepatosplenic schistosomiasis. On the upper right hand side, a coronal section of the 
abdomen captured by magnetic resonance imaging, showing periportal fibrosis (white 
arrow) and a huge spleen (S). During surgery, the nodular surface of the liver (on the left) 
and the spleen (on the right) is evident. (Image courtesy: Drummond et al., 2006) b) 
Puerto Rican children with abdominal distension suffering from hepatosplenic 
schistosomiasis (Image courtesy: Tropical Disease Research, WHO).  
 
1.4.2.4.1 Genital schistosomiasis  
Lodging of the parasite eggs in the internal genital organs presents with ulcerative lesions 
in the female lower reproductive tract (cervix, valva and vagina) with ovaries mainly 
affected by S. haematobium infections in 50-80% women and S. mansoni infections in 5-
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27% women. It is documented that female genital schistosomiasis facilitates the 
bidirectional transmission of sexually transmitted diseases as HIV-1 and human 
papillomavirus (Feldmeier et al., 1998, Poggensee et al., 2000). Another study indicates 
49% of infected women had impaired fertility (Takougang et al., 2008) supporting a report 
which lists lesions of the ovaries and fallopian tubes, fibrotic scars, hormonal disturbances 
and viral co-infections as the leading causes that explain infertility in schistosome-infected 
women (Feldmeier et al., 1998). In male patients the parasite eggs get lodged in the 
epididymis, testicles, spermatic chord, seminal vesicles and prostate glands with 
haemospermia (blood in the ejaculate) which is the most important symptom of  male 
genital schistosomiasis observed in travellers and men from endemic areas (Feldmeier et 
al., 1999). The epidemiology and pathogenesis of haemospermia during schistosomiasis is 
still unknown and therefore there is no definitive evidence that male genital 
schistosomiasis affects fertility although case reports indicate possibilities of testicular 
tumours (Lopes et al., 2003, Mortati Neto et al., 2004) suggesting that the disease 
outcome for male patients may be fatal. 
 
1.4.2.4.2 Central nervous system schistosomiasis  
Parasitic egg deposition in the central nervous system involves focal and generalised 
seizures, headache, myeloradiculopathy with lower limb and back pain and bladder 
dysfunction. Spinal schistosomiasis due to S. mansoni infection presents as transverse 
myelitis (Kogulan and Lucey, 2007) and is due to eggs trapped in the lower vertebral 
plexus affecting the lower spinal cord. Asymptomatic deposition of S. mansoni eggs in the 
brain and meninges is more frequent in hepatosplenic compared to intestinal 
schistosomiasis. Additionally, some patients with central nervous system schistosomiasis 
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present with epilepsy. While initially high, the mortality rate for patients with 
schistosomal myelopathy has fallen from 72% to 11.5%  since 1965 due to early treatment 
options (Scrimgeour and Gajdusek, 1985), but the risk for central nervous system 
schistosomiasis still persists.  
 
1.4.2.4.3 Pulmonary schistosomiasis  
Also known as, schistosomal cor pulmonale, pulmonary schistosomiasis develops in 5% 
of hepatosplenic S. mansoni infections. It is characterised by larval pneumonitis with a 
cough, mild wheezing, low-grade fever and pulmonary hypertension. Destruction of the 
wall of pulmonary arterial branches is common, and fibrin deposition causes thickening of 
the pulmonary artery walls. These acute lesions are due to schistosomal granulomata in the 
lung. It is observed that the incidence of schistosomal cor pulmonale is higher in women 
than in men but the reason for this difference is unknown. Death in patients with 
pulmonary schistosomiasis is often a result of congestive heart failure (Lopes de Faria, 
1954).  
 
1.5 Laboratory diagnosis 
1.5.1 Stool or urine analysis  
The most common method for diagnosis of schistosomiasis is microscopic identification 
of eggs in stool or urine, also known as the stool smear Kato-Katz method (Santos et al., 
2005). The difference in the egg morphology helps to differentiate between the 
Schistosoma spp. and has been described by the Division of Parasitic Diseases, Centers for 
Disease Control, USA.  The eggs of S. haematobium are spindle-shaped with a terminal 
spine. S. intercalatum have prominent terminal spine and equatorial (central) bulge. S. 
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japonicum eggs are oval with less conspicuous spine whereas S. mansoni eggs are spindle-
shaped with a lateral prominent spine. Lastly, S. mekongi eggs are oval and have a small 
knob on the side. The different egg morphologies are shown in Figure 1.6. While this 
method is the most common it is also insensitive and low intensity infections are hard to 
detect. 
 
 
FIGURE 1.6 Egg morphology of Schistosoma spp. The five species: S. haematobium, S. 
intercalatum, S. japonicum, S. mansoni, and S. mekongi have distinct egg structures (spp. 
arranged alphabetically, Image courtesy: Division of Parasitic Diseases, Centers for 
Disease Control and Prevention). 
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1.5.2 Immunoassays 
Recent use of antigen preparations for the detection of infection-specific antibodies has 
made schistosomiasis diagnosis easier. These antigen reagents are prepared by 
homogenising worms from infected tissue followed by subcellular organelle fractionation 
to generate vesicles from the broken endoplasmic reticulum called microsomes 
(nonexistent in live cells or tissues) which are rich in worm antigens. Therefore, the 
prepared antigen is called microsomal antigen. Thus, serum antibodies can be detected that 
are highly specific for S. mansoni adult worm microsomal antigen, with similar tests 
available for S. haematobium, and S. japonicum. These antigens are used in Enzyme 
Linked Immunosorbent Assay (ELISA) to detect infection. Antibodies from the infected 
serum recognise GP30 from adult worm antigen with S. mansoni infection, GP18, GP23 
or GP29 identifies S. japonicum, and GP23 identifies S. haematobium infections (Al-
Sherbiny et al., 1999). For S. mansoni infections, the assay sensitivity is 99%, for S. 
haematobium infection it is 95% and for S. japonicum infection the assay sensitivity is 
<50% (Courtesy: Division of Parasitic Diseases, Centers for Disease Control and 
Prevention, USA).   
 
The ELISA techniques for quantitative determination of circulating anodic antigen (CAA) 
and circulating cathodic antigen (CCA) in serum and urine samples are used to detect 
infection for S. mansoni and S. haematobium (Al-Sherbiny et al., 1999). CAA and CCA 
have been studied extensively in mouse models but little in human immunodiagnostic 
applications. Detection of these antigens is not sensitive in low intensity infections. Also, 
the amount of CAA or CCA detected in the circulation or in the urine does not reflect the 
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actual production by the worms during infection and can be a result of host metabolic 
activities (Dam et al., 1996). In addition to low sensitivity in low infections, the CCA and 
CAA tests are costly. Finally, none of these antibody tests can detect difference between 
past and current infection and are possible only when the individual has the prolonged 
schistosome infection.  
 
1.5.3 Parasite DNA detection  
In the last few years, a rapid 2-step polymerase chain reaction (PCR) has been is being 
used to detect S. mansoni DNA in human urine, faecal and serum samples and is 10 times 
more sensitive than the Kato-Katz examination (Pontes et al., 2002). This PCR technique 
can detect infections as early as 3-4 weeks (Sandoval et al., 2006) although its efficacy 
needs to be tested for acute human schistosomiasis infections. This test should allow a 
more reliable diagnosis of schistosomiasis infection especially with low intensity 
infections as it has low costs and easy protocols. Unfortunately, while it will diagnose 
schistosomiasis infection, it will be unable to determine whether the schistosomiasis is 
intestinal or hepatosplenic. This distinction must be made separately by imaging 
techniques, which are currently only useful during late stage of disease. 
  
1.5.4 Radio Imaging  
Ultrasound is an economical and non-invasive technique for assessment of schistosomiasis 
morbidity but it underestimates liver fibrosis and is ineffective at detecting early liver 
pathology during the chronic stage. Even when performed by experienced clinicians the 
reproducibility of ultrasound measurements are unsatisfactory in the early stages of 
fibrosis (Chiavaroli and Grima, 2008). Computed tomographic scanning and magnetic 
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resonance imaging are other conventional imaging techniques used for schistosomiasis 
morbidity detection. Unfortunately, these techniques like ultrasound are unable to provide 
a definitive diagnosis during early stages of schistosomiasis.  
 
In Schistosomiasis mansoni, ultrasound shows fibrotic bands along the portal veins 
(Figure 1.7). Computed tomography shows low-attenuation bands around the large portal 
vein branches in the central part of the liver with marked enhancement (Figure 1.8). 
Magnetic resonance imaging shows periportal fibrous thickening in the central part of the 
liver with shrunken and irregular liver (Figure 1.5). The use of magnetic resonance 
imaging for diagnosis of chronic schistosomiasis disease of the spinal cord has increased 
the importance of this imaging technique (Drummond et al., 2006) for assessment of 
schistosomiasis morbidity; however, this technique is very expensive.  
 
Ultrasound is a commonly used technique and therefore many authors have described 
various methods for the gradation of liver fibrosis during schistosomiasis infection.  In 
1992, Abdel-Wahab and co-workers described a grading method for ultrasound 
assessment of periportal fibrosis for hepatosplenic schistosomiasis patients according to 
the thickness of the portal tracts: grade I = 3-5 mm, grade II ≥ 5-7 mm, and grade III ≥ 7 
mm (Abdel-Wahab et al., 1992). Another method demonstrated by Mohamed-Ali and co-
workers graded the ultrasound detectable periportal fibrosis as F0, FI, FII and FIII based 
on the thickening of the peripheral periportal branch wall, secondary portal branches and 
the fibrosis reaching the surface of the liver (Mohamed-Ali et al., 1999). In two separate 
studies, the authors used similar image pattern grading method of A through F, depending 
on the extent of visible fibrotic tissue around the portal branch and throughout the 
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parenchyma. Grades A and B were considered to be normal livers, whereas grades C, D, E, 
and F represented increasingly severe manifestations of the schistosomiasis disease (Booth 
et al., 2004, Mwinzi et al., 2004). Details of the grading technique used by Mwinzi and 
co-workers are described in section 1.4.2.3 (hepatic fibrosis) (2004). These studies 
indicate that a standard and definitive grading method for schistosomiasis ultrasound 
imaging patterns needs to be considered to allow immediate treatment solutions. 
 
 
FIGURE 1.7 Ultrasound of S. mansoni infected 40-year-old man. Sonogram of the right 
(A) and left hepatic lobe (B) shows hyper-echoic, thick, fibrous bands along the portal 
vein branches (arrows) (Image courtesy: Manzella et al., 2008). 
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FIGURE 1.8 Computed tomography of a 69-year-old man with S. mansoni infection. 
Post-contrast CT image shows low-attenuation rings or bands around the portal vein 
branches (arrows). Note shrunken liver with undulated surface and ascites due to advanced 
liver cirrhosis (Image courtesy: Manzella et al., 2008).  
 
1.6 Treatment and prevention 
1.6.1 Anti-schistosomal drugs 
Anti-schistosomal drugs or anthelmintics are chemotherapeutic agents used to treat 
schistosomiasis. Currently, praziquantel (C19H24N2O2
 ), oxamniquine (C14H21N3O3
 ), 
metrifonate (C4H8Cl3O4P
 ) and artemisinins (C15H22O5
 ) are available for treatment, with 
praziquantel and oxamniquine being the drugs of choice. Praziquantel is the most common 
and has a cure rate greater than 85%. Infections with S. mansoni and S. haematobium are 
treated with a single dose of 40 mg/kg/d and S. japonicum and S. mekongi with 60 
mg/kg/d of praziquantel. Although a single dose is effective, the treatment becomes long-
term considering the high rates of re-infection. No vaccine or prophylactic chemotherapy 
is currently available. Additionally, co-infections in schistosomiasis especially HIV-1, 
HPV, malaria and many other infectious diseases pose a greater challenge to scientists. 
However, Utzinger and co-workers have described a negative association between 
infection intensity and praziquantel cure rates especially for S. mansoni infections 
(Utzinger et al., 2000) suggesting that host-related factors and pre-patent infections affect 
incomplete parasite clearance and thus treatment failures. 
 
1.6.2 Control measures  
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Molluscicides are pesticides against the intermediate snail host for schistosomes. Spread 
of schistosomiasis is prevented by using molluscicides and other biological agents to 
eliminate fresh water snails. However, snail susceptibility and/ or resistance phenotypes 
have hindered this process (Lardans and Dissous, 1998) and indicate that the use of 
molluscicides alone will not be effective. Proper education about schistosomiasis and 
related diseases has improved the status of prevention strategies. Regular health checkups, 
sanitation and improved water irrigation systems are some of the preventive measures 
applied in endemic areas. Unfortunately, in recent years, studies have reported that new 
dams, irrigation systems and reservoirs as well as the movement, growth and settlement of 
populations in new areas has reduced the previous effectiveness of schistosomiasis 
prevention programs (Jassim et al., 1987). 
 
1.7 Animal schistosomiasis studies 
1.7.1 Mouse studies  
Experimental schistosome infection of laboratory animals has been described in rabbits, 
primates, rodents and mice such as BALB/c or C57BL/6. Mouse models are often used for 
experiments, as they are easy to handle and amenable to genetic manipulation (i.e. 
transgenic mice or knock-out mice). Experimental S. mansoni infection models have been 
used to reproduce and study the anatomopathologic and pathophysiologic features of the 
infection as well as for the study of immunity and treatment. Various models have shown 
that development of schistosomiasis causes liver dysfunction by altering the metabolic 
processes through the up-regulation or down-regulation of enzymes (Harvie et al., 2007, 
Pearce, 2005, Wynn et al., 2004). Granulomas play an important role in the development 
of severe pathology in schistosomiasis and have been studied for the immunopathology 
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(Freeman Jr et al., 1996, Montesano et al., 2002, Stadecker, 1999). Comprehensive 
research in experimental murine models has contributed more broadly to the 
understanding of granulomatous inflammation and Th2-mediated fibrosis of the liver 
(Cheever et al., 2002). Experimental schistosomiasis has also become a model for Th2 
immune response development and regulation.  
 
1.7.2 C57BL/6 mouse model 
The C57BL/6 mouse model is a general multipurpose model. Availability of 
immunological reagents such as specific antibodies, recombinant proteins, specific cell 
types, soluble molecules (cytokines, chemokines, and circulating antibodies), etc. makes 
these mice suitable for immunological research purposes. These mice are commonly 
genetically modified for production of transgenic or gene deficient strains to examine the 
involvement of specific immune mediators. For example, in IL-4 deficient mice on the 
C57BL/6 background it was shown that IL-4 plays a protective role during schistosomiasis 
by controlling the regulation and generation of reactive oxygen and nitrogen intermediates 
in the liver (La Flamme et al., 2001). Most mice studies use the C57BL/6 mouse model 
(Cheever and Barral-Netto, 1985, Harvie et al., 2007) which display significantly smaller 
granulomas than other mouse strains (Rutitzky et al., 2001). The inability of the C57BL/6 
mice to survive chronic infections was studied by Colley et al. and led to the discovery 
that C57BL/6 granulomas were consistently half the volume of their counterpart lesions in 
CBA/J mice (Colley and Freeman Jr., 1980). Many researchers consider that C57BL/6 
mice have comparable results to intestinal schistosomiasis while CBA/J mice results are 
more similar to hepatosplenic schistosomiasis patients (Stadecker, 1999, Stadecker et al., 
2004), although this comparison is hotly debated.  
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Using animal models for schistosomiasis studies raises an important point regarding the 
intensity of experimental schistosome infections. The infection intensities in these studies 
is generally high and infections are given as a single exposure to cercariae. In contrast 
most schistosome infections in humans are acquired gradually over years.  Additionally, 
most humans exposed to schistosomiasis are born to mothers who are or have been 
infected hence in utero exposure to schistosome antigens or to idiotypic or anti-idiotypic 
antibodies may modify the response to subsequent infection in humans. Chronic human 
schistosomiasis is not reproducible in most animal models; therefore the relevance of these 
studies to human infection must be carefully considered (Cheever et al., 2002).  
 
1.7.3 CBA/J mouse model 
One model that reproduces the clinical forms of human hepatosplenic schistosomiasis with 
the same spectrum of the disease is the CBA/J mouse (Henderson et al., 1993). After 
infection 20% of CBA/J mice present with hypersplenomegaly syndrome (HSS) which 
resembles HS and 80% of the mice develop the moderate splenomegaly syndrome (MSS) 
similar to INT. HSS mice have enlarged livers with discoloured and coarse appearance 
due to granulomas. Liver from control mice are pink when compared to either MSS or 
HSS livers (Figure 1.9a). Moreover, the spleens from HSS mice are almost 5 times heavier 
compared to the control mice (Figure 1.9b). These prominent differences in pathology 
make HSS mice different from MSS mice.    
 
Anti-soluble egg antigen antibodies from MSS mice have distinct cross-reactive idiotypes 
(CRIs) and lymphocyte stimulatory abilities. These distinctive CRIs are also found in 
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patients with INT and are believed to regulate the immunopathogenesis of chronic 
infection in humans and mice. In contrast, CRI cannot be detected in HSS mice or HS 
patients. CRIs can be detected as early as 6 weeks post infection; thus, CRIs have the 
ability to predict chronic pathology. The early appearance of CRIs in infected male CBA/J 
mice and human patients anticipates no development of severe disease, whereas infected 
male CBA/J mice and human patients with no CRIs present with early death in mice or 
severe chronic disease in humans (Montesano et al., 2002).  
 
Being an ideal model for schistosomiasis fibrosis, researchers have investigated the 
mechanisms and pathology of fibrosis in CBA/J mice. A previous study used the CBA/J 
mouse model to study liver fibrogenesis in S. japonicum infections and demonstrated 
marked abscess, inflammatory responses and fibrosis in the liver (Hirata et al., 1993). 
Work in CBA/J neonatal mice exposed to CRI preparations showed that there is 
modulation of immune responses and liver fibrosis in such a manner that animals survive 
successive S. mansoni infections (Montesano et al., 1999). Another study investigated the 
immunopathogenesis and immunoregulation of CBA/J mice with MSS and HSS chronic 
pathologic syndromes and demonstrated the mice have distinct and different degrees of 
fibrosis (Freeman Jr et al., 1996). Together these studies support the relevance of this 
model for investigating chronic human schistosomiasis. 
 
a) Liver pathology in murine schistosomiasis 
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b) Spleen pathology in murine schistosomiasis 
                                   
FIGURE 1.9 The CBA/J mouse model mimics the human form of the disease. After 
infection, 20% of the CBA/J mice present with hypersplenomegaly syndrome (HSS) 
which resembles HS and remaining 80% of the mice develop the moderate splenomegaly 
syndrome (MSS) similar to INT. a) Granulomas in the liver show coarse appearance, note 
the colour variation from pink to pale for normal through MSS to HSS liver. b) The spleen 
presents with moderate splenomegaly for MSS and hypersplenomegaly for HSS mice 
compared to control mice.  
 
1.7.4 Animal fibrosis studies 
Mouse studies have been used extensively to study various aspects of schistosome-
induced fibrosis. There is increased synthesis of collagen isoforms due to schistosomiasis 
fibrosis (Dunn et al., 1977) and liver hydroxyproline is increased during experimental S. 
mansoni infection (El-Meneza et al., 1989). Also, liver enzymes like 
galactosylhydroxylysyl glucosyltransferase, hydroxylysyl galactosyltransferase and prolyl 
hydroxylase are increased post 6-week infection (Bolarin et al., 1985). These parameters 
were measured to evaluate molecular mechanisms related to liver collagen synthesis 
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during schistosomiasis and to understand the damage caused by hepatic fibrosis. In 
addition to collagen, intermediate filaments are important for structural stability and 
provide scaffolding function. They form complex signalling platforms and interact with 
various kinases, adaptor, and apoptotic proteins. Among the intermediate filament 
proteins, vimentin and cytokeratin 18 (keratin 18 or keratin D) play an important role in 
liver stability during schistosomiasis (Boehme et al., 1989, Chiarini et al., 2006). Previous 
studies have described the changes induced by schistosome infection on cytoskeletal 
composition during both the acute (Harvie et al., 2007) and chronic ((Silva et al., 2004)) 
stages and have highlighted changes in collagen, vimentin, actin and cytokeratin. 
Mechanisms leading to liver fibrosis are unclear (in mice as well as in humans) but it is 
thought to be caused by hepatic stellate cell activation and their transition to 
myofibroblast-like cells (Xu et al., 2009). 
 
1.7.5 Animal co-infection studies 
Schistosomiasis is a tropical disease that co-exists with many other infectious diseases.  In 
particular, schistosomiasis and malarial or HIV-1 co-infections pose a major problem as 
poly-parasitism affects host immunity and ultimately vaccine effectivity. The effects of 
co-infection with schistosomiasis-malaria in BALB/c mice demonstrated aggravated 
malaria severity, as shown by increased parasitemia (the quantitative content of parasites 
in the blood) and severe gross pathology of liver and spleen (Kanyugo et al., 2009). In an 
HIV study, when S. mansoni-infected rhesus monkeys were exposed to simian-human 
immunodeficiency virus, the animals demonstrated eosinophilia, higher IL-4 and IL-10 
mRNA levels compared to parasite negative control animals, consistent with a Th2-type 
response to schistosome infection. In the same study when the animals were inoculated 
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intravenously with a high titre simian-human immunodeficiency virus stock, animals with 
schistosomiasis developed early viral replication that was significantly elevated compared 
to that of control animals (Secor, 2005). The above experimental studies are indicative of 
comprehensive strategies applied to integrate research programs for the control or 
elimination of schistosomiasis.  
 
1.8 Human schistosomiasis studies 
Many human studies have focused on immunological aspects and late stage morbidities of 
the disease. Induced immune responses are mainly due to host response to parasitic 
antigens and at later stages of the disease are largely due to eggs embedded in the 
granulomas (De Morais et al., 2008). Epidemiological studies in endemic areas, combined 
with animal experiments, have led to the view that host genetics, infection intensity, 
schistosome antigen and co-infection status all influence the development of the immune 
response and disease severity (Pearce and MacDonald, 2002). The large number of factors 
that influence the development and severity of disease make the research related to 
discovery of drug targets and biomarkers quite complex. 
 
Research focused on schistosomiasis morbidity includes hepatic fibrosis, portal 
hypertension, cognitive function studies, and assessment of anaemia. Portal hypertension 
measured by hyperdynamic circulation using electron paramagnetic resonance 
spectroscopy (Battista et al., 1997), and fibrosis detected by liver biopsies (Camacho-
Lobato and Borges, 1998) are invasive techniques. Ultrasound is conventional and non-
invasive and can detect severe fibrosis as well as hepatosplenomegaly. However, 
ultrasound only detects at a late stage and is not sensitive enough to detect the earlier 
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stages (Pereira et al., 1998). Hepatic fibrosis due to schistosomiasis has been discussed in 
a previous section 1.4.2.2 and is one of the major topics targeted by human studies 
because of its importance in morbidity. Epidemiological studies indicate the effectiveness 
of control and prevention measures but it is difficult to follow individuals and patients in 
endemic locations where disease spread is rapid and education limited.  
 
1.8.1 Co-infection studies 
In most countries of sub-Saharan Africa, and in many other tropical and subtropical 
countries, at least five to six tropical diseases occur in the same region. As a result a 
considerable proportion of the population is co-infected with one or more pathogens. 
Multiple infections adversely affect childhood growth, cause micronutrient deficiencies, 
and lead to extensive organ pathology. The susceptibility of children and pregnant women 
to co-infections is the rationale behind an increased focus on research programs related to 
vaccines and drugs.  Likewise, co-infections in schistosomiasis are common and influence 
immune responses and response to treatments. The most common or well-studied co-
infections with schistosomiasis include malaria, HIV, tuberculosis and viral hepatitis are 
discussed in the following sections.   
 
1.8.1.1 Malaria and schistosomiasis  
Malaria and schistosomiasis are two major parasitic diseases in developing countries and 
are co-endemic, resulting in varied pathologies. Children are more vulnerable to co-
infections and present with impairment in growth and development. Plasmodium 
falciparum infected adults and children with schistosomiasis infection show increased 
malaria morbidity in children in contrast to the effects seen in co-infected adults indicate 
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that schistosomiasis co-infection can unbalance the regulation of inflammatory factors 
(Diallo et al., 2004). Co-infections in children with P. falciparum and S. mansoni result in 
lower percentages of activated T cells and T regulatory memory cells (Mouk et al., 2009). 
Recently, researchers have found a cross-reactive antigen, SmLRR shared between S. 
mansoni and P. falciparum sera from both humans and rats infected with either parasite 
species and is a promising therapeutic target (Helmby, 2007). A better understanding of 
the interactions between these two parasites might prove invaluable in the development 
and evaluation of new vaccine candidates or therapeutic strategies.  
 
1.8.1.2 HIV-1 and schistosomiasis  
HIV-1 and AIDS are prevalent in Africa and the pathology is aggravated in 
schistosomiasis co-infections. Granuloma formation and pathology during schistosomiasis 
is dependent on, and mediated by, CD4 cells responding to egg antigens. Likewise, CD4 
cells are critical in HIV-1/AIDS to maintain cell-mediated immunity. Experiments in vitro 
have shown that CD4 cells of persons with active schistosomiasis have higher distribution 
of specific cell surface chemokine receptors that make them more susceptible to HIV 
infections (Secor et al., 2003). Also, S. mansoni infected subjects with HIV-1 showed 
more rapid liver fibrosis (Mwinzi et al., 2004). These studies demonstrate that 
schistosomiasis increases the susceptibility to HIV-1/AIDS or aggravates the progression 
of HIV-1 disease (Secor et al., 2004). Finally, human co-infection studies become 
complex because individuals cannot be studied longitudinally without treating their 
schistosome or HIV-1 infections. Thus, the need to develop and use animal models is 
highlighted. 
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1.8.1.3 Tuberculosis and schistosomiasis 
In Africa, tuberculosis is highest among HIV-1 infected individuals and helminth 
infections. S. mansoni infection suppresses anti-mycobacterial immune responses through 
enhanced production of cytokines like TGF-β and IL-10, and promotes active tuberculosis 
development among HIV-1-infected Ugandans (Brown et al., 2006). In spite of the high 
incidence of these two infections in Africa, S. mansoni and Mycobacterium tuberculosis 
co-infections are rare. Recently a study demonstrated that schistosoma infection induces a 
cellular Th2 immune response and mycobacterial induced immunity is Th1 cell-mediated. 
This imbalance in the lymphocyte population could enhance susceptibility to 
mycobacterial diseases in co-infected individuals (Basile et al., 2007) and thus result in a 
fatal outcome.  This possibility emphasises the need for research into schistosome vaccine 
and drugs. 
 
1.8.1.4 Hepatitis and schistosomiasis 
Human studies on co-infection with Hepatitis B virus (HBV) and S. mansoni indicate 
aggravated disease pathology specifically associated with the liver. Some studies indicate 
the association of HBsAg (surface antigen of the hepatitis B virus), anti-HBsAg, anti-HBc 
(antibody to hepatitis B core antigen) with haematemesis and macronodular cirrhosis in 
patients with hepatosplenic schistosomiasis (Conceição et al., 1998). Another study 
correlated the presence of HBsAg in hepatosplenic schistosomiasis patients with 
aggravated chronic liver disease and chronic inflammation of the portal spaces (Lyra et 
al., 1976). While some studies maintain that there is no association of HBV and 
schistosomiasis (Abdella Eltoum et al., 1991), research also suggests a synergistic role of 
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HBV infection with S. mansoni in the development of chronic hepatic schistosomiasis 
(Kojiro et al., 1986). 
 
Schistosomiasis and hepatitis C virus (HCV) co-infections lead to severe fibrosis due to 
virological and immunologic interactions. Hepatosplenic schistosomiasis patients with 
HCV have significantly higher serum TNF-α than schistosomiasis patients, showing that 
HCV co-infection aggravates the liver pathology (Morais et al., 2006). Some studies 
indicated that use of liver function tests (alanine aminotransferase, aspartate 
aminotransferase, albumin, alkaline phosphatase, gamma-glutamyl transferase) is able to 
differentiate chronic schistosomiasis, HCV and co-infection (Fahim et al., 2000). In 2004, 
a study demonstrated that S. mansoni induced Th2 dominance down-regulates the Th1 
cytokine profile in HCV infection (el-Kady et al., 2004). Furthermore, some studies 
suggest that schistosome and HCV co-infections have higher incidence of hepatocellular 
carcinoma and mortality rates due to liver-related diseases (Kamal et al., 2001). 
Nonetheless, a study in Ethiopian population claims that HCV has no association with S. 
mansoni infection but HBV co-infection can predict levels of hepatic periportal 
thickening/fibrosis (Berhe et al., 2007).  
 
1.8.2 Schistosomiasis and cancer 
Schistosomiasis infection generates free radicals and immune-generated toxic oxygen 
compounds triggering carcinogenic activities during the disease (Mostafa et al., 1999). 
There is evidence that S. japonicum causes development of liver cancer in Japan and 
colorectal cancer in China. In schistosomiasis due to S. haematobium, the intensity of 
infection, the degree of haematuria and proteinuria, and the pathological changes in the 
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urinary bladder and ureters have been shown to induce malignancy leading to bladder 
cancer (Mostafa et al., 1999). Urinary schistosomiasis accounts for 16% of bladder cancer 
cases in an Egyptian population (Bedwani et al., 1998) suggesting carcinogenic effects of 
the helminths during schistosomiasis. There is no direct evidence that S. mansoni plays a 
role in the carcinogenesis but case reports link it to liver, colorectal and prostate cancer 
(Vennervald and Polman, 2009). In addition, S. mansoni infections clearly causes 
increased incidence of hepatocellular carcinoma in HCV patients (Kamal et al., 2000).  
 
S. haematobium is the only helminth that has been proven to be definitely carcinogenic in 
humans, although other schistosome spp. also may facilitate malignant transformations. 
Helminth infection-related cancers involve chronic inflammation which induces many 
complex mechanisms like host immune system modulation, intracellular communication 
inhibition and disruption of propagative and anti-propagative pathways. In addition, there 
is genomic instability, oxidation and damage of DNA, induction and propagation of 
malignant stem cell progeny (Mayer and Fried, 2007). A study demonstrated that S. 
mansoni infection alters the function of p53 protein in schistosomal colitis-associated 
colorectal cancer (Madbouly et al., 2007). Additionally, experimental work indicates 
somatic and metabolic antigens from S. mansoni induce reticular-cell hyperplasia and 
plasmocytic differentiation predisposing the spleen to the development of follicular 
lymphoma (Andrade and Abreu, 1971). Moreover, another study showed liver DNA had 
promutagenic methylation damage with increasing intensities of S. mansoni infection. The 
authors indicate that carcinogenic and/or toxic substances in schistosome eggs, 
schistosomulae and adult worms may have carcinogenic effects (Badawi et al., 1993). 
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Together these studies support a role for schistosome-mediated mechanisms and tissue 
damage in the development of cancer. 
 
 
1.8.3 Schistosomiasis and chronic renal failure 
Chronic renal failure is a marked feature of Schistosomiasis haematobium and also occurs 
in S. mansoni infections. In S. haematobium, direct egg deposition causes bladder 
pathology in 50% cases with increased bladder damage associated with parasite genetics, 
intensity of infection, proteinuria and haematuria (Brouwer et al., 2003). In addition to 
causing glomerular lesions due to schistosomal antigens and circulating immune 
complexes (antigen-antibody complexes) being deposited in the renal glomeruli, 
schistosome infections do cause schistosomal nephropathy which is a leading cause of 
progressive renal diseases (El-Koraie et al., 2002). Circulating immune complexes due to 
Schistosomiasis mansoni are heterogeneous in size and composition leading to different 
types of glomerular lesions in chronic schistosomiasis (Brito et al., 1979) and acute 
schistosomiasis (Lawley et al., 1979). Furthermore, S. mansoni-induced mesangiocapillary 
glomerulonephritis is an important cause of nephrotic syndrome and chronic renal failure 
(Martinelli et al., 1989). Investigating the immunochemical composition of the complexes 
and the pathophysiology involved in the initiation of renal injury could help to solve the 
mystery behind the mechanism of the schistosomal specific nephropathies and initiation of 
anti-schistosomal treatment. 
 
1.8.4 Schistosomiasis, allergies and autoimmune diseases 
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Recently, there has been growing appreciation in developed countries that chronic worm 
infections can prevent or suppress autoimmune and allergic disorders. Studies have shown 
that the prevalence of allergies and autoimmune diseases is negatively correlated to the 
prevalence of worm infections, potentially due to improved hygienic conditions. Although 
the development of allergies and auto-immunity are influenced by both genetic 
background and environment/lifestyle, studies have directly demonstrated that human 
schistosomiasis decreases immune responses to allergens and clinical manifestations of 
asthma in people living in helminth endemic areas (Araujo and De Carvalho, 2006). Other 
studies (La Flamme et al., 2003b, Sewell et al., 2003) demonstrate that exposure to S. 
mansoni eggs or chronic S. mansoni infection reduces incidence and delays progression of 
experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. A 
recent study with multiple sclerosis and worm infections demonstrates that parasite 
infections induce regulatory T cells generating immune modulators that alter the 
progression of multiple sclerosis (Correale and Farez, 2007). Additionally, infection with 
schistosoma helminth or exposure to schistosoma eggs significantly reduces the incidence 
of insulin dependent diabetes mellitus (IDDM), an autoimmune disease resulting in the 
destruction of insulin producing cells (Cooke et al., 1999). Thus, schistosome infection 
modulates the immune responses involved in pathology related to allergies and 
autoimmune diseases, and this approach is being investigated by researchers for parasitic 
molecules that might prove beneficial in treating the autoimmune and allergic diseases. 
 
1.9 Diagnostic markers or biomarkers for schistosomiasis 
In the light of global warming, climate change has lead to shifting of the isotherms that 
have caused the plant and animal species to adapt to new climates and colonizing new, 
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warmer habitats. These changes have facilitated the spread of schistosomiasis to new 
regions and highlighted the need for new prevention and treatment solutions (Githeko, 
2009). Recently, there have been significant advances in the decoding of the S. mansoni 
genome, transcriptome and proteome, which may uncover targets for new therapies for 
schistosomiasis (Berriman et al., 2009). Research focussed on new treatment solutions 
include chemotherapeutic strategies, integrated community-based interventions and 
clinical trials and accessible quality-assured diagnostic markers either related to 
schistosomiasis infection, host immunity and disease associated morbidity. 
 
1.9.1 Infection and immunity markers  
Although sensitive and specific tests have been developed to detect schistosome-specific 
antibodies, the tests are too vague. Serologic tests for anti-schistosomal antibodies cannot 
distinguish between past and current infections. In contrast, antigens excreted by worms 
and eggs are present during active infection and can be detected. Assays measuring 
circulating antigens like circulating anodic antigen (CAA) and circulating cathodic antigen 
(CCA) have been demonstrated in serum and urine but demand further validation in sero-
epidemiological studies. The recent development of the dipstick ELISA for CAA and 
CCA is proving to be a useful method for detecting and quantifying infection especially in 
epidemiological studies (Ouma et al., 2001). A study reported that schistosomal 
carbohydrate antigens could be used as targets for vaccination and/or serodiagnosis of 
chronic schistosomiasis in humans (Nyame et al., 2003). Re-infection studies in 
schistosomiasis demonstrated increased levels of protective molecules like IgE which 
resist re-infection while increased IgG4 was related to high risk of re-infection (Deelder, 
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1992) this information can help in the treatment of patients in sero-epidemiological studies 
and vaccine trials.  
 
The development of the PCR for detecting S. mansoni DNA in human faecal and serum 
samples (Pontes et al., 2002) is a breakthrough for clinicians struggling to effectively treat 
schistosomiasis although it requires rigorous testing for efficacy and validation for 
epidemiological and clinical settings. A study by Caldas et al. demonstrated the 
importance of cross-reactive idiotypes (CRIs) during pathology modulation in 
schistosomiasis (Caldas et al., 2008) suggesting it is important in directly mediating the 
disease outcome. Additionally, CRIs can be used to detect severe schistosomiasis 
morbidity at an  early stage in the infection and thereby help in treatment strategies 
(Montesano et al., 2002). Importantly, schistosomiasis infection triggers immune 
responses and therefore infection and immunity markers have to be used in combination.  
 
1.9.2 Markers of morbidity 
The primary markers of schistosomiasis morbidity are liver fibrosis and differential 
antibody levels in hepatosplenic compared to intestinal schistosomiasis. To address the 
problem of hepatic fibrosis in hepatosplenic schistosomiasis, researchers have identified 
connective tissue metabolites, carboxyterminal procollagen IV peptide as a potential 
biomarker that could be used in endemic areas (Kardorff et al., 1999). New research has 
used various other approaches to develop diagnostic markers including genomics, 
proteomics, transcriptomics and metabonomics. Urinary metabolic profiles of S. mansoni 
infected mice showed changes in the tricarboxylic acid cycle, glycolysis and amino acid 
metabolism suggesting that these are a part of the biological responses to parasitic 
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infections. This study showed that decreases in citrate, succinate, 2-oxoglutarate, taurine, 
2-oxoisocaproate, 2-oxoisovalerate and increases in pyruvate and tryptophan may be 
diagnostic for chronic schistosomiasis (Wang et al., 2004). Another study found elevated 
levels of peripheral blood cholylglycine (marker of portal blood in the systemic 
circulation), procollagen-III-peptide (cleavage product of collagen synthesis) and 
neopterin (macrophage product) in hepatosplenic schistosomiasis and suggests the use of 
these tests for clinical assessment (Zwingenberger et al., 1988). In spite of the extensive 
work on diagnostic markers for hepatosplenic schistosomiasis, markers identified using 
mouse models and human studies applied in clinical and epidemiological studies have 
failed to produce viable and robust biomarkers so far.  
 
1.10 Aim of the study 
The aim of this study was to identify diagnostic markers for hepatosplenic schistosomiasis. 
Early diagnosis of hepatosplenic patients can focus treatment on these patients. 
Eradication of the disease using chemotherapy has never been achieved due to moving 
populations, high re-infection rates and post-morbidity leaving sufficient scope for 
research in various aspects of the disease (like vaccines, drug development and diagnostic 
markers). Previous study by our group in the C57Bl/6 mice at 8-week infection showed 
differential expression of proteins like transferrin isoforms, cytokeratin isoforms, vimentin, 
dimethyl dehydrogenase and selenium binding protein using two-dimensional 
electrophoresis (Harvie et al., 2007). In the present study, we intend to use the CBA/J 
mouse model and 2D-DIGE coupled with MALDI-TOF mass spectrometry. The CBA/J 
mouse model is a reproducible mouse model that presents both pathological forms of the 
chronic disease: moderate splenomegaly syndrome (MSS) similar to INT and 
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hypersplenomegaly syndrome (HSS) similar to HS in humans. This model was used to 
identify candidate protein markers of HSS, and Dr. Evan Secor, Centres for Disease 
Control and Prevention, Atlanta, USA provided the CBA/J mouse liver and serum samples 
for the proteome analyses as well as the human serum samples for biomarker verification.  
 
 
The specific aims for this study were: 
1. Compare liver protein abundance in chronically (20-week) infected MSS and HSS 
mice to determine the distinct differences between the two late stage disease forms 
and to identify candidate liver protein markers unique to HSS and MSS. 
2. Analyse changes in liver protein abundance over time post-infection to identify 
candidate liver protein markers in liver samples from CBA/J mice infected for 6, 8, 
12 weeks and compare it with the abundance of proteins from 20 week infected 
mice and control CBA/J mice. This approach will identify differentially expressed 
proteins as early marker proteins, late marker proteins, and marker proteins which 
are consistently expressed through the progression of the hepatosplenic disease. 
3. Analyse mouse candidate liver protein markers, associated with the pathogenesis 
of schistosomiasis, in serum samples from infected mice and humans to develop 
the candidate liver protein markers as diagnostic markers for hepatosplenic disease. 
     40 
CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Mouse model, liver and serum sample collection 
Male CBA/J mice were obtained from The Jackson Laboratory and were maintained at the 
American Association for Accreditation of Laboratory Animal Care, Centers for Disease 
Control and Prevention, Atlanta, USA (CDC) in accordance with institutional guidelines 
and federal regulations. Mice were infected by subcutaneous injection of 45 cercariae of a 
Puerto Rican strain of S. mansoni that had been maintained in Biomphalaria glabrata 
snails. At 20-week of infection, animals were sacrificed and classified as having MSS or 
HSS, based on percent spleen body weight and gross pathological appearance at CDC. 
Liver and serum samples were collected from the three study groups (uninfected age-
matched controls, MSS and HSS; n = 5 per group) and snap frozen at -80 °C.  A second 
set of liver and serum samples similarly treated was collected for uninfected age-matched 
controls (n=5) and mice infected for 6-week (n=10), 8-week (n=10), 12-week (n=10), 20-
week (n=10) and all samples snap frozen at -80°C. Although the sets were collected 
separately, samples from each set were collected within the same time period to avoid bias 
due to collection time. Mice liver and serum samples sent by Dr. Secor were used for 
proteomics experiments at the Victoria University of Wellingtons‟ Proteomics Facility.   
The Victoria University of Wellington Animal Ethics Committee approved all 
experiments.  
 
2.2 Human serum samples 
Human serum samples were collected from car washers with intense S. mansoni infections 
in Kisumu, Kenya (Karanja et al., 2002). Study participants were occupationally exposed 
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car washers above 18 years of age. On approval by the participants, sera were tested for 
antibodies to HIV-1. The modified Kato Katz technique was used to quantify S. mansoni 
eggs in the faecal specimens expressed as eggs per gram. The CD4 cell counts were 
evaluated in persons with schistosomiasis liver pathology (Mwinzi et al., 2004). The HIV-
1 and CD4 cell counts were done by Mwinzi et al. (2004). 
 
Assessment of schistosomiasis morbidity was done using a portable Aloka SSD-620 
ultrasound machine with a 3.5 megahertz convex probe (Aloka Co., Ltd., Tokyo, Japan) 
and schistosome-induced pathology in the liver was evaluated according to the Niamey 
classification (Richter et al., 2000, Richter et al., 1992). The image pattern (IP) 
specifications have been discussed in Chapter 1 (section 1.2.4.3 hepatic fibrosis) and are 
based on the degree of liver fibrosis detected by ultrasound done by trained 
ultrasonographers in Kisumu. In our study, patients with image pattern IPA were classified 
as INT, image patterns IPC, IPD, IPE were classified as HS, and more specifically IPD 
and IPE were severe HS. Twenty three INT serum samples and fourteen HS serum 
samples were selected for the study with similar eggs per g (Figure 2.1). Thirteen age and 
sex matched controls were included from CDC. I used targeted assays for liver and serum 
hydroxyproline, transferrin (ELISA), CTGF (ELISA) and keratin D (western blot) 
measurements which were done at CDC. The institutional review boards of the Centers for 
Disease Control and Prevention, U.S. Department of Health and Human Services, and The 
Kenya Medical Research Institute approved all the human sera experiments.  
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FIGURE 2.1 Egg count per g of faeces in the two study groups INT and HS, mean ± SEM, 
serum samples with similar EPG between the groups.  
 
2.3 Extraction of protein from murine liver tissue 
Each liver sample was homogenised using disposable 1.5 mL polypropylene pestle with 
standard lysis buffer. For every 10 mg of tissue weighed 100 µL standard lysis buffer was 
added containing 30 mM Tris-HCl (Sigma-Aldrich, St. Louis, MO, USA), 2 M thiourea 
(MERCK, Darmstadt, Germany), 7 M urea (MERCK), 4% (w/v) 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS) (Sigma-Aldrich). Homogenates were 
vortexed for 10 min, and centrifuged at 13,000 rpm for 10 min and supernatants were 
collected for proteomic analysis. Liver total protein concentration was determined using a 
2D-Quant Kit (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) (Beddek et al., 2008) 
and a modified Bradford Assay (Viswanathan et al., 2006).  Lysates were stored at -20
o
C 
until further use.  
 
2.3.1 Modified Bradford assay  
Stock standard albumin (concentration 2.5 mg/mL) was prepared using 0.0125 gm bovine 
serum albumin (Sigma-Aldrich) in 5 mL standard lysis buffer. Working standards were 
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prepared with serial dilutions from 2.5 mg/mL to 2.0 mg/mL, 1.5 mg/mL, 1.0 mg/mL and 
0.5 mg/mL using standard lysis buffer. Standards and protein samples, 2 L each were 
added to 10 mL tubes inclusive of 2 L standard lysis buffer as blank. A volume of 1600 
L MilliQ deionised water (Millipore Corporation, 290 Concord Road, Billerica, MA 
01821, USA) was added to each tube and mixed with 400 L Bradford reagent (0.005% 
Coomassie blue G-250, 5% methanol, and 10% orthophosphoric acid) (Viswanathan et al., 
2006). A volume of 200 L of the above mixture was dispensed into a 96-well flat bottom 
plate and read on Molecular Devices Plate Reader (Molecular Devices, Orleans Drive, 
Sunnyvale, CA 94089-1136, USA) at 595 nm within 60 min of assay.  
 
2.3.2  2-D Quant kit  
A 2-D Quant Kit (GE Healthcare) was used to quantify lysates and serum samples for total 
protein concentration prior to two-dimensional differential in gel electrophoresis (2D-
DIGE) as per the manufacturer‟s guidelines. A standard curve was prepared using 2 
mg/mL bovine serum albumin (BSA) standard solution provided with the kit. The 
standard curve was generated with 0, 5, 10, 15, 20, 25 µL standard solution making up the 
volume with standard lysis buffer. Duplicates and double diluted samples were included in 
the assay. A volume of 500 µL precipitant was added to each tube (including the standard 
curve tubes). Tubes were vortexed briefly and incubated for 2–3 min at room temperature. 
Next, 500 µL co-precipitant was added to each tube and mixed briefly by vortexing or 
inversion. The tubes were centrifuged 10,000 x g for 5 min and then immediately the 
supernatants were decanted. The above process of addition of precipitant, co-precipitant, 
mixing, vortexing and decanting the supernatant was repeated. To avoid resuspension or 
dispersion of the pellets, the tubes were centrifuged again to bring any remaining liquid to 
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the bottom of the tube. A micropipette was used to remove the remaining supernatant from 
the tube with no residual liquid in the tube. A volume of 100 µL copper solution and 400 
µL MilliQ ((Millipore Corp., USA)) was added to each tube. The tubes were vortexed to 
dissolve the precipitated protein and 1 mL working colour reagent was added to each tube, 
mixed, and incubated for 15–20 min at room temperature. The absorbance was read at 480 
nm (Molecular Devices, USA) within 40 min of the addition of working colour reagent.   
 
2.4  2D-DIGE with Minimal CyDyes 
The Minimal CyDye Kit (GE Healthcare) was used to label the liver lysates using the 
manufacturer‟s recommended protocol. Lysates were thawed, vortexed and centrifuged 
before labelling and the pH was adjusted to 8.5 by addition of 1.5 M Tris-HCl pH 8.5. The 
internal standard, a pool of all liver lysates or serum samples (10 µg per sample, 5 Control 
+5 MSS + 5 HSS) was labelled using Cy2; individual samples were labelled with Cy3 and 
Cy5 (Figure 2.1). Ten µg of protein was labelled with 80 pmol of each of the amine 
reactive CyDyes reconstituted in anhydrous dimethylformamide (Sigma-Aldrich) for 30 
min, at 4 °C in the dark. The reaction was quenched by the addition of 1 µL 10 mM lysine. 
Labelled liver lysate and serum samples were combined for electrophoresis as indicated in 
experimental design 1, 2 and 3 that are listed in Appendix A. Additional information about 
DIGE chemistry is discussed in Appendix F. 
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FIGURE 2.2 Minimal CyDye Kit (GE Healthcare) was used to label the liver and serum 
samples. The flow diagram illustrates the procedure followed for combined samples 
electrophoresed on one SDS-PAGE precast gel and protein abundance patterns analysed 
using DeCyder software-Biological variation analysis. (Courtesy: GE Healthcare) 
 
2.5 Electrophoresis  
2.5.1 Isoelectric focusing for pI 4-7 IPG DryStrips 
The 7 cm Immobiline DryStrips, pI 4 to 7 were placed in contact with the 30 g labelled 
protein sample diluted to 125 µL with rehydration buffer containing 2 M thiourea, 7 M 
urea, 2% IPG buffer 3-10 (GE Healthcare), 2% dithiothreitol (DTT), 4% (w/v) CHAPS 
and 0.5% bromophenol blue. The strips were subjected to first dimension separation using 
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an IPGphor™ system (GE Healthcare, Figure 2.4) with the following protocol: 
temperature 20
o
C; current 50 A per strip. 
 
Setting Voltage (v) Time (h) 
S1-Step 300 0:30 
S2-Gradient 1000 0:30 
S3-Gradient 5000 1:25 
S4-Step 5000 0:25 
 Total time: 2:50 h 
 
2.5.2 Isoelectric focusing for pI 6-11 IPG DryStrips 
The 7 cm IPG 6-11 strips (GE Healthcare) were subjected to overnight rehydration 
without the CyDye labelled sample, using 125 µL rehydration buffer containing 2 M 
thiourea, 4 M urea, 1% IPG Buffer 6-11 (GE Healthcare), 2% (w/v) CHAPS, 10% 
isopropanol, 2.5% DTT, 5% glycerol and  0.5% bromophenol blue. Labelled samples were 
diluted to 100 µL with rehydration buffer and incubated overnight in the dark at room 
temperature. A Multiphor II™ system (GE Healthcare, Figure 2.4) was used to focus IPG 
6-11 strips using the following protocol: temperature 20 
o
C; current 2 mA per strip. 
 
Setting Voltage (v) Time (h) 
S1- Step 200 0:01 
S2-Gradient 3500 1:30 
S3-Gradient 3500 1:04 
 Total time: 2:35 h 
 
Samples were loaded by cup loading at the anodic end. The focused strips were 
equilibrated at room temperature for 10 min in equilibration buffer (50 mM Tris pH 8.8, 6 
M urea, 30% glycerol, 2% SDS, 0.5% bromophenol blue) with 1% DTT followed by an 
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equilibration at room temperature for 10 min in equilibration buffer with 2.5% w/v 
iodoacetamide.  
 
2.5.3 Two-dimensional gel electrophoresis 
The equilibrated strips were electrophoresed on NuPAGE® Novex 4-12% Bis-Tris 
ZOOM® Gels, 1.0 mm IPG well (Invitrogen, Carlsbad, CA) using NuPAGE® MOPS 
SDS Running Buffer with the addition of 0.5 mL NuPAGE® Antioxidant (Invitrogen) in 
the inner chamber. To prevent the CyDyes from photo-degradation, all the work was 
carried out in minimal light conditions. 
 
2.6 Scanning of CyDye labelled images 
Gels were scanned using a Fujifilm FLA-5100 (Fuji Photo Film Co., Tokyo, Japan). The 
Cy2, Cy3, and Cy5 images were scanned sequentially. A 473 nm laser and a BPB1/ 
530DF20 emission filter were used to scan Cy2 images. A 532 nm laser and a 
PBG/570DF20 emission filter were used to scan the Cy3 images. A 635 nm laser and a 
DBR1/R665 emission filter were used for the Cy5 images. All gels were scanned at 50 m 
resolution and 16 bits (Beddek et al., 2008).  
 
2.7 Image analysis using DeCyder software 
DIGE gels were analysed for differentially expressed proteins using DeCyder
TM
 2-D 6.5 
software (GE Healthcare). The internal standard was included in all gels and assisted in 
linking protein spots in-gel giving accurate quantitation and minimising the effects of 
variation between gels and each gel was matched to the standard. The Biological Variation 
Analysis (BVA) module was used for matching multiple gels, comparing protein spots and 
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calculating statistics for difference in protein spot abundance (Appendix B). The spot 
detection limit was set to 2500. The difference in protein spots between gels is expressed 
using the average volume ratio between the study groups. „+‟ indicating the increase in 
average volume ratio and „-‟ indicating the decrease in average volume ratio (Table 3.1, 
Table 4.2, Table 4.3, Table 5.1).  
 
The False Discovery Rate (FDR) is a statistical method to interpret the proportion of false 
positives among those proteins that are thought to be significantly changed.  Due to the 
high-dimensionality of the data, the FDR feature was applied as multiple test correction to 
minimise false positive discovery of protein spots and keep the overall error rate low.  The 
data was analysed according to the guidelines for a target power of 0.8 (i.e. a two-fold 
change in average volume ratio can be accepted using four replicates with one-way 
analysis of variance (1-ANOVA)  0.01) (Karp and Lilley, 2005, Karp et al., 2005).  
 
Multivariate analysis was performed by using the DeCyder-Extended Data Analysis 
module with the Principle Component Analysis (PCA) and Hierarchical Cluster Analysis 
(HCA) features. PCA and HCA reduced the multidimensionality of the protein spot data 
across gel images and analysed the protein spots with 2-fold change and 1-ANOVA  0.01. 
Additional information on the DeCyder software analysis is illustrated in Appendix B. 
 
2.8 Spot Picking and enzymatic digestion 
2.8.1 Preparative gels for spot picking 
The preparative gels (75 g protein per gel from Control, MSS and HSS liver lysate and 
serum samples each) NuPAGE® Novex 4-12% Bis-Tris ZOOM® Gels, 1.0 mm IPG well 
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(Invitrogen) were fixed in 50% ethanol, 3% orthophosphoric acid for 1 h followed by 
three washes with MilliQ deionized water (Millipore Corp., USA) of 30 min each. The 
gels were then incubated in a staining solution containing 17% ammonium bicarbonate, 
34% methanol, 3% orthophosphoric acid for 1 h before addition of 0.06% Coomassie G-
250. After a day the gels were washed with MilliQ deionised water three times for 30 min 
each before scanning. Soluble Egg Antigen (SEA) was prepared using 55,000 S. mansoni 
eggs homogenised using glass tissue grinder T4018-15 (Pyrex®, Corning Inc., MA, USA) 
and protein concentration determined as stated earlier (Section 2.3.1). 
 
2.8.2 Scanning of gels 
The gels were scanned using a Molecular Dynamics Scanner, Personal Densitometer SI 
(Sunnyvale, CA, USA), with 50 micron and 12 bit resolution.  
 
2.8.3 Spot excision and digestion  
Spots were excised from the preparative gels using a 1.5 mm Spot Picker Plus (The Gel 
Company, San Francisco, USA) and transferred to v-bottom shaped 96-well 
polypropylene plate (Greiner Bio-One, Germany) containing 100 µL MilliQ in each well. 
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2.8.3.1 Manual method for tryptic digestion of spots 
A step wise procedure was followed for the destaining of gel plugs and in-gel tryptic 
digestion done manually. 
Step Function Cycles Solutions used 
Volume 
required 
Time 
(min) 
1 Washing 2 MilliQ 100 µL 10 
2 Destaining 
1 
50% ACN and 
50 mM NH4HCO3 
100 µL 960 
1 
50% ACN and 
50 mM NH4HCO3 
100 µL 30 
3 Dehydration 1 100% ACN 100 µL 20 
4 
Drying 
(In laminar 
flow hood) 
1 - - 30 
5 Digestion 1 
Trypsin (trypsin 0.05 µg in 10 
µL of 20 mM NH4HCO3) 
10 µL 300 
6 
Peptide 
Recovery 
2 
50% ACN and 
0.1% TFA 
10 µL 15 
1 100% ACN 20 µL 15 
 
2.8.3.2 Ettan Digester method for tryptic digestion of spots 
 The Ettan™ Digester (GE Healthcare) was used with the following protocol. The gels 
plugs were destained by washing four times for 30 min each with 100 µL 50 mM 
ammonium bicarbonate (Sigma-Aldrich), 50% methanol (MERCK) and dried at room 
temperature for 60 min. Ten µL trypsin (0.05 μg/10 µL in 20 mM ammonium bicarbonate) 
(trypsin modified sequencing grade, Roche Diagnostics, Germany) was added to each well 
and the digestion was carried out for 5 h at room temperature. The tryptic digests were 
transferred to a fresh plate and the gel plugs washed with 10 L 0.1% TFA (Sigma-
Aldrich) in 50% ACN (MERCK) for 20 min two times each. At each peptide recovery cycle 
the peptides were transferred into a fresh plate. The digestion and wash solutions were 
collected and combined. All the solutions were made fresh prior to use and were filtered 
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and degassed. The tryptic peptides were dried overnight completely in a laminar flow 
hood.  
 
2.9 Protein identification using mass spectrometry 
2.9.1 Preparation of matrix  
The dried tryptic digests were resuspended in 1 µL of 10 mg/mL -cyano-4-
hydroxycinnamic acid (Sigma-Aldrich) solution prepared in a 50% (v/v) solution of 
ACN/aqueous 0.25% TFA and spotted onto a MALDI plate and air dried prior to mass 
spectrometry.  
 
2.9.2 Collection and analysis of spectra  
All tryptic digests were analysed by MALDI-TOF (Voyager-DE Pro MALDI-TOF Mass 
Spectrometer, Applied Biosystems, Foster City, CA) mass spectrometry. The spectra were 
collected over the range m/z 800– 3500 with approximate laser intensity of 2062, which 
changed  200 according to the size of the protein spot, and 120 laser shots were used. 
Spectra were processed using Data Explorer software (v 5.1, Applied Biosystems) to 
generate monoisotopic peptide masses which were used to identify proteins using Mascot 
Server, ProFound, v2.1.03 against the complete NCBInr and schistosome database 
updated 03/27/2007. Complete cysteine modification by iodoacetamide, methionine partial 
modification by oxidation, 50 ppm peptide tolerance and one missed trypsin cleavage 
were included as search parameters. Criteria for a match included number of 5 or more 
peptides matched, sequence coverage (correct cleavage sites, i.e. does the peptides 
terminate with: R or K) and difference in probability between first and second match 
should be 110-3 (Beddek et al., 2008). Protein spots identified using ProFound search 
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engine were validated against two other protein search engines: Matrix Science Peptide 
Mass Fingerprint and XProteo v1.2.2. 
 
2.9.3 Calibration of spectra 
2.9.3.1 External calibration  
External calibration was performed using the Calibration Mixture 2 of the Sequazyme
TM
 
peptide mass standards kit (Applied Biosystems) containing angiotensin I (m/z 1297.51); 
and fragments of adrenocorticotropic hormone 1–17 (m/z 2094.46), 18–39 (m/z 2466.72). 
One µL Calibration Mixture 2 was mixed with 100 µL CHCA matrix prepared as 
indicated above and spotted in between protein spots on the MALDI plate. Spectra for the 
Calibration Mixture 2 were acquired with the same laser intensity and number of laser 
shots as for the protein spots. 
 
2.9.3.2 Internal calibration 
Internal calibration was performed by using monoisotopic autolytic tryptic peaks (m/z = 
805.41 and 2163.05).   
 
2.10 Western blots 
2.10.1 One-dimensional electrophoresis 
To validate the DIGE experiment data, liver lysate and serum samples were treated with 
NuPAGE LDS sample buffer (4X) and NuPAGE reducing agent (10X) at 70 
0
C for 10 
min and separated by one-dimensional electrophoresis on a NuPAGE® BT Gel 
(Invitrogen). Liver lysates (20 g/well) control mice (n=3), MSS mice (n=3), HSS mice 
(n=3) and soluble egg antigen (20 g/well) were separated on a NuPAGE® BT Gel 
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(Invitrogen) for mouse liver PEPCK, MUP and transferrin western blots. The western blot 
for mouse serum transferrin was carried out using a serum dilution of 1:50 with phosphate 
buffered saline pH 7.4 for control (n=5), 8-week infected (n=10), 12-week infected (n=10) 
and MSS (n=5), and HSS (n=5) groups. A protein concentration of 10 g/well for each 
serum sample was separated on NuPAGE® BT Gel (Invitrogen). 
 
2.10.2 Western blot for mouse liver PEPCK, MUP, transferrin  
The proteins were transferred onto Hybond™-LFP a low-fluorescent, hydrophobic 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare) using a transfer buffer (39 
mM glycine, 48 mM Tris base, 0.037% (w/v) SDS, 20% (v/v) methanol) and probed with 
antibodies against mouse phosphoenolpyruvate carboxykinase (PEPCK), mouse major 
urinary protein (MUP) or mouse and serum transferrin. The proteins were transferred at 25 
V for 2.5 h at 4 
0
C. The membranes were blocked 1 h at room temperature using 5% non-
fat dry milk in Tris-buffered saline (TBST: 0.5 M Tris, 1.5 M NaCl, 0.1% Tween 20 
(Sigma-Aldrich), pH 7.4) for PEPCK and 1% casein (MERCK) in TBST for MUP and 
transferrin. The membranes were washed three times for 5 min with TBST and probed 
with the primary polyclonal antibodies (PEPCK rabbit polyclonal antibody, MUP goat 
polyclonal antibody and transferrin goat polyclonal antibody (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA) at a 1: 600 dilution overnight at 4 °C followed with three 
washes for 5 min with TBST.  The membranes were then incubated for 2 h with secondary 
Cy5-labelled anti-rabbit and anti-goat antibodies respectively (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) with dilution 1: 2000 at room temperature. Mouse 
anti-actin monoclonal antibody (CHEMICON International, Inc., Millipore, CA, USA) 
was used as a loading control with Cy3-labelled anti-mouse antibody (Jackson 
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ImmunoResearch Laboratories). Protein bands were visualised using a Fujifilm FLA-5100 
scanner (Fuji Photo Film Co.). ImageQuant™ 5.2v (GE Healthcare) software was used to 
analyse protein band volumes.  
 
2.10.3 Western blot for serum keratin D (cytokeratin 18) and transferrin  
Mouse and human serum samples with protein 10 g/well were separated by one-
dimensional electrophoresis using Bio-Rad Laboratories Criterion
TM
 Precast Gel (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) for 1 h at 200 V. The proteins were transferred at 
25 V for 1 h at 25 
0C onto Immobilon™-P PVDF Membrane (Millipore Corp., Sigma 
Aldrich, USA) using a transfer buffer (192 mM glycine, 25 mM Tris base, 0.037% (w/v) 
SDS, 20% (v/v) methanol) and probed with antibodies against keratin D/ cytokeratin 18. 
The membranes were blocked 1 h at room temperature using 1% casein in phosphate-
buffered saline (PBST: 0.1 M PBS, 0.1% Tween 20 (Sigma-Aldrich), pH 7.4). The 
membranes were washed three times for 5 min each with PBST and probed with 
cytokeratin 18 goat polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA) at 1: 600 dilution overnight at 4 °C followed with three washes for 5 min each with 
PBST.  The membrane was incubated for 2 h at room temperature with secondary Cy5-
labelled anti-goat antibody (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA) with 1: 2000 dilution. GAPDH rabbit polyclonal antibody (Santa Cruz 
Biotechnology, Inc.) was used as a loading control with Cy3-labelled anti-rabbit antibody 
(Jackson ImmunoResearch Laboratories). Mouse serum was diluted 1:50 with phosphate 
buffered saline pH 7.4 for transferrin western blot analysis. Ten g/L/well sample from 
control (n=5), 8-week (n=10), 12-week (n=10) and MSS (n=5) and HSS (n=5) infected 
mice was separated on SDS-PAGE gel, transferred to Hybond™-LFP PVDF membrane 
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(GE Healthcare) and probed with goat anti-transferrin polyclonal antibody (Santa Cruz 
Biotechnology, Inc.) followed by Cy5-labelled anti-goat IgG (Jackson ImmunoResearch 
Laboratories). Fluorescence intensity of protein bands was visualised using a Fujifilm 
FLA-5100 scanner (Fuji Photo Film Co.) and protein band volumes were analysed using 
ImageQuant™ 5.2v (GE Healthcare) software. 
 
2.11 Serum connective tissue growth factor (CTGF) development assay 
A human CTGF-ELISA Development Kit (Leinco Technologies, Inc., MO, USA) was 
used to measure CTGF. A 96-well microplate (Immulon 2B, Nunc, Thermo Fisher 
Scientific, Inc., Rochester, NY, USA) was coated with 50 µL capture antibody (rabbit 
anti-human polyclonal antibody, conc. 1 µg/mL) in 10 mL PBS (1: 200) pH 7.2 overnight 
at room temperature. The plate was washed 4 times with 300 µL wash buffer per well and 
blotted dry. The microplate was blocked with 300 µL blocking buffer (1% bovine serum 
albumin in PBS pH 7.2) for 1 h at room temperature. The standard (recombinant human-
CTGF) preparation was achieved by dilution of 3 µL kit standard (1000, 000 pg/mL) with 
747 µL diluent to generate a standard of concentration 4000 pg/mL (1:250). The 4000 
pg/mL standard was serially double diluted to generate a standard curve. After washing 
the plate as done previously, 100 µL standards (in triplicate) and serum samples (in 
duplicate) were added to each well and incubated at room temperature for 2 h. After 4 
washes, 100 µL detection antibody (biotinylated antigen-affinity purified rabbit anti-
human CTGF, concentration 0.25 μg/ml) was added per well (1: 200). With an incubation 
of 2 h at room temperature and after 4 washes, 100 µL ultra-avidin-horseradish 
peroxidise-conjugate per well (1:2000) was added. An incubation of 20 min in the dark at 
room temperature was followed by 4 washes. A volume of 100 µL TMB horseradish 
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peroxidase-substrate solution was added to each well and incubated at room temperature 
for 20 min. To stop the reaction 50 µL 1 M H2SO4 was added and colour development was 
monitored for 30 min with a plate reader at 450 nm (Molecular Devices, USA).  
 
2.12 Liver hydroxyproline assay 
Weighed liver samples were hydrolysed in 5 mL of 6 M HCl for 18 h at 110 °C in tightly 
sealed glass tubes (Montesano et al., 2002). After cooling, 40 mg Dowex / Norit mixture 
(Sigma-Aldrich) and 5 ml distilled water were added to each hydrolysate. The mixture was 
centrifuged for 15 min at 2000 rpm at 25 °C, and the supernatant fluid was filtered through 
#1 Whatman 9.0 cm filter paper into a clean tube. A volume of 2 mL of the filtrate was 
neutralised by adding one drop of 1% phenolphthalein and then titrated against 10 M 
NaOH until pink and neutralised using 3 M HCl till the filtrate turned yellow. The final 
volume was adjusted to 4 mL with MilliQ. To make a stock standard (400 g/mL), 40 mg 
hydroxyproline (Calbiochem Corporation, La Jolia, CA, USA) was dissolved in 100 mL 
MilliQ water. One mL stock and 9 mL MilliQ were mixed to prepare a working standard 
(40 g/mL). A standard curve was generated with concentrations 0, 10, 20, 30, 40 g/mL 
respectively using MilliQ water for dilutions. To 200 L of neutralised liver hydrolysate 
or the above standards, 400 L isopropanol was added and mixed. A volume of 200 L 
freshly prepared oxidant solution (chloramine-T/citrate buffer, pH 6.0) was added with 
mixing and incubated at 25 °C for 4 min. To the above mixture, 2500 µL freshly prepared 
Ehrlich's Reagent Solution was added, mixed, and incubated at 60 °C for 25 min. The 
tubes were cooled and the absorbance read at 570 nm using a microplate reader 
(Molecular Devices, USA). Hydroxyproline levels were expressed as µg. 
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2.13 Serum hydroxyproline assay 
One hundred microlitres of serum was hydrolysed using 400 L 6 M HCl for 3 h at 120 
°C in tightly sealed glass tubes (Uji et al., 1994). After cooling, 10 mg Dowex / Norit 
mixture (Sigma-Aldrich) was added to each hydrolysate. The mixture was centrifuged for 
15 min at 4000 rpm at 25 °C, and the supernatant fluid was filtered through Millex
R
-GV, 
Low Protein Binding Durapore (PVDF) membrane, 0.22 m filter (Millipore, USA) unit 
into a clean 1.5 mL tube. Fifty microliter filtrate was neutralised by adding 1 L of 1% 
phenolphthalein and then titrated against 10 M NaOH until pink and neutralised using 3 M 
HCl till the filtrate turned yellow. The final volume was adjusted to 100 L with MilliQ. 
The standard was prepared similarly as for liver hydroxyproline assay. A volume of 12.5 
µL neutralised hydrolysate and standards were added to each well of a 96-well microplate 
and mixed followed by 25 µL isopropanol. Freshly prepared oxidant solution (chloramine-
T/citrate buffer, pH 6.0), 12.5 µL was added to each well with mixing and incubated at 25 
°C for 4 min. Ehrlich's Reagent solution was freshly prepared and 155 µL was added to 
each well, mixed, and incubated at 60 °C for 25 min. The plate was cooled and the 
absorbance read at 570 nm using a microplate reader (Molecular Devices, USA). 
Hydroxyproline levels were expressed as µg per mL serum. 
 
2.14 Serum transferrin assay 
A serum transferrin assay kit (Alpha Diagnostic Intl., Inc., San Antonio, TX, USA) was 
used for human serum transferrin measurement. All reagents were brought to room 
temperature before use. Human serum samples were diluted to 1:20000 using sample 
diluent. A volume of 300 µL wash buffer was added to each well for 30 min before 
sample addition to activate the pre-coated plate. The plate was washed 4 times and patted 
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dry. One hundred microlitres of standards diluted human serum samples or controls were 
added each to pre-determined wells and incubated for 60 min at room temperature. After 
washing the plates 4 times, 100 µL diluted anti-human transferrin-horseradish peroxidise-
conjugate (1: 1000) was added to each well and incubated for 30 min. The plate was 
washed 5 times before adding 100 µL TMB substrate (Kirkegaard and Perry Laboratories, 
Inc., Gaithersburg, MD, USA) and incubated for 15 min in the dark. A volume of 100 µL 
of 2 M H2SO4 was added to stop the enzyme reaction. The absorbance was read at 450 nm 
(Molecular Devices, USA) within 30 min of addition of H2SO4.  
 
2.15 Bicinchoninic acid (BCA) protein determination assay 
BCA protein assay (Pierce, Pierce Chemical, Rockford, Illinois, USA) was used for mouse 
and human serum total protein measurements. 1X PBS pH 7.4 was used for standard 
preparations and sample dilutions. Fresh working BCA reagent was prepared by mixing 5 
mL BCA Reagent A (Pierce, USA) with 100 L BCA Reagent B (Pierce, USA) to form a 
clear green solution. The dilution for each sample was 1:10. The final volume of each 
sample in the microplate was set to 20 L. The standard curve for the assay was generated 
by using 2 mg/mL albumin standard (Pierce, USA). The serial dilutions from 2.0 to 0.25 
mg/mL were done using 1X PBS. Twenty microliter from each of the albumin standards 
and the diluted mouse and human serum samples was assayed in 96-well microplate. A 
volume of 150 µL freshly prepared BCA reagent was added to each well and mixed. The 
plate was incubated in a 37-40 
0
C water bath for 20 min and absorbance read at 570 nm 
(Molecular Devices, USA). 
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2.16 Statistical Analysis 
Individual protein spot volumes extracted from the DeCyder software and western blot 
band volume data acquired form Image Quant and human serum samples data from CDC, 
Atlanta  were analysed using GraphPad Prism (v4.0, GraphPad, San. Diego, CA, USA). 
Protein spot Gene Ontology functional data was generated manually using UniProtKB 
database and plotted using SPSS (v16.0.1, SPSS Inc, Chicago, Illinois, USA). Multiple 
regression analyses were performed using SPSS. For statistical analysis spot volumes with 
skewed distribution (for five study groups: transferrin, RBP1, keratin D, interleukin2, 
MUP, Sm-PEPCK, peroxiredoxin6, GSTPi) were logarithmically (loge) transformed to 
satisfy the assumption of normality according to the statistics applicable to 2D-DIGE 
dataset spot volumes (Chich et al., 2007). 
 
Details of reagents and experimental procedures are listed in Appendix D. 
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CHAPTER 3: DIFFERENTIAL PATTERNS OF MURINE 
LIVER PROTEINS AT 20-WEEK POST-INFECTION (MSS 
AND HSS)  
 
3.1 Introduction 
In 90% of infected individuals egg-associated inflammation recedes resulting in INT while 
10% present with HS. The CBA/J mouse model reproduces these forms of the disease 
found in infected humans. Liver proteomic signatures from control (uninfected), MSS and 
HSS CBA/J mice were compared to identify differential protein patterns for 20-week 
infection. 2D-DIGE was used to study protein patterns and the candidate liver protein 
markers were identified using matrix adsorption laser desorption ionisation-time of flight 
(MALDI-TOF), correlated to the development of hypersplenomegaly syndrome and 
verified using western blot techniques to confirm the association pattern. The 
experimental design 1 for DIGE experiments is listed in Appendix A. 
 
3.2 Results  
All of the 20-week S. mansoni-infected CBA/J mice had enlarged, fibrotic and 
granulomatous livers, and were classified as MSS or HSS by percent spleen to body 
weight ratio and gross pathologic characteristics. The average percent spleen to body 
weight ratio for uninfected mice was 0.272, for MSS mice 0.578 and for HSS mice it was 
2.314 (Figure 3.1). The spleen to body weight ratio for MSS was 2 times and HSS was 8.5 
times more than the control mice. This ratio is a robust measure of the pathology 
associated with HSS. 
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FIGURE 3.1 Comparison of percent spleen to body weight ratio from fifteen CBA/J mice 
(5 controls, 5 MSS, 5 HSS), 1-ANOVA p ≤ 0.01. ***p ≤ 0.001 HSS compared to MSS 
and control mice by Newman-Keuls Multiple Comparison Test. 
 
 
FIGURE 3.2: A pseudocolour map of total liver proteins from uninfected and HSS mice 
separated by 2D-DIGE. Liver lysate from control/uninfected liver was labelled with Cy5 
(green), lysates from 20-week infected HSS liver was labelled with Cy3 (red) and a pooled 
internal standard of liver lysates from all mice in the study (n=15) was labelled with Cy2 
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(blue; not shown). Isoelectric focusing was performed on 7 cm IPG strips, pI 4-7 and pH 
6-11 and proteins were then separated using SDS-PAGE. The image overlays of Cy5 and 
Cy3 labelled proteins appear yellow. The numbers correspond to the numbers (No.) of 
protein spots in Table 3.1. Note that the MUP (protein spots 45-49) are green showing 
high abundance in control mice and collagen (protein spots 16-23) are red showing high 
abundance in HSS mice. 
 
Figure 3.2 is a pseudocolour map of superimposed 2D-DIGE images for pI 4-7 and 6-11 
IPG DryStrips; and compares control liver lysate to 20-week infected HSS liver lysate. 
The DeCyder software detected 2550 spots each in the 4-7 and 6-11 pI range using the 
BVA module. The number of protein spots that changed for 4-7 and 6-11 pI ranges were 
295 and 129, respectively.  Furthermore, 134 and 38 protein spots in 4-7 and 6-11 pI 
ranges showed  2-fold change in average volume ratio with ANOVA p  0.01; these 
were designated as proteins of interest. Application of false discovery rate (FDR) to 
remove false positives gave a total of 107 and 17 protein spots for each pI range 
respectively (although the application of FDR eliminated the false positive protein spots, 
we believe that these eliminated protein spots may be important in the pathogenesis of 
schistosomiasis). The 124 spots were subjected to MALDI-TOF mass fingerprinting and 
matched to database sequences, resulting in the identification of 80 protein spots listed in 
Table 3.1 (Figure 3.2 and Table A1). Additional information of the identified protein spots 
is listed in Appendix C. 
 
The identified 80 protein spots were assessed according to the Gene Ontology molecular 
function categories. In particular, structural proteins, immune response proteins and acute 
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phase proteins showed increased abundance while the proteins related to energy 
metabolism; choline metabolism and xenobiotic metabolism were decreased in abundance 
(Figure 3.3). These specific protein spot changes will be discussed in the following 
sections in the context of these functional categories. 
 
 
FIGURE 3.3 Distribution of protein abundance by Gene Ontology molecular function 
categories, during the development of chronic schistosomiasis. APP, acute phase protein; 
CHO, Choline Metabolism; EGM, energy metabolism; IMM, immune response; MYL, 
methylation; PRF, protein folding; ROX, redox reactions; STR, structural protein; XBM, 
xenobiotic metabolism. 
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TABLE 3.1: Experiment design 1: Identified protein spot comparisons for 20-week 
infected mice (MSS and HSS) with control mice for pI ranges 4-7 and 6-11 with 2-fold 
change, 1-ANOVA p ≤ 0.01 and FDR. 
Spot 
No. 
Protein ID 
(pI 4-7) 
AVR1 
H/C 
AVR1 
M/C 
AVR1 
H/M 
gi 
Number 
pI1 
Mw1 
(kDa) 
Func. 2 Ref.1 
1 Actin +2.12 +1.81 +1.17 809561 5.8 39.45 STR (Harvie et al., 2007) 
2 Actin +2.39 +2.04 +1.17 49868 5.8 39.45 STR (Harvie et al., 2007) 
3 Albumin +3.26 +1.88 +1.73 19353306 5.8 70.73 APP (Harvie et al., 2007) 
4 Albumin +2.84 +1.71 +1.66 33859506 5.8 70.73 APP (Harvie et al., 2007) 
5 Albumin +2.83 +1.73 +1.63 19353306 5.8 70.73 APP (Harvie et al., 2007) 
6 Albumin -2.13 -1.51 -1.41 26341396 5.5 67.04 APP (Harvie et al., 2007) 
7 
Aldehyde 
dehydrogenase 9 
+2.87 +1.90 +1.51 9910128 6.6 54.47 ROX 
(Dragani et al., 1996, 
Vasiliou et al., 2000) 
8 Annexin 5 +4.52 +2.17 +2.08 6753060 4.8 35.78 SIG (Mulla et al., 2004) 
9 
ATP5 beta 
synthetase (ATPS) 
-2.05 -1.88 -1.09 23272966 5.2 56.65 EGM 
(Capuano et al., 1997, 
Harvie et al., 2007) 
10 ATPS -2.13 -1.72 -1.24 23272966 5.2 56.65 EGM 
(Capuano et al., 1997, 
Harvie et al., 2007) 
11 
Betaine 
homocysteine  
methyltransferase 2 
+3.80 +2.54 +1.50 62533211 6.0 40.28 MYL 
(Forestier et al., 2003, 
Sun et al., 2007) 
12 
Brain and 
reproductive organ-
expressed protein 
+3.04 +2.08 +1.46 38173925 5.7 43.95 APO 
(Chen, 2008, Li et al., 
2004) 
13 
Carbamoyl 
phosphate synthase 
-2.60 -1.87 -1.39 73918911 6.5 165.8 EGM 
(Harvie et al., 2007, 
Thome-Kromer et al., 
2003) 
14 
Chaperonin 
containing TCP-1 
theta subunit 
(Chaperone CCT8) 
-2.85 -1.78 -1.60 5295992 5.4 60.06 PRF 
(Agaton et al., 2003, 
Harvie et al., 2007) 
15 Collagen 6a1 +17.8 +12.2 +1.45 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
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16 Collagen 6a1 +47.8 +32.3 +1.48 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
17 Collagen 6a1 +55.8 +36.2 +1.54 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
18 Collagen 6a1 +47.8 +31.9 +1.50 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
19 Collagen 6a1 +34.7 +24.2 +1.43 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
20 Collagen 6a1 +21.0 +15.5 +1.36 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
21 Collagen 6a1 +10.2 +7.81 +1.30 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
22 Collagen 6a1 +5.38 +4.94 +1.09 12805443 5.8 44.76 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
23 Collagen XIV +5.13 +2.40 +2.13 30420885 5.0 194.3 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
24 Collagen XIV +4.27 +2.78 +1.54 30420885 5.0 194.3 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
25 Collagen XIV +7.13 +3.61 +1.97 30420885 5.0 194.3 STR 
(Saber et al., 1983, 
Stickel et al., 2001) 
26 
Dimethylglycine 
dehydrogenase 
(DMDH) 
-2.04 -1.71 -1.20 59808083 7.8 97.44 CHO (Harvie et al., 2007) 
27 DMDH -2.21 -1.74 -1.27 59808083 7.8 97.44 CHO (Harvie et al., 2007) 
28 DMDH -2.34 -1.76 -1.33 59808083 7.8 97.44 CHO (Harvie et al., 2007) 
29 
Epoxide hydrolase 
(EH) 
-2.46 -1.78 -1.38 15929294 5.9 63.07 XBM (Murray et al., 1993) 
30 EH -2.41 -2.03 -1.19 15929294 5.9 63.07 XBM (Murray et al., 1993) 
31 EH -2.82 -1.85 -1.52 15929294 5.9 63.10 XBM (Murray et al., 1993) 
32 
Formyl 
tetrahydrofolate 
dehydrogenase (10-
FTHFDH) 
-2.52 -1.49 -1.69 20380027 5.6 99.55 MYL 
(Krupenko and Oleinik, 
2002, Vasiliou et al., 
2000) 
33 10-FTHFDH -2.56 -1.43 -1.79 20380027 5.6 99.55 MYL 
(Krupenko and Oleinik, 
2002, Vasiliou et al., 
2000) 
34 10-FTHFDH -2.28 -1.54 -1.48 23271467 5.6 99.55 MYL 
(Krupenko and Oleinik, 
2002, Vasiliou et al., 
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2000) 
35 10-FTHFDH -2.36 -1.51 -1.56 20380027 5.6 99.55 MYL 
(Krupenko and Oleinik, 
2002, Vasiliou et al., 
2000) 
36 10-FTHFDH -2.47 -1.70 -1.46 23271467 5.6 99.55 MYL 
(Krupenko and Oleinik, 
2002, Vasiliou et al., 
2000) 
37 Glucosidase II  +3.53 +2.47 +1.43 57013837 4.4 59.74 PRF 
(Altmann, 2007, Rudd 
et al., 2001) 
38 Glucosidase II  +2.47 +2.13 +1.16 57013837 4.4 59.74 PRF 
(Altmann, 2007, Rudd 
et al., 2001) 
39 
Group specific 
component 
+2.89 +1.81 +1.60 51172612 5.4 55.18 APP 
(Meier et al., 2006, 
Schiødt, 2008) 
40 Keratin D +2.43 +1.52 +1.60 293682 5.3 47.47 STR 
(Boehme et al., 1989, 
Salmhofer et al., 1994) 
41 
Lymphocyte 
cytosolic protein 1 
(Plastin 2) 
+4.17 +3.06 +1.36 26326929 5.2 70.77 PRF 
(Strathmann et al., 
2007) 
42 Plastin 2 +3.24 +2.45 +1.32 26326929 5.2 70.77 PRF 
(Strathmann et al., 
2007) 
43 
Major urinary 
protein (MUP) 
-8.11 -1.69 -4.80 53271 4.8 17.71 PHE (Dragani et al., 1989) 
44 MUP -7.54 -1.50 -5.02 12851568 4.8 17.71 PHE (Dragani et al., 1989) 
45 MUP -10.3 -2.61 -3.96 13276755 4.8 17.71 PHE (Dragani et al., 1989) 
46 MUP -5.56 -2.35 -2.37 494384 4.8 17.71 PHE (Dragani et al., 1989) 
47 MUP -3.51 -1.50 -2.34 38488789 4.8 21.73 PHE (Dragani et al., 1989) 
48 
Myosin light 
polypeptide 6 
-2.15 -1.68 -1.28 33620739 4.6 17.09 STR (Wegrzyn et al., 2006) 
49 
NADH 
dehydrogenase 
(Ubiquinone) Fe-S 
protein 1 
-2.12 -1.75 -1.21 21704020 5.5 80.76 EGM (Blanc et al., 2005) 
50 
Protein disulfide-
isomerase A3, 
Erp57 
+3.17 +1.94 +1.63 26353794 5.8 57.12 ROX 
(Harvie et al., 2007, 
Santos et al., 2007) 
51 Pyruvate -3.44 -2.17 -1.58 26346581 6.1 103.8 EGM 
(Hammond and 
Balinsky, 1978, Harvie 
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carboxylase et al., 2007) 
52 
Pyruvate 
carboxylase 
-2.35 -1.72 -1.36 26346581 6.1 103.8 EGM 
(Hammond and 
Balinsky, 1978, Harvie 
et al., 2007) 
53 
Retinol binding 
protein Type- I 
+2.73 +1.91 +1.43 21730472 5.1 15.86 APP (Uchio et al., 2002) 
54 
Ribonuclease/angio
genesis inhibitor 
+2.15 +2.16 -1.00 14577933 4.6 51.21 IMM (Chu et al., 2003) 
55 
S-Adenosyl 
homocysteine 
hydrolase 
-2.10 -1.68 -1.25 63471580 6.1 48.08 MYL (Leal et al., 2008) 
56 
Sarcosine 
dehydrogenase 
(SARDH) 
-2.16 -1.35 -1.59 26352359 6.4 57.84 CHO (Lim et al., 2002) 
57 SARDH -2.80 -1.46 -1.92 26352359 6.4 57.84 CHO (Lim et al., 2002) 
58 SARDH -6.43 -3.23 -1.99 26352359 6.4 57.84 CHO (Lim et al., 2002) 
59 
Selenium binding 
protein 2 (SBP2) 
-3.66 -2.40 -1.53 188848341 5.8 53.16 XBM 
(Harvie et al., 2007, 
Henkel et al., 2006) 
60 SBP2 +2.99 +1.63 +1.84 18848341 6.0 52.90 XBM 
(Harvie et al., 2007, 
Henkel et al., 2006) 
61 
Succinate 
dehydrogenase Fp 
subunit 
-2.33 -1.81 -1.29 15030102 6.2 59.27 EGM (Blanc et al., 2005) 
62 Transferrin +2.83 +1.43 +1.98 62027488 7.0 78.87 APP (Harvie et al., 2007) 
63 Transferrin +4.17 +1.66 +2.52 62027488 7.0 78.87 APP (Harvie et al., 2007) 
64 Transferrin +4.72 +1.71 +2.76 62027488 7.0 78.87 APP (Harvie et al., 2007) 
65 Transferrin +4.60 +1.68 +2.74 62027488 7.0 78.87 APP (Harvie et al., 2007) 
66 Tropomyosin 3 +2.19 +1.61 +1.37 26341416 4.7 27.88 STR 
(Harvie et al., 2007, 
Otogawa et al., 2009) 
67 
Valosin containing 
protein 
+4.76 +3.68 +1.29 26350783 5.1 80.70 PRF 
(Yamamoto et al., 
2003) 
68 Vimentin +2.31 +2.67 -1.16 31982755 4.9 53.73 STR 
(Boehme et al., 1989, 
Harvie et al., 2007) 
69 Vimentin +2.54 +2.68 -1.06 31982755 4.9 53.73 STR 
(Boehme et al., 1989, 
Harvie et al., 2007) 
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No. 
Protein ID  
(pI 6-11) 
AVR1 
H/C 
AVR1 
M/C 
AVR1 
H/M 
gi 
Number 
pI1 
Mw1 
(kDa) 
Func. 2 Ref. 1 
70 
Aldehyde 
dehydrogenase A1 
-2.62 -2.02 -1.41 32484332 8.3 55.08 ROX 
(Dragani et al., 1996, 
Vasiliou et al., 2000) 
71 Catalase 1 -3.00 -2.61 -1.15 15004258 7.8 60.01 ROX 
(Gharib et al., 1999, 
Harvie et al., 2007) 
72 
Glutamate 
dehydrogenase 
-2.76 -2.12 -1.30 26354278 8.6 61.60 EGM 
(Morand et al., 2005, 
Van Waes and Lieber, 
1977) 
73 
Glutathione S-
transferase Pi class 
-3.27 -2.05 -1.59 2624496 8.3 23.52 XBM 
(Harvie et al., 2007, 
Hayes et al., 1991) 
74 
MHC class I H2 Q4 
like 
+5.01 +3.23 -1.55 51770518 7.3 71.74 IMM 
(Grzych et al., 1991, 
Hernandez et al., 1997) 
75 
MHC class I H2 Q4 
like 
+8.09 +4.88 -1.66 51770518 7.3 71.74 IMM 
(Grzych et al., 1991, 
Hernandez et al., 1997) 
76 
MHC class I H2 Q4 
like 
+12.2 +7.29 -1.67 51770518 7.3 71.74 IMM 
(Grzych et al., 1991, 
Hernandez et al., 1997) 
77 
MHC class I H2 Q4 
like 
+18.3 +11.6 -1.58 51770518 7.3 71.74 IMM 
(Grzych et al., 1991, 
Hernandez et al., 1997) 
78 
MHC class I H2 Q4 
like 
+17.2 +10.4 -1.66 51770518 7.3 71.74 IMM 
(Grzych et al., 1991, 
Hernandez et al., 1997) 
79 
Sm-Phosphoenol 
pyruvate 
carboxykinase 
+14.4 +8.05 -1.79 74828716 6.8 71.46 GLN (Asahi et al., 2000) 
80 Prohibitin-2 +3.25 +1.61 +2.02 
61556754 
(76363295) 
9.8 33.29 PRF 
(Asamoto and Cohen, 
1994, Mishra et al., 
2005) 
 
1
AVR: average volume ratio between study groups (C, control; M, MSS; and H, HSS); pI: 
isoelectric pH; Mw: molecular weight; Ref: references refer to association of protein with 
various diseases.  
2
Func (Functions): APO, anti-apoptotic; APP, acute phase protein; CHO, Choline 
Metabolism; EGM, energy metabolism; GLN, gluconeogenesis; IMM, immune response; 
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MYL, methylation; PHE, pheromone; PRF, protein folding; PRM, protein metabolism; 
ROX, redox reactions; SIG, cell signalling; STR, structural protein; XBM, xenobiotic 
metabolism. 
 
3.2.1 Acute phase proteins 
Nine negative acute phase protein spots (4 transferrins, 3 albumins, 1 retinol binding 
protein, 1 group specific component) increased in abundance due to schistosome infection, 
while one spot in particular for albumin decreased in abundance. The greatest changes 
were found with the transferrin spots. Overall transferrin abundance increased from 2.8 to 
4.7 fold for HSS mice and as spot volumes for transferrin isoforms changed with 
schistosome infection. Specifically spots 63, 64 and 65 increased significantly by 4-fold 
and 2-fold for HSS when compared to control and MSS mice (Table 3.1 and Figure 3.2, 
Figure 3.4) indicating a disease form specific change. 
 
 
FIGURE 3.4 Comparison of spot volumes of transferrin spots, 1-ANOVA p ≤ 0.01 for all 
spots. *p ≤ 0.001 HSS compared to control, # p ≤ 0.01 compared to MSS, @p ≤ 0.05 MSS 
compared to control by Newman-Keuls Multiple Comparison Test. 
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The spot volume data for albumin isoforms, another negative acute phase protein, showed 
three spots (spot 3, 4, 5; Figure 3.5) with increased abundance while one spot (spot 6) 
decreased with abundance. Group specific component (GSC) spot (Spot 29, Figure 3.2, 
Table 3.1) showed increased abundance in HSS mice alone. Similarly, retinol binding 
protein-1 (RBP1) spot (Spot 53, Figure 3.2, Table 3.1, Figure 3.7) showed increased 
abundance in HSS mice. The spot volume comparison for RBP1 showed 2-fold increase 
for HSS and MSS mice and was statistically significant. Ideally, negative acute phase 
proteins decrease with any infection and/or pathology, but our results are in contrast with 
this pattern and suggest that these changes during schistosomiasis are unique.   
 
 
FIGURE 3.5 Comparison of spot volumes of albumin spots, 1-ANOVA p ≤ 0.01 for all 
spots. *p ≤ 0.01 compared to control, #p ≤ 0.05 compared to MSS by Newman-Keuls 
Multiple Comparison Test. 
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3.2.2 Structural proteins 
Overall, the extracellular matrix and cytoskeletal proteins increased in abundance. A total 
of 16 structural protein spots increased in abundance in response to schistosome infection. 
As expected collagen 6a1 spot volumes were increased by 5-fold to 55-fold and collagen 
XIV spot volumes increased from 4-fold to 7-fold significantly. Taking all the spot 
volumes together for collagen 6a1 protein, the increase was almost 300-fold for HSS mice 
and 165-fold for MSS mice when compared to control mice (Figure 3.2, Figure 3.6 and 
Table 3.1). These changes are in line with the known fibrotic changes that occur during 
chronic infection. 
 
Like collagen, two actin spots (spots 1, 2) and two vimentin (spots 68, 69) spots (Figure 
3.2, Table 3.1, Figure 3.7) increased in abundance from 2-fold to 2.6-fold. A single keratin 
D spot (spot 40) increased in the severe disease. Spot volume comparison for keratin D 
between control, MSS and HSS was significant (1-ANOVA p ≤ 0.05, Figure 3.8). These 
results are likely due to the granulomatous response to the eggs embedded in the liver 
which involved increased deposition of extracellular matrix components like collagen, 
actin, vimentin and keratin D. 
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FIGURE 3.6 Comparison of spot volumes of collagen spots, 1-ANOVA p ≤ 0.01 for all 
spots. *p ≤ 0.05 compared to control, #p ≤ 0.05 compared to MSS by Newman-Keuls 
Multiple Comparison Test. 
 
 
FIGURE 3.7 Comparison of spot volumes of various liver protein spots, 1-ANOVA p ≤ 
0.01 for all spots. *p ≤ 0.05 compared to control, #p ≤ 0.05 compared to MSS by 
Newman-Keuls Multiple Comparison Test. RBP-1=Retinol Binding Protein 1. 
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FIGURE 3.8 Comparison of spot volume for spot 40-Keratin D, 1-ANOVA p ≤ 0.05 for 
all spots. Newman-Keuls Multiple Comparison Test for comparison between groups was 
not significant. 
 
3.2.3 Energy metabolism proteins 
There was a decrease in seven protein spots related to energy metabolism. Two spots with 
ATP synthase-beta subunit (ATPase beta) activity showed 2-fold decreased abundance 
(spots 9, 10, Figure 3.2, Table 3.1). Additionally, two spots of pyruvate carboxylase, one 
spot of NADH dehydrogenase (ubiquinone) Fe-S protein 1, one spot of glutamate 
dehydrogenase (GLDH) and one spot of carbamoyl phosphate synthase 1 were decreased 
in abundance by above two fold (Table 3.1). Based on these results it can be presumed 
that energy metabolism capacity is decreased during 20-week schistosomiasis infection. 
 
3.2.4 Choline metabolism proteins 
There was decreased abundance of two proteins associated with choline catabolism, 
dimethylglycine dehydrogenase (DMDH, spots 26-28) and sarcosine dehydrogenase 
(SARDH, spots 56-58) (Figure 3.2, Table 3.1, Figure 3.9). These six protein spots 
decreased significantly in MSS and HSS mice compared to control mice and indicate that 
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infection but not disease form-specific changes. These decreases could mean that there are 
alternative pathways for choline utilisation during schistosome infection.  
 
 
FIGURE 3.9 Comparison of spot volumes of dimethylglycine dehydrogenase and 
sarcosine dehydrogenase spots, 1-ANOVA p ≤ 0.01 for all spots. *p ≤ 0.05 compared to 
control, #p ≤ 0.05 compared to MSS by Newman-Keuls Multiple Comparison Test. 
 
3.2.5 Xenobiotic metabolism proteins 
During disease and infection, xenobiotic metabolising proteins are increased providing 
protection to the host from harmful molecules such as free radicals. The overall decreased 
abundance of these protein spots in schistosomiasis infection may be explained by 
decreased synthesis during disease condition and may indicate an impaired ability to deal 
with oxidative stress. Five spots decreased and two spots increased in abundance related to 
xenobiotic metabolism. Catalase (Spot 71, Figure 3.2, and Table 3.1) was decreased by 3-
fold in HSS mice and 2-fold in MSS mice. Two spots of selenium binding protein-2 
(SBP2) were identified, one with increased activity (+2.99, pI 6.0) and other with 
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decreased activity (-3.66, pI 5.8). Glutathione S-transferase Pi (GSTPi) was decreased by 
above 3-fold in HSS and above 2-fold in MSS mice. Three epoxide hydrolase spots 
showed decreased abundance by 2-fold for HSS mice and two spots for MSS mice. Also, 
two spots with aldehyde dehydrogenase activity were identified, one spot with pI 6.6 
showed increased expression of 2.8-fold while one spot with pI 8.3 showed 2.6 and 2.0-
fold decreased activity in HSS and MSS mice respectively (Figure 3.2, Table 3.1).  
 
3.2.6 DNA methylation-related proteins 
Protein spots related to DNA methylation showed overall decreased abundance. Five spots 
decreased in abundance and two spots showed increased abundance. One spot of betaine-
homocysteine S-methyltransferase (BHMT) was identified (Figure 3.2, Table 3.1, spot 11). 
The acidic spot showed 2.5 to 3.8-fold increase in abundance in schistosome infection. 
One spot with S-adenosylhomocysteine hydrolase (SAH) activity was increased by 2-fold. 
Five spots of 10-formyl tetrahydrofolate dehydrogenase (10-FTHDH) were decreased by 
above 2-fold in HSS mice alone (Figure 3.2, Table 3.1, spot 32-36). The proteins 
discussed in this category are associated with metabolic processes that are involved in 
synthesis of methyl groups. These methyl groups are used for methylation of DNA, which 
is necessary for the proper functioning of the DNA. The decreased abundance of these 
proteins in our study may suggest an imbalance in DNA methylation and function.  
 
3.2.7 Immune response proteins 
Given the involvement of the immune response in schistosomiasis, it is not surprising that 
significant changes occurred in this functional category. In MSS and HSS mice, there was 
a 2-fold to 18-fold significant increased abundance of MHC class I histocompatibility 
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antigen H2 Q4 alpha chain precursor like (MHC Class 1 H2Q4 like protein)  (Figure 3.2, 
Table 3.1 spots 74-78, Figure 3.10). Two spots 75 and 76 are particularly interesting due 
to the significantly increased abundance in HSS when compared to MSS mice, and may be 
worth studying indepth as a severe disease specific marker. Two other immune-related 
proteins, lymphocyte cytosolic protein 1 (plastin-2) and prohibitin-2 were significantly 
increased in the study. The two plastin-2 spots increased by 3.2 to 4.2 fold for HSS and 
MSS mice, while just one spot of prohibitin-2 increased by 3.2-fold for HSS mice (Figure 
3.2, Table 3.1, Figure 3.11). Overall immune response protein spots showed increased 
abundance from 2-fold to 18-fold in MSS and HSS mice when compared to control mice.  
 
 
FIGURE 3.10 Comparison of spot volumes of MHC class I histocompatibility antigen H2 
Q4 alpha chain precursor spots, 1-ANOVA p ≤ 0.01 for all spots. *p ≤ 0.05 compared to 
control, #p ≤ 0.05 compared to MSS by Newman-Keuls Multiple Comparison Test. 
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FIGURE 3.11 Comparison of spot volumes of plastin-2 and prohibitin-2 spots, 1-
ANOVA p ≤ 0.01 for all spots. *p ≤ 0.01 compared to control, #p ≤ 0.05 compared to 
MSS by Newman-Keuls Multiple Comparison Test. 
 
3.2.8 Other liver proteins 
Several proteins that changed significantly but did not fall into discrete functional 
categories were annexin 5, chaperonin containing TCP-1 theta subunit, glucosidase II beta 
subunit and major urinary protein isoforms. The annexin 5 spot volume comparison 
showed the protein increased by 2.1 to 4.5-fold in HSS and MSS, although the increase for 
HSS was significantly higher than MSS mice (Figure 3.7). Brain and reproductive organ-
expressed protein was increased by 3-fold in HSS mice and by 2-fold in MSS mice 
(Figure 3.2, Table 3.1, spot 12). We identified two proteins involved in protein folding as 
chaperonin containing TCP-1 theta subunit (chaperone CCT8) and glucosidase II beta 
subunit. One spot with chaperone CCT8 activity decreased in abundance and two spots of 
glucosidase II beta subunit increased in abundance by 2.4 to 3.5-fold.  
 
Major urinary proteins (MUP) are type of pheromone proteins synthesised in the liver. 
Male mice excrete MUPs under hormonal control to co-ordinate social behaviour. We 
found five MUP spots (Figure 3.2, spots 43-47) decreased by 2 to 10-fold specifically in 
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HSS mice while MSS mice showed only two spots with 2.6-fold decreased abundance. 
MUP spot volume comparison for 5 spots showed significantly high decrease for HSS 
mice when compared to MSS and control mice (Figure 3.12). 
 
 
FIGURE 3.12 Comparison of spot volumes of major urinary protein spots, 1-ANOVA p ≤ 
0.01 for all spots. *p ≤ 0.05 compared to control, # p ≤ 0.05 compared to MSS by 
Newman-Keuls Multiple Comparison Test. 
 
3.2.9 Parasite proteins 
Schistosoma mansoni- phosphoenolpyruvate carboxykinase (Sm-PEPCK, Mw 71.46 and 
pI 6.8; Figure 3.2, spot 79 and Figure 3.13, Table 3.1) was the only parasitic protein 
identified in the study. The Sm-PEPCK abundance increased above 14-fold in HSS and 8-
fold in MSS livers. With the purpose of verifying, confirming and locating Sm-PEPCK, 
soluble egg antigen (SEA) proteome was investigated for pI ranges 3-10, 4-7 and 6-11. 
Proteomic signatures from control and infected liver samples were compared with SEA 
proteome to determine the parasite generated proteins (non-host-derived factors) that 
contribute to the severe disease pathology. Spots 32, 33, 36 in Figure 3.14 were identified 
as Sm-PEPCK using schistosome genome databases. Additionally, the schistosome 
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genome and proteome helped verify that the identified protein spots were either parasite or 
host derived. Additional information of the identified protein spots using preparative gels 
is listed in Appendix C. 
 
 
FIGURE 3.13 Comparison of spot volumes of Sm-PEPCK for control, MSS and HSS, 1-
ANOVA p ≤ 0.01 for all spots. *p ≤ 0.001 compared to control, @p ≤ 0.01 compared to 
control, #p ≤ 0.05 compared to MSS by Newman-Keuls Multiple Comparison Test. 
Spectrum for Sm-PEPCK shown in Appendix C (Figure C9). 
 
 
FIGURE 3.14 The SEA proteomic signature pI range 6-11 (75 g protein) showing spots 
1, 2 and 3 identified as Sm-PEPCK.  
 
3.2.10 Multivariate analysis 
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To visualise differences in the most statistically significant protein spots associated with 
each mouse in the study the principle component analysis (PCA) and hierarchical cluster 
analysis (HCA) was performed. PCA compared the protein spot map data from the control, 
MSS and HSS mice. This supervised analysis showed close clustering of the individual 
2D-DIGE spot maps within each group and thus revealed that the control, MSS, and HSS 
mice have distinct and distinct liver protein patterns (Figure 3.15 and Figure 3.16). The 
protein spots within the ellipse shows 72 protein spots representing 95% significance level, 
while the 8 protein spots outside the ellipse are very strongly differentially expressed 
proteins (collagen spots and major urinary protein spots). Protein spots within the ellipse 
in the light blue circle were upregulated in MSS and HSS mice when compared to the 
control mice. Protein spots within the ellipse in the dark blue circle were downregulated in 
MSS and HSS mice when compared to control mice. The protein spots for the pI range 4-7 
had outliers outside the ellipse; these were strongly differentially expressed proteins, 
within the light blue circle were the collagen isoforms and in the dark blue circle it was the 
MUP isoforms. The PCA for the pI range 4-7 clearly defines and differentiates between 
the study groups: control, MSS and HSS (Figure 3.15). In contrast, the PCA for the pI 
range 6-11 is not conclusive as for pI 4-7. The plot shows cluster of MSS and HSS mice 
together, which may be due to the poor resolution of the protein spots for the pI range 6-
11 (Figure 3.16).   
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FIGURE 3.15 Principle component analysis scatter plot for protein spots in the pI range 
4-7 with 2-fold change and 1-ANOVA  0.01, FDR. Protein spots within the ellipse show 
highly abundant (light blue circle, infected mice compared to control mice) and lowly 
abundant (dark blue circle, infected mice compared to control mice) protein spots. Spot 
maps (2D-DIGE images) show the best separation of the moderate and severe disease 
from the control (uninfected) CBA/J mice. 
 
 
FIGURE 3.16 Principle component analysis scatter plot for protein spots in the pI range 
6-11 with 2-fold change and 1-ANOVA  0.01, FDR. Protein spots within the ellipse 
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show highly abundant (light blue circle, infected mice compared to control mice) and 
lowly abundant (dark blue circle, infected mice compared to control mice) protein spots. 
Spot maps (2D-DIGE images) show the best separation of the moderate and severe disease 
from the control (uninfected) CBA/J mice. 
 
The HCA is an unsupervised multivariate analysis depicted by a dendrogram and heat map, 
this analysis gave an overview of the different proteins and study groups with similar 
expression profiles grouped together (Figure 3.17 and Figure 3.18). As seen on the left 
hand side of the heat map, the proteins with similar functional groups are clustered 
together while the 2D-DIGE spot maps with similar protein expression are segregated into 
experimental groups as stated in this study. The HCA for the pI range 4-7 and 6-11 
showed well defined separation of the control, MSS and HSS mice, supporting the %SBW 
difference between the three groups. The heat map best describes the distinct pattern of 
proteins during schistosomiasis disease.  
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FIGURE 3.17 Hierarchical cluster analysis dendrogram and heat map for 108 protein 
spots in the pI (4-7) range (C, control; M, MSS; H, HSS mice). The dendrogram and heat 
map illustrates the distinct protein pattern between the three study groups: control, MSS 
and HSS mice with clustering of proteins with similar physiology. The colour scale goes 
from green (more abundant protein spots) to black (no change in protein abundance) to red 
(less abundant protein spots) with a heat map interval of 1 representing 10-fold increased 
abundance and -1 representing 10-fold decreased abundance.  
 
     84 
 
FIGURE 3.18 Hierarchical cluster analysis dendrogram and heat map for 17 protein spots 
within the pI (6-11) range (C, control; M, MSS; H, HSS mice). The dendrogram and heat 
map illustrates the distinct protein pattern between the three study groups: control, MSS 
and HSS mice with clustering of proteins with similar physiology. The colour scale goes 
from green (more abundant protein spots) to black (no change in protein abundance) to red 
(less abundant protein spots) with a heat map interval of 1 representing 10-fold increased 
abundance and -1 representing 10-fold decreased abundance.  
 
3.2.11 Protein verification by western blot analysis 
To verify the changes in the abundance of S. mansoni-phosphoenolpyruvate 
carboxykinase (Sm-PEPCK), mouse major urinary protein (MUP) and mouse liver 
transferring, western blot analysis was performed for liver lysates from control, MSS, and 
HSS mice (Figure 3.19a). Liver lysates from 3 mice per group were analysed and probed 
for the expression of MUP, PEPCK, transferrin or actin as a loading control. The antibody 
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used to detect PEPCK was known to recognise mouse PEPCK but its reactivity to Sm-
PEPCK was unknown, and thus soluble schistosome egg antigen (SEA) was included to 
test its specificity. Although there was no reaction with the schistosome protein, there was 
increased abundance of mouse PEPCK in MSS and HSS (Figure 3.19b). The 2D-DIGE 
analysis failed to identify the mouse PEPCK either because the protein spot was not 
resolved satisfactorily on the gel or the spot volume for mouse PEPCK was just below the 
2-fold, 1-ANOVA ≤ 0.01, FDR criteria set for the analysis in our study.  
 
The MUP band intensity was decreased for MSS and HSS mice compared to control mice. 
In addition, 21 kDa and 17 kDa MUP bands (Figure 3.19a and Table 3.1) further add 
support to the 2D-DIGE results that showed variation among MUP spots 43-47 (Figure 
3.2). The transferrin protein bands intensity for HSS mice was significantly higher (p≤0.05) 
compared to MSS and control mice (Figure 3.19b) and supported the 2D-DIGE results for 
transferrin spots 62-65 (Figure 3.2 and Figure 3.16). The band volume data for mouse 
PEPCK, MUP and mouse transferrin is suggestive of a distinct protein pattern associated 
with the HSS mice compared to MSS and control mice.  
 
a)  
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b)  
FIGURE 3.19 Liver lysate western blot analysis of MUP, PEPCK and transferrin. a) 
Lysates (20 g/well) form control (C; n=3), MSS (M; n=3), and HSS (H; n=3), liver 
samples and soluble egg antigen (SEA; 20 g/well) were separated on SDS-PAGE gel, 
transferred to PVDF membrane and probed with rabbit anti-murine PEPCK polyclonal 
antibody, goat anti - MUP, goat anti-transferrin polyclonal antibody , or mouse anti-actin 
monoclonal antibody followed by Cy5-labelled anti-goat, anti-rabbit IgG and Cy3-labelled 
anti-mouse IgG respectively. b) Protein band fluorescence intensity of HSS mice liver 
lysate compared with control and MSS mice liver lysate. Shown are the means SEM, *p 
≤ 0.05 compared to control, #p ≤ 0.05 compared to MSS by Newman-Keuls Multiple 
Comparison Test. Western blot images included in Appendix G. 
 
3.3 Discussion 
The aim of this work was to identify changes in chronically infected mice that were 
unique to the severe disease form. Using 2D-DIGE we identified 80 significant changes 
and found that MSS, HSS and control mice had distinct proteomic signatures. The average 
percent spleen to body weight ratio for the control, MSS and HSS mice was similar to 
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previous findings (Henderson et al., 1993) and supported the 2D-DIGE data. A previous 
has used the 2DE approach to understand the impact of infection on 8-week S. mansoni-
infected C57BL/6 mice and reported impairment of multiple functional pathways in the 
liver during schistosomiasis (Harvie et al., 2007). These findings were consistent with the 
results in our study and therefore the functional pathways were assessed similar to the 
study of Harvie et al. (Figure 3.3 and Table 3.1). In particular, structural proteins, immune 
response proteins and acute phase proteins showed increased abundance while the proteins 
related to energy metabolism; choline metabolism and xenobiotic metabolism were 
decreased in abundance. Similar to our findings, a murine Schistosomiasis mansoni study 
demonstrated reduced levels of the tricarboxylic acid cycle intermediates (energy 
metabolism) and disturbance in amino acid metabolism (Wang et al., 2004) indicating that 
there are changes in biological processes during parasitic infections.  In the following 
sections, specific proteins of interest related significantly to the pathophysiology of the 
disease will be discussed. 
 
3.3.1 Acute phase proteins 
Acute phase proteins are a group of proteins that increase or decrease during inflammation 
in response to infection and cell injury. In this study we compared the average volume 
ratios for transferrin, albumin, group specific component and retinol binding protein 1 
between control, MSS and HSS mice. Transferrin is a negative acute phase protein and 
decreased serum levels have been reported in patients with liver diseases (Otegbayo et al., 
2005) while high levels are linked to alcoholic fatty liver  disease (Potter et al., 1985). In 
patients with hepatosplenic (Saif et al., 1977) and urinary schistosomiasis (Arinola, 2004, 
Salawu and Arinola, 2004) both increased (Salawu and Arinola, 2004) and decreased 
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(Arinola, 2004, Saif et al., 1977) serum levels have been reported. Previous work in 
C57BL/6 mice has shown increased liver transferrin at 8-week S. mansoni infection 
(Harvie et al., 2007), and similarly, our study showed a significant 2.5 to 4.6-fold increase 
in 4 transferrin spots in CBA/J mice with HSS but not MSS mice (Figure 3.2-spots 62-65; 
Figure 3.4; Figure 3.19 and Table 3.1). The increased abundance of transferrin may be 
attributed to the growth of schistosome worms since a previous study found that 
schistosomes require iron and bind host transferrin for development (Clemens and Basch, 
1989). The increased abundance of transferrin isoforms was confirmed by western blot 
analysis. The band volume fluorescence intensity for transferrin in HSS mice was 
significantly higher when compared to control and MSS mice (Figure 3.19).  The 
increased transferrin in HSS mice is a feature of that disease form and thus has potential as 
a biomarker for HS.  
 
Albumin is a major transport protein that increased with infection specifically for 
hepatosplenic disease and is a novel finding in our study (Figure 3.2, Table 3.1, Figure 
3.5). This findings is in contrast to previous studies which indicate a decrease in albumin 
due to hepatocellular diseases in murine schistosomiasis (Saber et al., 1983) One reason 
for increased abundance of albumin may be that albumin is required in the circulation to 
maintain oncotic pressure, for transport of toxins and other metabolites generated during 
infection. Another reason for the increase of albumin is the increased consumption by 
schistosome larvae during their development in the host (Arinola, 2004).  
 
Another acute phase reactant, the group specific component (also called -2-globulin 
Gc-globulin or vitamin D-binding protein) is a multifunctional protein from the albumin 
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family and its main physiological role is to scavenge actin. It has also been described as an 
acute phase reactant (Dahl et al., 2001). GSC is synthesised in the liver and decreased 
serum levels have been documented in hepatotoxicity and acute liver failure due to hepatic 
insufficiency (Meier et al., 2006, Schiødt, 2008).  In comparison, our study showed high 
GSC levels in HSS mice and this may be due to scavenging activity towards high 
intracellular actin levels reported in this study.  
 
Retinol binding protein 1 regulates uptake, intracellular trans-intracellular transport and 
esterification of retinol. It is also a negative acute phase protein extensively studied in 
liver fibrosis due to hepatoxicity and metabolic syndromes. In 2002, Uchio and co-
workers, working with male murine models of liver fibrosis showed that RBP1 expression 
increased in response to hepatic fibrogenesis and plays a major role in hepatic tissue repair 
(Uchio et al., 2002). Thus, schistosomiasis induced fibrosis could account for the 
increased RBP1 levels in HSS (Figure 3.7). Together the acute phase proteins identified in 
our study were negative phase reactants, yet conversely showed increased abundance a 
unique feature of our study. 
 
3.3.2 Structural proteins 
Hepatosplenic schistosomiasis is marked by periportal fibrosis and is the major cause of 
pathology of this disease. Increases in deposition of collagen including collagen 6a and 
XIV is suggestive of fibrosis and has been documented previously in murine 
schistosomiasis (Saber et al., 1983), human alcoholic cirrhosis (Stickel et al., 2001), and 
human hepatosplenic schistosomiasis (Camacho-Lobato and Borges, 1998, Shahin et al., 
1992). In our study similar results were obtained, with 11 collagen spots that increased in 
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volume from 2-fold to 55-fold (Figure 3.2, Table 3.1). The PCA analysis confirmed the 
differential expression of five collagen spots during disease (protein spots outside the 
ellipse in the light blue circle, Figure 3.15). Extensive fibrosis is triggered by molecules 
like TGF- induce CTGF expression and increased collagen synthesis. CTGF is a 
profibrogenic molecule that is overexpressed in many fibrotic lesions and promotes 
hepatic stellate cell adhesion, proliferation, locomotion, and collagen production in hepatic 
fibrosis similar to processes seen in hepatosplenic schistosomiasis. CTGF is strongly 
expressed during liver fibrogenesis. Hepatic stellate cells are the major cellular sources of 
CTGF in the liver (Paradis et al., 1999). Given the known connection between CTGF and 
fibrosis, it can be a new therapeutic target for this disease (Rachfal and Brigstock, 2003). 
Importantly it can be detected in serum and may predict the development of 
schistosomiasis fibrosis (Kovalenko et al., 2009). Moreover, the amino acid 
hydroxyproline is found in collagen and is synthesised by hydroxylation of proline in pre-
formed collagen. Detection of hydroxyproline followed by acid hydrolysis of liver can be 
used as a measure of hepatic collagen (Cetre-Sossahc. C. B. , 2007). During hepatic 
fibrosis there is increased abundance of hydroxyproline which may be due to its 
requirement in collagen synthesis (Dunn et al., 1977) or impaired collagen degradation 
(Takahashi et al., 1980). The increased collagen isoforms (Figure 3.6) in our study 
therefore would be expected to correlate to increased hydroxyproline levels.  
 
We found a 2-fold increase in actin levels in schistosome infection suggestive of changes 
in the hepatocellular composition during schistosomiasis.   Harvie et al., have shown 
similar findings in the C57BL/6 mice with increase of up to 20-fold at 8-weeks of 
infection (2007). Vimentin is an intermediate cytoskeletal filament that increased in both 
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MSS and HSS above 2.5-fold. This increase is similar to previous studies (Boehme et al., 
1989, Harvie et al., 2007) (Figure 3.7). Tropomyosin is one of the actin-associated 
proteins that modulate the interaction between actin and myosin to stabilise the actin 
filament structure. The 2-fold increase of tropomyosin 3 in our study is similar to the 
findings in ketotic livers (Xu and Wang, 2008). Another study in progressive liver fibrosis 
is suggestive of tropomyosin as a new marker of activated stellate cells and a useful 
diagnostic marker for liver fibrosis (Otogawa et al., 2009). 
 
The intermediate filament cytoskeletal protein, keratin D (type-I) in mouse liver 
corresponds to keratin 18 (type I, acidic pI) in human liver and is associated with liver 
diseases (Strnad et al., 2008). In toxicity, induced liver damage a study demonstrated post-
translational modifications that were associated with phosphorylation and proteolytic 
degradation of keratin filaments (Salmhofer et al., 1994). These authors investigated the 
structural disturbances caused by modification of keratin in alcoholic hepatitis. Our study 
showed that similar protein change develops in severe schistosome-mediated liver disease. 
Indeed, increased levels of keratin D were associated with HSS but not MSS, which is a 
finding unique to our study (Figure 3.2, Figure 3.8). Furthermore, research in patients with 
schistosomiasis infection showed autoantibodies to keratin (Boehme et al., 1989) which 
together with the findings in this study may indicate that the development of a response to 
modified cytoskeletal proteins such as keratin is a feature of the disease pathology. 
 
Overall, we found different isoforms of collagen, actin and vimentin increased from 2 to 
50-fold as well as one keratin D spot due to schistosome infection, suggesting induction of 
different mechanisms during schistosome infection that contribute to the deposition of 
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these extracellular components and intermediate filament proteins. If investigated further, 
the specific isoforms can be used as unique markers for schistosomiasis. 
 
3.3.3 Energy metabolism proteins 
We found decreased abundance of three proteins and increased abundance of one protein 
related to energy metabolism. A study showed decreased enzymatic activity of ATPase 
beta in hepatocellular carcinomas (Capuano et al., 1997). In our study we have a similar 
finding with the levels of ATPase beta decreased by 2-fold, indicative of hepatic response 
similar to carcinogenesis occurring in schistosome infection during the development of the 
severe disease. Different isoforms of carbamoyl phosphate synthase 1, a urea cycle 
enzyme, are dysregulated in liver pathobiology, carcinogenesis and hepatotoxicity 
(Thome-Kromer et al., 2003), similarly we found one spot with decreased carbamoyl 
phosphate synthase 1 activity. This decrease in carbamoyl phosphate synthase 1 was also a 
particularly marked finding in Harvie et al. 
 
Glutamate dehydrogenase (GLDH) is widely used to assess liver dysfunction along with 
other liver function tests. GLDH is down-regulated by 6-fold in fructose-fed insulin 
resistant hamster liver, a form of liver injury (Morand et al., 2005) but circulating levels 
increase in liver necrosis (Van Waes and Lieber, 1977). We found 2-fold GLDH decrease 
in schistosomiasis liver tissue; this may be due to its infiltration into the circulating system 
as previously reported (Camacho-Lobato and Borges, 1998). Valosin-containing protein 
(VCP) also called AAA-ATPase p97 is involved in export of proteins through the 
endoplasmic reticulum into the cytosol and inhibits apoptosis. Its expression increases in 
various carcinomas (Yamamoto et al., 2003). Similarly, we found 3 to 5- fold increases in 
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VCP activity in MSS and HSS mice indicating that apoptosis could be a mechanism 
involved in schistosomiasis pathology. Taken together the results for proteins related to 
energy metabolism are suggestive of disturbance in this biological process during 
schistosomiasis.  
 
3.3.4 Choline metabolism 
The mitochondrial dehydrogenases, dimethylglycine dehydrogenase (DMDH) and 
sarcosine dehydrogenase (SARDH) catalyse the final steps of choline metabolism 
converting dimethylglycine to sarcosine, and then sarcosine to glycine. The predicted 
native masses of the proteins are 97.3 and 101.7 kDa respectively for DMDH and SARDH 
corresponding to their positions on the gels. Both proteins have predicted post-
translational modifications including phosphorylation that would potentially give rise to 
isoforms that differ in isoelectric point. In HSS livers, three DMDH spots (spots 26-28, 
Figure 3.2, Figure 3.9) showed greater than 2-fold loss with a smaller non-significant 
decrease in MSS compared to controls (Table 3.1).  Three SARDH isoforms (Figure 3.2, 
Table 3.1 spots 56-58) also decreased more than 2-fold in HSS with smaller decreases in 
MSS. The greatest loss of more than 6-fold in HSS mice, was for the most basic (spot 58) 
of the three SARDH isoforms (Figure 3.9). The loss of DMDH has been reported 
previously in 8-week S. mansoni infection (Harvie et al., 2007) and the loss of SARDH in 
hepatocellular carcinoma (Lim et al., 2002). Our research found 2 to 6.4- fold decreases in 
the SARDH spots, suggesting similar hepatic responses in schistosomiasis and 
hepatocarcinogenesis. Furthermore, SARDH may be useful to differentiate between HSS 
and MSS since the average volume ratio decrease for three SARDH spots in HSS is large 
as opposed to MSS suggestive of an isoform pattern specific for severe disease. 
     94 
Additionally, schistosomes use host lipids for survival as they do not make sterols or fatty 
acids de novo. Choline is crucial for phosphatidylcholine biosynthesis in schistosome 
development, especially females (Ancelin et al., 1987). The decreased SARDH and 
DMDH reported in our study could mean increased choline diversion towards 
phosphatidylcholine biosynthesis. 
 
3.3.5 Xenobiotic metabolism proteins 
Schistosome worms and eggs in the host liver microvasculature induce alterations in the 
redox balance and invites oxidative stress from immune-generated radicals (La Flamme et 
al., 2001). Moreover, the release of toxic heme and ferrous ions generated due to 
consumption of haemoglobin by schistosome larvae (Brindley et al., 1997) contributes to 
the increase in xenobiotic molecules. Our study showed decreased abundance of 
xenobiotic metabolising proteins (Figure 3.3) similar to the study by Harvie et al., 2007.  
Xenobiotic metabolising proteins provide protection form oxidant stress and a decrease of 
the proteins during disease state indicates increased abundance of toxic molecules in the 
host which can be fatal.  We found decreased activity of catalase, protein disulphide-
isomerase A3, selenium binding protein 2, glutathione S-transferase Pi, epoxide hydrolase 
and aldehyde dehydrogenase. 
 
Catalase is one such protein that protects the cell from the toxic effects of hydrogen 
peroxide by breaking it down to molecular oxygen and water with no generation of free 
radicals. Previous studies have demonstrated decreased activity of this enzyme in 
schistosome infected liver during 6-week infection (La Flamme et al., 2001) and 8-week 
infection (Gharib et al., 1999), this correlates with the findings in our study where the 
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decrease is above 3-fold. Another protein that regulates the redox status of MHC class 1 
during antigen presentation is protein disulphide-isomerase A3 (Santos et al., 2007) and 
increased activity has been recorded previously in 8-week CBL57/6 S. mansoni infection 
(Harvie et al., 2007) consistent to the finding in our study. We report a single PDIA3 spot 
with increased abundance in HSS mice concomitant with high levels of MHC class 1 
protein.  
 
Selenium binding protein 2 (SBP2) is down-regulated in liver fibrosis possibly due to 
portal hypertension (Henkel et al., 2006) which leads to increased cell proliferation 
(Giometti et al., 2000), similar to the finding in our study. We found one SBP2 spot 
decreased by above 3-fold with pI 5.8, Mw 53.16. The reason for the upregulation of spot 
pI 6.0, Mw 52.90 needs to be evaluated, but is similar to the previous findings in liver of 
HFE-deficient mice (human haemochromatosis protein gene-deficient mice) with 
downregulated SBP2 (Petrak et al., 2007).  
 
The glutathione S-transferase (GST) enzyme family is associated with the detoxification 
of endogenous and exogenous toxins. In our study, we found among the proteins of 
interest (2-fold change, 1-ANOVA p ≤ 0.01, before FDR was applied) there were GST 
enzymes that were significantly associated with schistosomiasis pathology. These include 
GST class mu1 (GSTmu1), GST class mu3 (GSTmu3) and GST class Pi (GSTPi) protein 
spots. However, with the FDR criteria for the DIGE analysis, only GSTPi showed 
significant change. The GSTPi spot (spot 73, Figure 3.2, Table 3.1) decreased in MSS and 
HSS mice and this decrease may represent variation in protein abundance during the 
chronic stage. In contrast, increased levels of GSTPi have been reported in tumor tissues 
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(Hayes et al., 1991) and acute schistosomiasis (Harvie et al., 2007). We found GSTmu1 
protein spot decreased by 2-fold in both MSS and HSS mice compared to control mice. A 
GSTmu3 protein spot showed increased abundance in HSS mice alone (the average 
volume ratio for HSS/control=+3.45, HSS/MSS=+3.33 and MSS/control=+1.04). Among 
the GST family, the class mu enzymes are the most efficient in detoxifying mutagenic 
epoxides and studies have shown increased abundance of these enzymes in human 
hepatocellular carcinoma (Murray et al., 1993) and rat hepatocellular carcinoma (Qi et al., 
2008). Other studies have also demonstrated increased abundance of GST mu1 and mu3 in 
hepatotoxicity (Ward et al., 2006) and GST mu1 in acute schistosomiasis (Harvie et al., 
2007). The results for GST mu3 in our study are similar to previous studies and were more 
specific for HSS mice while the results for GST mu1 are in contrast to previous findings. 
Our study revealed some interesting and important patterns for the GST enzymes during 
schistosomiasis but require further investigation.   
 
Aldehyde dehydrogenases (ALDH) are a family of enzymes that protect the body from 
aldehydes. (Dragani et al., 1996) described the down regulation of ALDH in murine lung 
tumours which is supported by the study  from Sun et al. that showed a 2.5-fold decrease 
in ALDH in human hepatocellular carcinoma (Sun et al., 2007). Earlier studies have 
documented the decrease in expression of ALDH but our study indicates a spot with 
increase ALDH abundance in hepatosplenic disease. If studied further it can possibly 
explain the exact mechanism involved in the pathogenesis of severe disease. Altogether, 
the decreased abundance of xenobiotic metabolising proteins in our study suggests that 
schistosome infection induces certain biological responses that decrease the synthesis of 
these proteins during disease and leave the liver vulnerable to chronic oxidative damage. 
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3.3.6 DNA methylation-related proteins 
The results in our study showed that schistosome infection affects the abundance of DNA 
methylation-related proteins including betaine homocysteine methyltransferase (BHMT), 
S-adenosylhomocysteine hydrolase (SAH) and formyltetrahydrofolate dehydrogenase (10-
FTHDH) and this may cause imbalance in DNA methylation. BHMT is an enzyme 
involved in the methylation cycle in the liver, one spot with BHMT activity was 
upregulated and is in contrast to earlier work which demonstrated that BHMT is down-
regulated in hepatocellular carcinoma (Sun et al., 2007) (Figure 3.2, Table 3.1, spot 11). 
SAH has been described as a potential molecular target for anti-parasitic drugs due to its 
role in methylation reactions (Grillo and Colombatto, 2008). We found one downregulated 
SAH spot during schistosomiasis similar to a previous study that demonstrated decreased 
activity of the SAH in tumour tissues (Leal et al., 2008). 10-FTHDH enzyme is involved 
in detoxification, one-carbon metabolism and DNA methylation (Vasiliou et al., 2000). 
The decreased activity of the enzyme in five protein spots may relate to decreased 
detoxification in the schistosomiasis disease as well as downregulation of DNA 
methylation. Previous work by Krupenko and co-workers stated that 10-formyl 
tetrahydrofolate dehydrogenase is involved in several cellular processes and is down-
regulated in tumour tissues (Krupenko and Oleinik, 2002). All of the above results may 
suggest pro-cancerous activities that are specifically induced during severe 
schistosomiasis and may promote cancer development.  
 
3.3.7 Immune response proteins 
Schistosome eggs are well characterised inducers of immune responses (Henderson et al., 
1993) and therefore liver-derived immune related proteins were evaluated. Our study 
     98 
identified several immune related proteins that were significantly altered during chronic 
infection. These proteins include MHC class I histocompatibility antigen H-2 Q4 alpha 
chain precursor like protein, plastin 2 and prohibitin 2. The increased abundance of MHC 
class I histocompatibility antigen H-2 Q4 alpha chain precursor like protein (MHC 
Class 1 H2Q4 like protein), a non-classical MHC class Ib-like molecule may reflect 
increased or altered immune recognition to parasite-derived products (Figure 3.2, Table 
3.1 spots 74-78, Figure 3.10). While Hernandez et al. showed that classical MHC Class II 
but not MHC class I molecules are involved in granuloma formation in early stage disease 
(Hernandez et al., 1997), our data suggests a possible role for the non-classical MHC class 
1 H2 Q4 like protein  in the development of schistosome-induced immune responses.  
 
Plastin-2 is an actin-binding protein expressed in monocytes, B lymphocytes and myeloid 
cells. A recent study showed increase abundance of lymphocyte cytosolic protein 1 in 
chemically induced mouse liver tumours (Strathmann et al., 2007), and another study 
reports 3-fold increase of lymphocyte cytosolic protein 1 transcripts using affymetrix 
microarray profiling in C57BL/6J mice with traumatic brain injury (Israelsson et al., 2008). 
Albeit the technique, mouse model and tissue studied differ, we have similar findings with 
two lymphocyte cytosolic protein 1 spots (Figure 3.2, spot 41, 42, Figure 3.11) showing 
increased protein abundance (3 to 4-fold). Taken together, the increased levels of this 
protein are associated with tissue injury and stress conditions, and suggest effects on stress 
metabolism in moderate and severe schistosomiasis. 
 
Prohibitin-2 (B-cell receptor-associated protein 37) is closely related and complexed with 
prohibitin 1 (p32). It plays a role in tumour suppression and cell cycle regulation as well 
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as inducing apoptosis (Guo et al., 2007). Prohibitin gene expression increases in rat 
bladder carcinomas and prohibitin interacts with tumor-suppressor-gene proteins 
(Asamoto and Cohen, 1994), it has been highlighted as a possible therapeutic target 
(Mishra et al., 2005). Our study showed 3.25-fold increase in HSS (spot 80-Figure 3.2, 
Table 3.1, Figure 3.11) but not MSS mice and may indicate its involvement in cell 
proliferation and/or apoptosis during severe disease. Finally, the increased abundance of 
immune response proteins provides support to the idea that similar pathological 
mechanisms may be occurring during schistosome-mediated liver disease, stress induced 
tissue injury and carcinogenesis. 
 
3.3.8 Other liver proteins 
In this study we identified hepatic proteins that were differentially expressed during 
schistosome infection and a subset of these may have been altered due to simultaneous 
hepatocarcinogenesis or other liver complications or due to hepatotoxicity. The annexins 
are a family of such proteins described in cancerous cells and tissues and annexin 5 in 
particular increases during carcinogenesis. The 5-fold increase in annexin 5 (Figure 3.7) 
may possibly mean that liver injury in schistosome infection follows the same course as 
development of hepatocellular carcinoma. A recent study suggests annexin 5 as a 
tumourogenic protein (Mulla et al., 2004) which can be a possibility with the findings in 
our study in mice with S. mansoni infection.  
 
Brain and reproductive organ-expressed protein (BRE) inhibits the mitochondrial 
apoptotic pathway and is a stress modulating protein. These activities could be the reason 
for its increase in schistosomiasis as they may enhance cellular survival during disease 
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state (Li et al., 2004). Additionally, a class of proteins called molecular chaperones are 
present in various compartments of the cell assisting in the proper folding of various 
proteins in health and disease. Chaperonin containing TCP-1 theta subunit (Chaperone 
CCT8) functions during actin and tubulin folding. An increase in chaperone CCT8 in 
tumour cells has been recorded by (Agaton et al., 2003) using affinity proteomics. Our 
results associate decreased levels of the protein with HSS mice similar to the findings of 8-
week infected mice (Harvie et al., 2007) and in contrast to the results in tumour cells that 
showed strong expression of chaperone CCT8 (Agaton et al., 2003). Moreover, studies have 
demonstrated increased abundance of glycosylation during immunologic responses to 
infections and allergy (Altmann, 2007, Rudd et al., 2001). In particular, glucosidase II 
beta subunit an enzyme involved in the glycosylation, allows folding and incorporation 
of glucosides in many secreted and membrane-bound proteins. Our study showed 2.5 to 
3.5-fold increases in two glucosidase II beta subunit spots, certainly a distinctive feature of 
this study. Together, the 2D-DIGE data for annexin 5, chaperone CCT8 and glucosidase II 
beta subunit protein spots demonstrated that hepatic responses to schistosome infection 
and the importance of the follow-up of these proteins in human schistosomiasis may 
possibly be useful for diagnosis.  
 
Major urinary protein (MUP) is from the lipocalin family and functions as a pheromone 
transporter in mouse urine. MUP has similarity to human epididymal-specific lipocalin-9 
but more elaborate studies are needed to understand the relationship between this protein 
in mice and humans (Virtanen and Kinnunen, 2008). Previous research has demonstrated 
decreased abundance of MUP as an early event in the development of mouse liver 
tumours and hence may be used as a tumour marker in mouse hepatocarcinogenesis 
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(Dragani et al., 1989). We found five MUP spots (Figure 3.2, spots 43-47) decreased 2 to 
10-fold specifically in HSS livers while these same spots in MSS livers show only a 
moderate decrease in expression comparatively and these differences were verified by 
western blot. The PCA analysis confirmed the differential expression of three MUP spots 
during disease (protein spots outside the ellipse in the dark blue circle, Figure 3.15).The 
band volumes for HSS mice MUP bands were significantly high when compared to 
control and MSS mice (Figure 3.19). This is the first report of a specific alteration in this 
protein during schistosomiasis (Figure 3.2, Figure 3.11, Figure 3.12 and Table 3.1). The 
large decrease of MUP in HSS livers lends further support to the possibility of early stage 
responses to pro-cancerous activities in hepatosplenic schistosomiasis. Since MUP is 
significantly decreased in HSS mice and has similarity to human lipocalin 9 it would be 
worth investigating in mouse and human sera. 
 
3.3.9 Parasite proteins 
The only parasite protein identified in our study was Sm-PEPCK. This enzyme is 
responsible for the glucose metabolism in schistosomes. PEPCK carboxylates 
phosphoenolpyruvate to oxaloacetate that is then converted to malate for  the parasites‟ 
energy needs (Mehlhorn, 2009).  Given that miracidia contain Sm-PEPCK mRNA 60 
times the adult level and sporocysts contain 10 times the adult level, it has been suggested 
that immature and mature schistosomes can synthesise glucose via gluconeogenesis or 
glycerol via glyceroneogenesis, using glutamine as a precursor (Yang et al., 2009). 
Additionally, many parasitic proteins are glycosylated or phosphorylated and these 
modifications play an important part in the host immune responses (Cummings and 
Nyame, 1996) or during schistosome development and growth (Tarrab-Hazdai et al., 
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2005).  Thus, the pattern for the spots described from the SEA proteomics signatures 
(Figure 3.14, spots 32, 33, 36) suggests that the protein may be post-translationally 
modified as indicated by changes in the molecular weight and pI of the protein spots. 
 
A study by Asahi et al. proposes that Schistosoma mansoni phosphoenolpyruvate 
carboxykinase (Sm-PEPCK) is a novel antigen for schistosome infection and suggests its 
potential as a disease specific protein marker (Asahi et al., 2000). While mice do express a 
murine PEPCK, the results from the proteomic analyses have matched the protein spot to 
the parasite and not the mouse PEPCK. Thus due to the large increase of 8-fold to 13-fold 
in Sm-PEPCK (Figure 3.2, Table 3.1, Figure 3.10), we agree with the conclusions of Asahi 
et al. that this protein is a good candidate for development as a biomarker for schistosome 
infection. Furthermore, the western blot PEPCK results propose that in addition to the 
increase in Sm-PEPCK detected by DIGE, the liver enzyme also increased in abundance 
(Figure 3.19), thereby a potential for enhanced gluconeogenesis in infected liver through 
increased activity of the hepatic enzyme. These results suggest that PEPCK of mouse 
origin as well as Sm-PEPCK incresed in MSS and HSS mice, and that further studies will 
need to be designed to target Sm-PEPCK specifically. 
 
3.3.10 Multivariate analysis 
The results of the supervised (PCA) and unsupervised (HCA) multivariate analysis (Figure 
3.15, 3.16, 3.17 and 3.18) indicate that MSS and HSS mice have distinct proteomic 
signatures that reflect the pathology in schistosomiasis. The close clustering of the control 
mice separated from the MSS mice clustering together and HSS mice grouped together in 
PCA and HCA indicate the strong differential protein abundance between the three study 
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groups which supports previous work (Freeman Jr et al., 1996, Henderson et al., 1993).  
Further analysis of the unique protein changes may provide insight into the molecular 
changes that drive the two chronic disease forms. Although previous schistosomiasis 
studies have analysed gene expression and metabolic profiles, none of the studies have 
studied protein spot abundance profiles using multivariate analysis like PCA and HCA.  
 
3.4 Conclusion 
The use of the CBA/J mouse model allowed us to explore the changes in various protein 
isoforms and variants associated with MSS and HSS disease forms.  The liver 2D-DIGE 
profiles depicted a distinct picture of protein patterns expressed between MSS and HSS 
and revealed an increased abundance of proteins associated with the energy metabolism, 
choline metabolism and xenobiotic metabolism. The uniqueness of this study lies in the 
fact that lymphocyte cytosolic proteins 1 isoforms, sarcosine dehydrogenase isoforms, 
prohibitin 2, transferrin isoforms, and MUP have not previously been associated with 
hepatosplenic schistosomiasis. Additionally, Sm-PEPCK proves to be a promising 
candidate for detection of schistosome infection. It is anticipated that these proteins may 
be valuable as potential diagnostic biomarkers that may assist in early detection and 
treatment of schistosomiasis patients in the future.  
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CHAPTER 4: LIVER PROTEIN ABUNDANCE AT 
VARIOUS TIMES POST-INFECTION IN MURINE 
SCHISTOSOMIASIS 
 
4.1 Introduction 
Although MSS and HSS are identified pathologically at 20-weeks post infection, these 
forms can be distinguished immunologically as early as 6 weeks after infection  due to the 
development of cross-reactive idiotypes (CRIs) in MSS mice (Montesano et al., 2002). 
Unfortunately, the CRIs reagent is not appropriate for commercial development. However, 
because these forms show distinct immunological differences very early after egg laying 
begins, it is likely that other distinctive changes may be identified that can differentiate 
MSS from HSS earlier than 20 weeks. To identify differential protein abundance patterns 
driving the segregation of the two chronic pathologic forms, liver proteomic signatures 
from CBA/J mice infected for 6, 8, 12 weeks were compared with the abundance of 
proteins from 20-week infected mice and control CBA/J mice. This proteomic approach 
helped identify proteins expressed differentially and consistently at early stages of the 
disease as well as those expressed only at the late stage of the disease. The 20-week 
infected samples were classified as MSS (n=5) and HSS (n=5) according to liver 
pathology as described in Chapter 3 and the six groups (control, 6-week, 8-week, 12-week, 
MSS, HSS) were studied for protein pattern changes. At 20-week post-infection, 20% 
CBA/J mice present with HSS and 80% with MSS disease. In the present experiment we 
used 10 mice/group for the 6, 8 and 12 week time point infections, so that it can be 
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expected that approximately 2 mice/group will develop HSS.  Experimental design 2 for 
DIGE experiments is listed in Appendix A. 
 
4.2 Results  
4.2.1 Comparison between %SBW for experimental design 2 and 1 
Experimental design 2 was used to perform this 5 time point experiment. A comparison of 
the percent spleen to body weight ratio (%SBW) of control and 20-week infected mice 
from experimental design 2 with experimental design 1 was done to assess similarity of 
samples. The two experiments showed similar results for the three groups despite being 
from independent experiments suggesting that this mouse model is highly reproducible 
(Figure 4.1). The differential patterns of protein abundance from control/uninfected (n=5), 
6-week (n=10), 8-week (n=10), 12-week (n=10), MSS (n=5) and HSS (n=5) (or 20-week 
infected mice, n=10) mice infected with S. mansoni was assessed using 2D-DIGE. The 
differentially expressed protein spot volumes detected for the control, MSS and HSS mice 
were similar to the protein spots in experimental design 1, supporting the robustness of 
our experimental system and previous results (Chapter 3). (The spot volume haemoglobin 
results from experimental design 2 and 1 were similar, results discussed in Appendix E.) 
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FIGURE 4.1 Percent spleen to body weight ratio comparisons for animals in experimental 
design 2 and experimental design 1. C1, M1, H1=control, MSS, HSS respectively from 
experimental design 1 and C2, M2, H2=control, MSS, HSS respectively from experimental 
design 2, 1-ANOVA p ≤ 0.01. *p ≤ 0.001 compared to control, #p ≤ 0.001 compared to 
MSS by Newman-Keuls Multiple Comparison Test. Pairing of the animals between the 
two sets for control, MSS, HSS mice was statistically significant with p ≤ 0.0001. 
 
4.2.2 Correlations between splenomegaly and hepatomegaly 
Comparison of the %SBW between the six study groups showed HSS mice were 
statistically different (p ≤ 0.0001) from the other five groups (Figure 4.2). Percent liver to 
body weight ratio, a measure of hepatomegaly, was elevated in the five groups when 
compared to control mice (Figure 4.3). %SBW was log transformed to normalise the data. 
Linear regression analyses demonstrated significant correlations between percent liver to 
body weight ratio levels and %SBW at 6, 8, 12 and 20 week of infection (Figure 4.4) with 
r square value showing a strong effect of the liver on the spleen during the pathogenesis in 
hepatosplenic schistosomiasis. At 8-week, 12-week and 20-week infection the liver 
showed almost 90%, 94% and 53% respectively correlations with splenomegaly indicating 
a major role of the liver in schistosomiasis. 
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FIGURE 4.2 Percent spleen to body weight ratio comparisons between seven study 
groups from experimental design 2, p ≤ 0.001 when HSS mice compared to control, 6-
week, 8-week, 12-week infected mice and MSS mice, p ≤ 0.01 when 12-week, 8-week 
infected mice compared to control, 6-week mice. Blue lines represent the mean  SEM. 
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FIGURE 4.3 Percent liver to body weight ratio comparisons between six study groups 
from experimental design 2, p ≤ 0.001 when 8-week, 12-week, HSS mice compared to 
control mice and 6-week infected mice, p ≤ 0.01 when MSS compared to  HSS and 
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control mice, p ≤ 0.05 when 6-week infected mice compared to control mice. Blue lines 
represent the mean  SEM. 
 
 
FIGURE 4.4 Scatter plot and linear regression analysis for percent liver to body weight 
ratio and %SBW between 6-week, 8-week, 12-week and 20-week infected mice (MSS and 
HSS). The linear regression r square shows the contribution of the liver and spleen with 
respect to the progress of the schistosomiasis disease. 
 
4.2.3 Liver protein abundance at time post- infection  
Liver lysate was used to determine the total protein, which gives a measure of the soluble 
protein fraction, but not necessarily the membrane bound proteins in the liver. It is also a 
gross measure to estimate protein synthesis in the liver. In order to assess if schistosomal 
infection induces impairment of protein synthesis, we measured the total protein in the 
liver of control, 6-week, 8-week, 12-week, MSS and HSS infected mice. We found that 
MSS and HSS mice had significantly lower levels (p ≤ 0.001) when compared to the 
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control mice, 6-week, 8-week, 12-week infected mice (Figure 4.5). Decreased total protein 
abundance may be due to decreased ability of the wounded liver to synthesise proteins 
during schistosome infection. 
 
 
FIGURE 4.5 Mouse liver total protein levels (mg protein per mL of liver lysate) in liver 
lysate for control, 6-week, 8-week, 12-week, MSS and HSS mice. Shown are mean ± 
SEM, 1-ANOVA p  0.01. *p ≤ 0.001 HSS and MSS compared to control, 6-week, 8-
week, 12-week infected mice; #p ≤ 0.001 12-week and 8-week infected mice compared to 
6-week infected mice and control; 
@p ≤ 0.05 6-week infected mice compared to control 
mice; comparison between 8-week and 12-week infected mice, HSS and MSS was 
statistically not significant (ns) as indicated, comparison tests by Newman-Keuls Multiple 
Comparison Test. 
 
A total of 2523 and 2422 protein spots were detected in the pI ranges 4-7 and 6-11 
respectively. The resolved protein spots were 299 and 136 for the two pI ranges 
respectively. The abundance of 63 and 13 protein spots between the six study groups 
changed significantly with 1- ANOVA ≤ 0.01, 2-fold change in average volume ratio and 
application of FDR using the DeCyder software. MALDI-TOF mass finger printing was 
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used to identify 44 protein spots which are listed in Table 4.1. An overview of the 
identified protein spots for experimental design 2 is illustrated in Figure 4.6. The protein 
spots that changed significantly post infection among the five study groups when 
compared to control mice are summarised in Table 4.2. Additional information on the 
identified protein spots is listed in Appendix C. 
 
 At 12-week infection, 59 spots in pI 4-7 range and 69 spots in pI 6-11 range had greater 
than 2-fold change with ANOVA ≤ 0.01 and FDR. A total of 94 spots together, for pI 
range 4-7 and 6-11 decreased in abundance (almost 73 %), while 34 protein spots 
increased in abundance (Table 4.2). The maximum number of protein spots that changed 
compared to control was for 12-week infected mice and a total of 58 protein spots were 
identified using MALDI-TOF. Table 4.3 lists 23 identified protein spots decreased in 
abundance, exceptionally and distinctly during 12-week infection. The identified protein 
spots that changed for 12-week infection were assessed according to Gene Ontology 
function categories which showed increased protein abundance for immune response 
proteins and structural proteins and decreased abundance for proteins related to amino 
acid metabolism, one carbon metabolism, redox reaction proteins and xenobiotic 
metabolism proteins (Figure 4.7). These results suggest that this time point may be 
important in the down-regulation of the egg-induced pathology.  
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FIGURE 4.6 A pseudocolour map of 44 liver proteins from uninfected and HSS mice 
separated by 2D-DIGE for the experimental design 2. Liver lysate from control/uninfected 
liver was labelled with Cy5 (green), lysates from 20-week infected HSS liver was labelled 
with Cy3 (red) and a pooled internal standard of liver lysates from control, MSS and HSS 
mice in the study (n=15) was labelled with Cy2 (blue; not shown). Isoelectric focusing 
was performed on 7 cm IPG strips, pI 4-7 and pI 6-11, and proteins were then separated 
using SDS-PAGE. The image overlays of Cy5- and Cy3-labeled proteins appear yellow. 
The numbers correspond to the numbers (No.) of protein spots in Table 4.2. Note that the 
MUP (protein spots 26, 27) are green showing high abundance in control mice and 
transferrins (protein spots 43, 44) are red showing high abundance in HSS mice. (NOTE: 
Transferrin has pI 7.0 and therefore it can be visualised in both pI ranges 4-7 and 6-11 as 
seen in Chapter 3.) 
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TABLE 4.1 Experiment design 2: Identified protein spot comparisons between control 
mice, 6-week, 8-week, 12-week and 20-week (MSS and HSS) infected mice for the pI 
ranges 4-7 and 6-11 with 2-fold change, 1-ANOVA ≤ 0.01 and FDR.  
Spot 
No. 
Protein Name 
(pI 4-7) 
gi Number 
AVR 
H/C1 
AVR 
H/M1 
AVR 
H/81 
AVR 
H/121 
AVR 
M/C1 
AVR 
12/C1 
AVR 
8/C1 
AVR 
6/C1 
1 
60S ribosomal 
protein 
12846804 -2.12 +1.07 +1.57 -1.38 -2.27 -1.54 -3.34 -2.17 
2 Actin 49868 +3.80 +1.92 +2.16 +2.26 +1.98 +1.68 +1.75 +1.63 
3 Actin 809561 +2.54 +2.95 +2.80 +1.60 -1.16 +1.58 -1.10 -1.81 
4 Albumin 26341396 -2.69 -2.38 -1.42 +1.06 -1.13 -2.85 -1.90 -1.21 
5 Albumin1 26341396 +3.32 +1.26 -1.02 +1.56 +2.64 +2.12 +3.40 +1.21 
6 Annexin5 6753060 +3.07 +2.01 +1.77 +1.46 +1.53 +2.10 +1.73 -1.34 
7 BA-DHAK1 81879195 -2.52 -2.01 -1.62 +1.03 -1.25 -2.61 -1.56 -1.05 
8 BRE1 38173925 +2.74 +1.21 +1.38 +1.37 +2.26 +2.01 +1.98 +1.05 
9 
Cu/Zn superoxide 
dismutase 
226471 -2.15 -1.62 -1.25 -1.47 -1.33 -1.46 -1.72 +1.48 
10 
Dihydrodiol 
dehydrogenase 
21618806 -2.05 -1.70 -1.27 +1.18 -1.20 -2.41 -1.61 -1.21 
11 
Dimethylglycine 
dehydrogenase 
(DMDH) 
59808083 -2.37 -1.54 -1.18 +1.41 -1.54 -3.34 -2.00 -1.49 
12 DMDH 59808083 -2.30 -1.52 -1.13 +1.60 -1.51 -3.68 -2.03 -1.64 
13 Eno1 protein 54114937 -2.07 -1.96 -1.46 +1.17 -1.05 -2.43 -1.41 +1.10 
14 
Epoxide 
hydrolase 
15929294 -2.35 -1.72 -1.31 +1.13 -1.36 -2.66 -1.80 -1.03 
15 
Epoxide 
hydrolase 
15929294 -2.57 -1.75 -1.42 +1.23 -1.46 -3.14 -1.80 -1.01 
16 FTCD1 18252784 -2.22 -1.74 -1.09 +1.38 -1.28 -3.08 -2.03 -1.05 
17 FBPase1 14547989 -2.10 -1.95 -1.56 -1.03 -1.08 -2.04 -1.35 -1.02 
18 
Glutathione 
synthetase 
6680117 +3.53 +1.76 1.12 -1.17 +2.00 +4.14 +3.15 +2.22 
19 Heat shock 70kD 31981722 +3.29 +1.08 -1.18 +1.30 +3.05 +2.53 +3.89 +1.69 
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protein 
20 Interleukin-2 1504135 +2.86 +1.17 -1.20 -1.14 +2.44 +3.25 +3.42 +1.24 
21 Keratin D 293682 +4.99 +3.53 +4.55 +1.90 +1.41 +2.63 +1.09 -1.18 
22 Keratin D 293682 +4.93 +3.23 +3.00 +1.43 +1.52 +3.46 +1.64 +1.08 
23 Keratin D 293682 +2.75 +2.22 +2.16 +1.66 +1.24 +1.66 +1.27 +1.04 
24 
Laminin receptor1 
(40S ribosomal 
protein SA) 
62024907 +2.87 +1.40 +1.04 -1.04 +2.05 +3.00 +2.75 +1.21 
25 
Lymphocyte 
cytosolic protein 1 
26326929 +2.48 +1.67 +1.26 -1.11 +1.48 +2.75 +1.97 -1.14 
26 MUP1 12851568 -8.14 -4.11 -2.85 -4.62 -1.98 -1.76 -2.86 -1.83 
27 MUP 31 494384 -2.98 -2.18 -1.42 -1.99 -1.37 -1.49 -2.10 -1.21 
28 Peroxiredoxin6 6671549 -3.72 -2.32 -1.15 +1.24 -1.60 -4.62 -3.23 +1.09 
29 
Retinol Binding 
Protein1 
21730472 +3.32 +1.47 +1.22 -1.02 +2.26 +3.38 +2.71 +1.07 
30 RAI11 31981748 +5.22 +3.00 +2.54 +1.65 +1.74 +3.16 +2.06 +1.08 
31 RAI11 14577933 +4.27 +3.04 +2.49 +1.27 +1.40 +3.36 +1.72 -1.23 
32 Tropomyosin 26341416 +2.30 +1.51 +1.43 +1.15 +1.53 +2.00 +1.61 +1.16 
33 Vimentin 31982755 +2.03 +1.66 +1.35 -1.34 +1.22 +2.72 +1.51 -1.14 
No. 
Protein Name 
(pI 6-11) 
gi Number 
AVR 
H/C1 
AVR  
H/M1 
AVR 
H/81 
AVR 
H/121 
AVR 
M/C1 
AVR 
12/C1 
AVR 
8/C1 
AVR 
6/C1 
34 
Carbonic 
Anhydrase III 
226778 -3.98 -2.17 -1.48 -1.30 -1.84 -3.06 -2.69 -1.14 
35 
Carbonic 
Anhydrase III 
226778 -3.62 -1.88 -1.49 -1.11 -1.92 -3.26 -2.44 -1.16 
36 
Carbonic 
Anhydrase III 
226778 -3.86 -1.96 -1.43 -1.33 -1.97 -2.90 -2.69 -1.26 
37 GST Pi 2624496 -2.25 -1.49 -1.09 -1.25 -1.51 -1.80 -2.06 -1.56 
38 GST Pi 2624496 -2.53 -1.35 +1.05 -1.31 -1.88 -1.93 -2.67 -1.15 
39 Hemoglobin 12846939 -2.62 -2.00 -2.33 -1.88 -1.31 -1.40 -1.13 -1.20 
40 Hemoglobin 12846939 -2.26 -2.21 -2.49 -1.94 -1.02 -1.17 +1.10 +1.11 
41 
MHC Class1 
HLA 
51770518 +5.42 +1.73 +1.03 -1.59 +3.14 +8.63 +5.25 -1.86 
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42 Sm-PEPCK 56753812 +5.11 +1.79 +1.78 +1.04 +2.85 +4.89 +2.88 -2.17 
43 Transferrin 62027488 +2.74 +1.94 +1.73 +4.92 +1.41 -1.80 +1.58 +1.53 
44 Transferrin 62027488 +4.42 +3.04 +3.43 +9.52 +1.45 -2.15 +1.29 +2.20 
 
1
AVR: average volume ratio between study groups (C, control; 6, 6-week infected; 8, 8-
week infected; 12, 12-week infected; M, MSS; and H, HSS);  
BA-DHAK= Bifunctional ATP-dependent dihydroxyacetone kinase, BRE = Brain and 
reproductive organ-expressed protein, FBPase = Fructose-1,6-bisphosphatase 1, FTCD = 
Formimino transferase cyclodeaminase, MUP = Major urinary protein, RAI1= 
Ribonuclease/angiogenin inhibitor 1. (NOTE: Transferrin has pI 7.0 and therefore the 
DeCyder data generated in both pI ranges 4-7 and 6-11 as seen in Chapter 3). 
 
TABLE 4.2 Summary of number of protein spots for the five study groups compared to 
the control mice for the pI ranges 4-7 and 6-11 with 2-fold change, 1-ANOVA ≤ 0.01 and 
FDR.  represents decreased abundance and  represents increased abundance. 
pI range 4-7 6-11 
Study groups Protein spots with 1-ANOVA ≤ 0.01, 2-fold change, FDR 
6-week infection 4 , 2  
 
 
 
 
1 ,1  
8-week infection 16 ,19  7 ,2  
12-week infection 27 , 32  67 , 2  
MSS 3 , 12  2  
HSS 32 , 31  8 , 5  
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TABLE 4.3 Experiment design 2: Listed below are 58 protein spots specifically for 12-
week infected mice with 2-fold change, 1-ANOVA ≤ 0.01, FDR for pI range 4-7 and 6-11 
when compared to control mice, 6-week, 8-week and 20-week infected mice (MSS and 
HSS).  
Sr. No. Protein Name pI 4-7 
gi 
Number 
AVR 
H/C1 
AVR 
M/C1 
AVR 
6/C1 
AVR 
8/C1 
AVR 
12/C1 
1 Albumin 26341396 -2.69 -1.13 -1.21 -1.9 -2.85 
2 Albumin 1 26341396 +3.32 +2.64 +1.21 +3.4 +2.12 
3 Annexin 5 6753060 +3.07 +1.53 -1.34 +1.73 +2.10 
4 
Bifunctional ATP-
dependent 
dihydroxyacetone 
kinase/FAD-AMP lyase 81879195 -2.52 -1.25 -1.05 -1.56 -2.61 
5 
Brain and reproductive 
organ-expressed protein 38173925 +2.74 +2.26 +1.05 +1.98 +2.01 
6 
Carbamoyl Phosphate 
Synthetase 73918911 -1.63 -1.04 +1.17 -1.73 -3.33 
7 Dihydrodiol dehydrogenase 21618806 -2.05 -1.20 -1.21 -1.61 -2.41 
8 
Dimethylglycine 
dehydrogenase 59808083 -2.37 -1.54 -1.49 -2.00 -3.34 
9 
Dimethylglycine 
dehydrogenase 59808083 -2.3 -1.51 -1.64 -2.03 -3.68 
10 Eno1 protein 54114937 -2.07 -1.05 +1.1 -1.41 -2.43 
11 Epoxide Hydrolase 15929294 -2.35 -1.36 -1.03 -1.80 -2.66 
12 Epoxide Hydrolase 15929294 -2.57 -1.46 -1.01 -1.80 -3.14 
13 
Formiminotransferase 
cyclodeaminase 18252784 -2.22 -1.28 -1.05 -2.03 -3.08 
14 
Fructose-1; 6-
bisphosphatase 1 14547989 -2.1 -1.08 -1.02 -1.35 -2.04 
15 Glutathione synthetase 6680117 +3.53 +2.00 +2.22 +3.15 +4.14 
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16 Heat shock 70kD protein 5 31981722 +3.29 +3.05 +1.69 +3.89 +2.53 
17 Interleukin-2 1504135 +2.86 +2.44 +1.24 +3.42 +3.25 
18 Keratin D 293682 +4.99 +1.41 -1.18 +1.09 +2.63 
19 Keratin D 293682 +4.93 +1.52 +1.08 +1.64 3.46 
20 
Laminin receptor 1 
(ribosomal protein SA) 62024907 +2.87 +2.05 +1.21 +2.75 +3.00 
21 
Lymphocyte cytosolic 
protein 1 26326929 +2.48 +1.48 -1.14 +1.97 +2.75 
22 Peroxiredoxin 6  6671549 -3.72 -1.60 +1.09 -3.23 -4.62 
23 Protein Disulfide Isomerase 74203945 +1.07 -1.05 -1.10 1.42 +2.17 
24 Protein Disulfide Isomerase 74203945 +1.37 +1.03 +1.03 +1.72 +2.81 
25 Retinol Binding Protein 21730472 +3.32 +2.26 +1.07 +2.71 +3.38 
26 
Ribonuclease/angiogenin 
inhibitor 1 31981748 +5.22 +1.74 +1.08 +2.06 +3.16 
27 
Ribonuclease/angiogenin 
inhibitor 1 14577933 +4.27 +1.40 -1.23 +1.72 +3.36 
28 Sarcosine Dehydrogenase 26352359 -2.42 -1.52 -1.05 -1.67 -2.85 
29 Tropomyosin 26341416 +2.30 +1.53 +1.16 +1.61 +2.00 
30 Vimentin 31982755 +1.95 +1.59 +1.26 +2.11 +2.53 
31 Vimentin 31982755 +2.03 +1.22 -1.14 +1.51 +2.72 
Sr. No. Protein Name pI 6-11 
gi 
Number 
AVR 
H/C1 
AVR 
M/C1 
AVR 
6/C1 
AVR 
8/C1 
AVR 
12/C1 
32 
acetyl-Coenzyme A 
acetyltransferase 2  20810027 +1.13 +1.38 +1.53 +1.12 -2.24 
33 Aldh1a1 protein  32484332 -1.24 +1.10 +1.24 -1.21 -2.08 
34 Aldolase 2, B isoform  21707669 +1.61 +1.37 +1.95 +1.30 -2.36 
35 
argininosuccinate 
synthetase 6996911 -1.15 +1.09 +1.21 -1.10 -2.81 
36 
argininosuccinate 
synthetase 6996911 -1.02 +1.26 +1.29 -1.39 -2.57 
37 Betaine-homocysteine 62533211 -1.07 1.15 1.42 -1.21 -2.62 
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methyltransferase  
38 Carbonic Anhydrase III 226778 -3.62 -1.92 -1.14 -2.44 -3.26 
39 Carbonic Anhydrase III 226778 -3.98 -1.84 -1.16 -2.69 -3.06 
40 Carbonic Anhydrase III 226778 -3.86 -1.97 -1.26 -2.69 -2.9 
41 Catalase 15004258 -1.41 -1.11 1.15 -1.41 -2.63 
42 catalase 26344712 -1.33 1 1.17 -1.34 -2.5 
43 
Electron transfer 
flavoprotein beta-subunit  21759114 -1.40 -1.00 -1.04 -1.52 -2.64 
44 
Enoyl Coenzyme A 
hydratase, short chain, 1, 
mitochondrial 12805413 -1.09 +1.21 +1.08 -1.28 -2.92 
45 glutamate dehydrogenase  26354278 +1.08 +1.28 +1.31 -1.03 -2.02 
46 
Glutathione S-Transferase 
Class Pi 2624496 -1.81 -1.30 +1.06 -1.95 -2.47 
47 
Glutathione S-Transferase 
Class Pi 2624496 -1.64 -1.27 +1.21 -1.55 -2.09 
48 
homogentisate 1, 2-
dioxygenase  7549763 -1.3 -1.07 +1.17 -1.35 -2.85 
49 
homogentisate 1, 2-
dioxygenase  7549763 +1.10 -1.01 +1.25 -1.04 -2.72 
50 
homogentisate 1, 2-
dioxygenase  7549763 -1.06 -1.01 +1.43 -1.12 -2.26 
51 hydroxyacid oxidase 1, liver  6754156 -1.40 +1.11 +1.17 -1.27 -2.58 
52 isocitrate dehydrogenase 2 6647554 -1.11 +1.15 +1.24 -1.17 -2.77 
53 MHC Class 1 HLA 51770518 +5.42 +3.14 -1.86 +5.25 +8.63 
54 PEPCK 56753812 +5.11 +2.85 -2.17 +2.88 +4.89 
55 phosphoglycerate kinase 202423 -1.01 +1.13 +1.44 -1.15 -2.56 
56 solute carrier family 25 16741519 +1.33 +1.28 +1.52 +1.10 -2.44 
57 Transferrin 62027488 +4.42 +1.45 +1.61 +1.29 -2.15 
58 urate oxidase  6678509 +1.14 +1.15 +1.32 -1.10 -2.00 
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1
AVR: average volume ratio between study groups (C, control; 6, 6-week infected; 8, 8-
week infected; 12, 12-week infected; M, MSS; H, HSS mice). Sr. No. = serial number 
 
 
FIGURE 4.7 Liver proteins during 12-week infection: 20 protein spots increased (up-
regulated) in abundance and 38 protein spots decreased (down-regulated) in abundance. 
Numbers represent the number of protein spots in each category. The protein spots were 
identified using MALDI-TOF mass spectrometry and plotted according to their Gene 
Ontology function.   
 
4.2.4 Multivariate analysis 
The multivariate analysis using the principle component analysis (PCA) showed good 
separation of the study groups for pI range 4-7 and 6-11 (Figure 4.8 and 4.9) along with 
the grouping of the 8-week infected and 12-week infected mice with, MSS and/or HSS 
mice in the 2D-DIGE spot maps. The pI 4-7 PCA plot distinguished the six study groups: 
6-week, 8-week, 12-week MSS and HSS mice and control mice. The 6-week infected 
mice were clustered very close to the control mice. The MSS and HSS mice showed 
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distinct clustering. In contrast, while most 8-week and 12-week infected mice were 
clustered into distinct groups, some 8-week and 12-week mice clustered with the 20-week 
infected mice (Figure 4.8). For the pI 6-11 range PCA plot, control and 6-week infected 
mice again clustered together whereas the 8-week, 12-week, MSS and HSS mice together 
formed less distinct clusters. These results may be because the proteins in the pI range 6-
11 are difficult to resolve on gels even with the most standardised conditions (Figure 4.9). 
For both the pI ranges, the protein spots within the ellipse showed 95% significance level. 
The protein spots within the ellipse in the light blue circle were increased in abundance in 
disease groups (6-week infected, 8-week infected, 12-week infected, MSS and HSS mice) 
when compared to control mice. The protein spots within the ellipse in the dark blue circle 
showed decreased protein spot abundance in disease groups when compared to control 
mice. The PCA plot for the pI range 4-7 showed one protein outlier (outside the ellipse) in 
the dark blue circle, which is a MUP isoform very strongly differentially expressed protein 
during schistosomiasis. 
 
The unsupervised, hierarchical cluster analysis segregated the protein spots and study 
groups according to the individual disease status in each mouse for pI range 4-7 and 6-11 
(Figure 4.10 and 4.11). The heat map showed a distinct protein pattern for MSS and HSS 
mice for pI 4-7 range (Figure 4.10). The mice numbers wk0805, wk0809, wk1203 and 
wk1205, had relatively high %SBW ratio when compared within the 8-week and 12-week 
infected mice groups but had similar %SBW when compared to the %SBW of HSS mice. 
The %SBW ratios for the above mice numbers were 19.32, 17.65, 27.80 and 23.30 
respectively. These mice in the pI 4-7 dendrogram were clustered (flanked) by MSS mice 
on the left and HSS mice on the right with the heat map colour pattern showing similar 
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protein patterns between these mice and confirming the fate of these mice leading towards 
severe disease. Thus, the HCA dendrogram and heat map for pI 4-7 showed clustering of 
mice from HSS group with mice from other study groups having similar %SBW (wk0805, 
wk0809, wk1203 and wk1205). However, the dendrogram and heat map for pI range 6-11 
showed clustering of wk0809, wk1203 and wk1205 mice together with 12-week infected 
mice, while one mouse wk0805 clustered with MSS and HSS mice (Figure 4.11). The 
reason for the inconclusive result for pI 6-11 protein spots may be that the proteins are 
difficult to resolve, and/or co-migration of different protein spots being another possibility, 
and therefore the heat map for pI 6-11 is not as consistent as the result for pI 4-7. 
 
 
FIGURE 4.8 Principle component analysis plot for the pI range 4-7 protein spots with 2-
fold change and 1-ANOVA  0.01, FDR for the five time point experiment with 63 
protein spots. Protein spots within the ellipse show highly abundant (light blue circle, 
infected mice compared to control mice) and lowly abundant (dark blue circle, infected 
mice compared to control mice) protein spots. Spot maps (2D-DIGE images) show the 
best separation of the control and 6-week, MSS and HSS infected mice with 8-week 
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infected and 12-week infected mice showing grouping with the above 20-week infected 
mice (MSS and HSS).  
 
 
FIGURE 4.9 Principle component analysis plot for the pI range 6-11 protein spots with 2-
fold change and 1-ANOVA  0.01, FDR for the five time point experiment with 13 
protein spots. Protein spots within the ellipse show highly abundant (light blue circle, 
infected mice compared to control mice) and lowly abundant (dark blue circle, infected 
mice compared to control mice) protein spots. Spot maps (2D-DIGE images) show the 
best separation of the control and MSS, HSS mice together with 6-week infected, 8-week 
infected, 12-week infected mice showing grouping with the above three study groups.  
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FIGURE 4.10 Hierarchical cluster analysis dendrogram and heat map for five time point 
experiment for the pI range 4-7 with 63 protein spots in the 2-fold change and 1-
ANOVA<0.01, FDR criteria. The dendrogram and heat map illustrates distinct protein 
pattern between the six study groups with the segregation and alignment of the protein 
spots with similar functional groups and clustering of experimental groups with similar 
disease pathology. The colour scale goes from green (more abundant protein spots) to 
black (no change in protein abundance) to red (less abundant protein spots) with a heat 
map interval of of 1 representing 10-fold increased abundance and -1 representing 10-fold 
decreased abundance. (C=control, wk0601-10= 6-week infected, wk0801-10=8-week 
infected, wk1201-10=12-week infected, M=MSS, H=HSS). Pink arrows indicate mice 
with high %SBW. 
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FIGURE 4.11 Hierarchical cluster analysis dendrogram and heat map for five time point 
experiment for the pI range 6-11 with 13 protein spots in the 2-fold change and 1-ANOVA 
≤ 0.01, FDR criteria. The dendrogram and heat map illustrates distinct protein pattern 
between the six study groups with the segregation and alignment of the protein spots with 
similar functional groups and clustering of experimental groups with similar disease 
pathology. The colour scale goes from green (more abundant protein spots) to black (no 
change in protein abundance) to red (less abundant protein spots) with a heat map interval 
of 1 representing 10-fold increased abundance and -1 representing 10-fold decreased 
abundance. (C=control, wk0601-10= 6-week infected, wk0801-10=8-week infected, 
wk1201-10=12-week infected, M=MSS, H=HSS). Pink arrows indicate mice with high 
%SBW. 
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4.2.5 Linear regression correlations 
To understand if changes in protein abundance correlated to the severity of pathology, 
protein spot volumes from each mouse were plotted against %SBW and simple linear 
regression correlations were performed. This approach helped analyse the effect of each 
protein on development of splenomegaly. Since 20-week classification of the mice into 
MSS or HSS was based on the %SBW and gross pathological changes in the liver, a clear 
distinction in the %SBW for these mice can be seen. However, with the 8-week and 12-
week a range of %SBWs can be observed. The relationship between %SBW and spot 
volume was investigated for several protein spots including transferrin, retinol binding 
protein1, keratin D, hydroxyproline, MUP, Sm-PEPCK, peroxiredoxin 6 and epoxide 
hydrolase which are addressed below according to their GO function categories and their 
relation to the disease pathology. In the graph representing linear regression analyses: pink 
line = 8-week infected, purple line = 12-week infected and black line = 20-week infected 
mice. Only statistically significant linear regression line data has been shown in 
subsequent figures.  
 
4.2.5.1 Acute phase proteins  
Acute phase proteins like retinol binding protein 1 and transferrin are known to decrease 
during inflammation as a result of infection and disease. Retinol binding protein-1 is 
abundant in liver cells, particularly in hepatic stellate cells. We reported increased 
abundance of this protein in HSS mice in Chapter 3. Similarly, we found retinol binding 
protein 1 was significantly higher in HSS mice compared to other five study groups. In 
12-week infected mice, the spot volumes were higher compared to control and 6-week 
infected mice (Figure 4.12). Although linear regression analysis did not show a correlation 
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within individual study groups, when all values are analysed together (r square=0.6046, p 
< 0.0001) the increased abundance of the protein strongly correlated to splenomegaly, 
independent of the time of infection. At 20-week infection the slope for the linear 
regression analysis showed r square=0.7284, p = 0.0017 relating to increased abundance 
of retinol binding protein 1 during HSS, indicating requirement of this protein possibly for 
tissue repair (Figure 4.13) 
 
 
FIGURE 4.12 Mouse retinol binding protein 1 spot volumes were significantly high in 
HSS mice when compared to control, 6-week, 8-week, 12-week infected mice and MSS 
mice. Shown are mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.05 when 12-week 
infected mice compared to control, 6-week infected mice, #p  0.001 when HSS compared 
to control and 6-week, 8-week, 12-week infected mice and MSS mice by Newman-Keuls 
Multiple Comparison Test. (20wk = MSS + HSS.) 
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FIGURE 4.13 Comparison of spot volume fluorescence intensity of liver retinol binding 
protein 1-spot 29 with percent spleen to body weight ratio from control, 6-week infected, 
8-week infected, 12-week infected and 20-week infected mice. (Linear regression line: 
pink = 8-week infected, purple = 12-week infected and black = 20-week infected mice). 
 
The spot volumes for liver transferrin (two spots together, spot 43 and 44) increased for 
6-week, 8-week, 12-week, MSS and HSS infected mice when compared to control mice 
(Figure 4.15). These findings were similar to the results in Chapter 3 for 20-week infected 
mice. The linear regression analysis for spot 43-liver transferrin showed significantly 
strong relationship with %SBW for all groups independent of time post-infection (r 
square=0.6637, p=0.0001), in particular, liver transferrin at 12-week infection (r 
square=0.7538, p<0.0001) correlated strongly with disease severity (%SBW). The linear 
regression for 20-week infected mice showed that increased transferrin abundance 
correlated with 92% splenomegaly in schistosomiasis (Figure 4.16). In particular, at 8-
week and 12-week infections, there were two mice in each of the group that had increased 
transferrin abundance suggesting that these mice are likely to develop the disease similar 
to HSS mice.   
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FIGURE 4.14 Comparison of spot volume fluorescence intensity of spot 43 and 44 
together for liver transferrin from control, 6-week infected, 8-week infected, 12-week 
infected, MSS and HSS mice. Shown are mean ± SEM with 1-ANOVA p  0.01 for all. 
***p  0.001 when HSS mice were compared to control and 6-week, 8-week, 12-week 
infected mice and MSS mice by Newman-Keuls Multiple Comparison Test. (20wk = MSS 
+ HSS.) 
 
 
FIGURE 4.15 Comparison of spot volume fluorescence intensity of liver transferrin spot 
43 with percent spleen to body weight ratio from control, 6-week infected, 8-week 
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infected, 12-week infected and 20-week infected mice. (Linear regression line: pink = 8-
week infected, purple = 12-week infected and black = 20-week infected mice). 
 
4.2.5.2 Structural proteins 
Structural proteins provide structural stability to the cell/tissue/organ. We found increased 
abundance of collagen isoforms although the increase was not statistically significant.  
Keratin D is an intermediate filament protein and is thought to be hepatoprotective. In 
Chapter 3, we found a single spot of liver keratin D with increased abundance for HSS 
mice alone. Similarly, we found three spots of liver keratin D with increased abundance 
in HSS mice compared to five study groups (Table 4.1, Figure 4.6). Taken together all the 
spot volumes for the three liver keratin D spots (Table 4.2, spot 21, 22, 23, Figure 4.6), 
there was almost 13-fold increased abundance for HSS mice, 4-fold increase for MSS 
mice and 12-week infected mice had almost 8-fold increase in the average volume ratio 
when compared to control mice (Figure 4.16). In particular, the spot volume for spot-21 
showed HSS mice had significantly higher levels (p ≤ 0.05) compared to other five study 
groups (Figure 4.16). The linear regression analysis for spot 21-keratin D for the six 
study groups compared with the %SBW gave an r square value of 0.3537, p<0.0001 for all 
spots independent of the time of infection (Figure 4.17) confirming its relation to disease 
severity. The linear regression lines for 8-week and 12-week infection are indicative of the 
mice from these groups inclining towards the severe form of the disease (HSS). The 
increased abundance of liver keratin D correlated with 42% splenomegaly at 20-week 
infection. The increased abundance of this protein indicates the responses of the liver to 
chronic infection. 
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FIGURE 4.16 Mouse keratin D spot volumes were high in HSS mice when compared to 
control, 6-week, 8-week, 12-week infected mice and MSS mice. Shown are mean ± SEM 
with 1-ANOVA p  0.01 for all. *p  0.05 when HSS compared to control and 6-week, 8-
week, 12-week infected mice and MSS mice by Newman-Keuls Multiple Comparison 
Test. (20wk = MSS + HSS.) 
 
 
FIGURE 4.17 Comparison of spot volume fluorescence intensity of liver keratin D-spot 
21 with percent spleen to body weight ratio from control, 6-week, 8-week, 12-week 
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infected mice and 20-week infected mice. (Linear regression line: pink = 8-week infected, 
purple =12-week infected and black = 20-week infected mice). 
 
Collagen contains the amino acid hydroxyproline that is formed by hydroxylation of 
proline in preformed collagen and therefore can be used as a measure of collagen-
associated fibrosis. Liver hydroxyproline was measured using liver tissue from control and 
infected mice but was not a consequence of the 2D-DIGE analysis. The liver 
hydroxyproline content per g of liver tissue (g/g of liver tissue) for the six study groups 
showed high levels in HSS mice than the MSS, 8-week and 12-week infected mice 
compared to control mice (Figure 4.18). The linear regression analysis for the liver 
hydroxyproline content per g of liver tissue, increased significantly in HSS mice 
indicating increased fibrosis in severe disease and the r square
 
value of 0.6833 confirming 
statistically significant strong relationship, which was independent of time of infection 
(Figure 4.19). However, the linear regression r square=0.4710, p = 0.0280 for 8-week 
infected mice (pink line) and r square=0.8666, p < 0.0001 for 12-week infected mice 
(purple line) showed a strong influence of hydroxyproline on %SBW during the early 
infection pathogenesis in schistosomiasis and suggesting that mice from these study 
groups definitely separate into severe disease form (Figure 4.19). Additionally, at 20-week 
infection, hydroxyproline showed almost 72% correlation with disease pathology (%SBW) 
(Figure 4.19). These results for the 8-week, 12-week and 20-week infected mice suggest a 
strong association of hydroxyproline with the pathogenesis of the schistosomiasis. 
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FIGURE 4.18 Mouse liver hydroxyproline levels per g of liver tissue were high in HSS 
mice when compared to control, 8-week, 12-week and MSS infected mice. Shown are 
mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.001 when 8-week, 12-week, MSS 
and HSS infected mice compared to control mice, #p  0.001 when HSS compared to 8-
week, 12-week infected mice and MSS, &p  0.001 when MSS compared to 8-week, 12-
week by Newman-Keuls Multiple Comparison Test. (20wk = MSS + HSS.) 
 
 
FIGURE 4.19 Linear regression correlations of mouse liver hydroxyproline per g of liver 
tissue with percent spleen to body weight ratio for five study groups:  control mice, 6-
week, 8-week, 12-week and 20-week infected mice. The r square value of 0.6833 is 
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indicative of the strong effect of the progression of disease and fibrosis. (Linear regression 
line: pink = 8-week infected, purple = 12-week infected and black = 20-week infected 
mice). 
 
4.2.5.3 Immune related proteins 
Immune responses to eggs embedded in the liver are a marked feature of schistosomiasis.  
Proteins in the immune system that protect the host from the disease mediate these 
immune responses. We studied two proteins related to immune responses among the five 
study groups in detail, they include MHC class I histocompatibility antigen H2 Q4 
alpha chain precursor (MHC class 1 H2Q4 like protein) and interleukin 2. Similar 
results were observed for MHC class 1 H2Q4 like protein as in Chapter 3. The results 
obtained in Chapter 3, for interleukin 2 showed increased abundance of the protein in 
MSS and HSS mice compared to control mice but were not statistically significant 
because the protein spot was not satisfactorily resolved on the gel.   
 
The MHC class 1 H2Q4 like protein spot volume comparison between six study groups 
showed that 12-week infected mice had significantly higher protein abundance when 
compared to other study groups (Figure 4.20). These results suggest that at 12-week 
infection there is imbalance in immune responses. Linear regression analysis for MHC 
class 1 H2Q4 like protein demonstrated a strong correlation between protein spot volume 
intensity for MSS and %SBW (r square=0.9785) (Figure 4.21). The r square for 20-week 
infected mice (r square=0.7408) suggests that MHC class 1 H2Q4 like protein may be 
involved in immunomodulation of host response to the eggs embedded in the liver. 
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The mean values for the cytokine interleukin 2 were significantly higher for 8-week, 12-
week, MSS and HSS mice form the control and 6-week mice (Figure 4.22). The linear 
regression analysis showed (r square=0.2542, p=0.0004) that interleukin 2 does play an 
important role in contributing towards splenomegaly (Figure 4.23). Moreover, the 
inclination of the linear regression line for 20-week infected mice when compared to 8-
week and 12-week infection suggests down-modulation of interleukin 2 during chronic 
disease stage (Figure 4.23). Finally, the linear regression scatter plot for both the immune 
related proteins at 8-week and 12-week infection showed spot volumes spread out 
inconsistently (Figure 4.21 and 4.23) this may be due to individual variability in the mice 
during pathogenesis of schistosomiasis. 
 
 
FIGURE 4.20 Comparison of spot volume fluorescence intensity of MHC class I 
histocompatibility antigen H2 Q4 alpha chain precursor-spot 61 from control, 6-week 
infected, 8-week infected, 12-week infected, MSS and HSS mice. Shown are mean ± SEM 
with 1-ANOVA p  0.01 for all. **p  0.05 when 12-week infected compared to other 
study groups by Newman-Keuls Multiple Comparison Test. (20wk = MSS + HSS.) 
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FIGURE 4.21 Comparison of spot volume fluorescence intensity of MHC class I 
histocompatibility antigen H2 Q4 alpha chain precursor -spot 61 with percent spleen to 
body weight ratio from control, 6-week infected, 8-week infected, 12-week infected and 
20-week infected mice. (Linear regression line: pink = 8-week infected, purple = 12-week 
infected and black = 20-week infected mice). 
 
 
FIGURE 4.22 Comparison of spot volume fluorescence intensity of interleukin 2-spot 20 
from control, 6-week infected, 8-week infected, 12-week infected, MSS and HSS mice. 
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Shown are mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.05 when 8-week, 12-
week, MSS and HSS infected mice compared to control and 6-week infected mice by 
Newman-Keuls Multiple Comparison Test. (20wk = MSS + HSS.) 
 
 
FIGURE 4.23 Comparison of spot volume fluorescence intensity for interleukin-2-spot 
20 with percent spleen to body weight ratio from control, 6-week infected, 8-week 
infected, 12-week infected and 20-week infected mice. (Linear regression line: pink = 8-
week infected, purple = 12-week infected and black = 20-week infected mice). 
 
4.2.5.4 Xenobiotic metabolism proteins 
During disease, xenobiotic metabolising proteins help removal of toxic molecules.  We 
found two proteins with xenobiotic removal function very interesting these were 
peroxiredoxin 6 and epoxide hydrolase. The Chapter 3 results of peroxiredoxin 6 showed 
decreased abundance by 2-fold for HSS mice only however the results were not significant 
after the application of FDR. In Chapter 3 there were three spots with decreased epoxide 
activity in MSS mice (6-fold) and HSS mice (8-fold).  
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The spot volumes for peroxiredoxin 6 significantly decreased for 6-week, 8-week, 12-
week, MSS and HSS infected mice when compared to control mice (Figure 4.24) 
consistent with the findings in Chapter 3. At 8-week and 12-week infections the 
abundance decreased significantly indicated by the linear regression lines, however at 20-
week the levels coming close to levels at 6-week infections. The protein abundance at 20-
week infection showed 46% influence on the disease (Figure 4.25). These results indicate 
that active disease pathology at 8-week and 12-week infection may have impaired the 
synthesis or functioning of peroxiredoxin 6.  
 
 
FIGURE 4.24 Comparison of spot volume fluorescence intensity for Spot 28-
Peroxiredoxin 6 from control, 6-week infected, 8-week infected, 12-week infected, MSS 
and HSS mice. Shown are mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.05 when 
6-week, 8-week, 12-week, MSS and HSS mice compared to control,  
@
p  0.05 when 8-
week and 12-week compared to MSS mice, #p  0.05 when MSS and HSS compared to 6-
week mice by Newman-Keuls Multiple Comparison Test. (20wk = MSS + HSS.) 
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FIGURE 4.25 Comparison of spot volume fluorescence intensity for Spot 28-
Peroxiredoxin 6 with percent spleen to body weight ratio from control, 6-week infected, 8-
week infected, 12-week infected and 20-week infected mice. (Linear regression line: pink 
= 8-week infected, purple = 12-week infected and black = 20-week infected mice). 
 
Epoxide hydrolase is located in the peroxisomes and play a significant role in the 
metabolism of reactive oxygen species produced in response to stress conditions. Similar 
to the results in Chapter 3, we found one spot with decreased abundance at 8-week, 12-
week and HSS infected mice. The epoxide hydrolase spot volume fluorescence intensity 
for MSS was slightly higher than HSS mice indicating the resolved liver pathology during 
MSS. The protein abundance decreased at 8-week and 12-week infection and was similar 
to that of HSS mice (Figure 4.26). The epoxide hydrolase-spot-14 correlated with 28% 
splenomegaly as analysed by linear regression irrespective of the time of infection. 
However, at 20-week infection the linear regression for the protein abundance showed r 
square 0.7732 indicating the strong association with the disease (Figure 4.27). Taken 
together these results indicate that epoxide hydrolase plays a significant role during 
chronic schistosomiasis.   
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FIGURE 4.26 Comparison of spot volume fluorescence intensity for Spot 14-Epoxide 
hydrolase from control, 6-week infected, 8-week infected, 12-week infected, MSS and 
HSS mice. Shown are mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.05 when 8-
week, 12-week, HSS mice compared to control mice by Newman-Keuls Multiple 
Comparison Test. (20wk = MSS + HSS.) 
 
 
FIGURE 4.27 Linear regression analysis for spot 14-epoxide hydrolase with percent 
spleen to body weight ratio from control, 6-week infected, 8-week infected, 12-week 
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infected and 20-week infected mice. (Linear regression line: pink = 8-week infected, 
purple = 12-week infected and black = 20-week infected mice). 
 
4.2.5.5 MUP and Sm-PEPCK  
MUP is a pheromone protein and its decreased abundance is related to infection and 
disease. We found two spots with decreased MUP activity in HSS mice. These findings 
were similar to the results in Chapter 3. The mean MUP spot volumes showed 
significantly decreased levels in HSS mice compared to other five study groups (Figure 
4.28).  The r
 
square value for MUP spot volume linear regression was 0.395, p<0.0001 
independent of the time of infection. Although the linear regression for 8-week and 12-
week infected mice was not statistically significant the regression line inclined towards the 
20-week infected mice linear regression line indicating that some mice display protein 
patterns similar to severe disease (Figure 4.29) and may follow the same path as for the 
chronic disease. 
  
 
FIGURE 4.28 Comparison of spot volume fluorescence intensity of liver MUP-spot 26 
from control, 6-week infected, 8-week infected, 12-week infected, MSS and HSS mice. 
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Shown are mean ± SEM with 1-ANOVA p  0.01 for all. *p  0.001 when 6-week, 8-
week, 12-week, MSS and HSS infected mice compared to control mice, #p 0.05 when 
HSS compared to 6-week, 12-week and MSS mice by Newman-Keuls Multiple 
Comparison Test. (20wk = MSS + HSS.) 
 
 
FIGURE 4.29 Comparison of spot volume fluorescence intensity of liver MUP-spot 26 
with percent spleen to body weight ratio from control, 6-week infected, 8-week infected, 
12-week infected and 20-week infected mice. (Linear regression line: pink = 8-week 
infected, purple = 12-week infected and black = 20-week infected mice). 
 
Sm-PEPCK, a parasite protein showed increased abundance during disease progression 
confirming the results in Chapter 3. In particular, the protein abundance increased for 12-
week and HSS mice indicating the role of this protein at these time points post-infection 
(Figure 4.30). The r square value of 0.3971 showed a significant association of the protein 
on splenomegaly during schistosomiasis. Two mice each from 8-week and 12-week 
infected mice display protein patterns similar to 20-week infected mice (HSS mice) 
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confirmed by the linear regression lines for 8-week and 12-week infection (Figure 4.31). 
The r square 0.8732 showed the increased abundance of this protein during chronic stage 
of the disease (Figure 4.31). We believe our results for Sm-PEPCK suggest that increased 
abundance may indicate the orientation of the disease towards severity.  
 
 
FIGURE 4.30 Comparison of spot volume fluorescence intensity of S. mansoni- 
phosphoenolpyruvate carboxykinase-spot 62 from control, 6-week infected, 8-week 
infected, 12-week infected, MSS and HSS mice. Shown are mean ± SEM, 1-ANOVA p  
0.01 for all. *p  0.001 when HSS mice compared to control mice, 6-week, 8-week and 
MSS mice, #p 0.01 when HSS compared to 12-week mice, @p 0.001 when 12-week 
mice compared to control and 6-week mice, 
&
p  0.01 when 12-week mice compared to 
MSS mice
 
by Newman-Keuls Multiple Comparison Test. (20wk = MSS + HSS.) 
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FIGURE 4.31 Comparison of spot volume fluorescence intensity of Schistosoma mansoni 
phosphoenolpyruvate carboxykinase-spot 62 with percent spleen to body weight ratio 
from control, 6-week infected, 8-week infected, 12-week infected, and 20-week infected 
mice. (Linear regression line: pink = 8-week infected, purple = 12-week infected and 
black = 20-week infected mice). 
 
4.2.6 Multiple regression analysis 
We used multiple regression analysis to test the multiple protein spot volumes 
(independent variables) simultaneously and investigate the concurrent effects of different 
proteins on disease pathology represented by %SBW (splenomegaly) or %LBW 
(hepatomegaly) in our study.  In this analysis, the standardised  value indicates the extent 
of effect of the independent variable on the dependent variable in the presence of other 
independent variables and the coefficient of determination (r square) shows the linear 
relationship between the two variables (dependent and independent). The protein spot 
volumes were logarithmically (loge) transformed to normalise the data.  All the protein 
spot volumes, on univariate analysis significantly related to the disease progression, were 
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entered by the forward stepwise method into a multiple regression analysis to identify the 
determinants of splenomegaly and hepatomegaly (dependent variables). 
 
We found that liver hydroxyproline was the strongest predictor of splenomegaly (r square 
= 0.757, standardised  = 0.870, p=0.000) and hepatomegaly (r square = 0.455, 
standardised  = 0.674, p = 0.000) indicating it major role in disease pathology. As 
hydroxyproline was such a strong predictor of splenomegaly and hepatomegaly, in order 
to identify other protein predictors, the data was analysed independent of hydroxyproline 
in a similar way as described above. We found that MUP, Sm-PEPCK, keratin D and IL-2 
together, predicted 81% of splenomegaly with MUP being the dominant predictor and 
related inversely to the development of the disease. In a separate analysis, we found that 
MUP, Sm-PEPCK and IL-2 together, correlated with 58% hepatomegaly, with MUP and 
IL-2 levels related inversely to hepatomegaly. (The negative value for standardised beta 
means that the independent variable is inversely proportional to dependent variable). 
Importantly, keratin D was the distinct predictor of splenomegaly (Table 4.4).  
 
TABLE 4.4 Predictors of splenomegaly and hepatomegaly. 
 r square Standardised  Coefficient p value 
Predictors of splenomegaly 
MUP 0.604 -0.612 0.000 
Keratin D 0.129 +0.287 0.000 
Sm-PEPCK 0.054 +0.169 0.043 
IL-2 0.019 +0.175 0.050 
Predictors of hepatomegaly 
MUP 0.373 -0.451 0.000 
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Sm-PEPCK 0.161 +0.296 0.015 
IL-2 0.042 -0.256 0.048 
 
With the aim of identifying the predictors of splenomegaly and hepatomegaly at each time 
post-infection, a stepwise multiple regression analysis was done using liver 
hydroxyproline, transferrin, peroxiredoxin 6, MUP, keratin D, Sm-PEPCK, carbonic 
anhydrase III, interleukin 2, GSTPi as independent variables. At 8-week, 12-week and 20-
week infections, liver hydroxyproline was the strongest predictor of splenomegaly (Table 
4.5). Our data suggest that splenomegaly at 8-week infections was suppressed by 
transferrin (standardised  = -0.705).  Hepatomegaly was predicted strongly by liver 
hydroxyproline except at 8-week infections, where transferrin was the strongest variable 
that negatively correlated to 61% (standardised  = -0.772) hepatomegaly (Table 4.6). 
Additionally, peroxiredoxin 6 had significant effects on hepatomegaly at 8-week and 20-
week infections. Peroxiredoxin 6 change was negatively associated with 55% 
hepatomegaly at 20-week infection (standardised  = -0.556) (Table 4.6). The results from 
multiple regression analyses suggest that hydroxyproline has an important role in 
aggravated disease pathology with a simultaneous effect of acute phase protein transferrin 
to diminish the effects of pathology on the scarred liver.   
 
Taken together, the results for protein abundance data, the linear regression and multiple 
regression analyses and the %SBW for all study groups indicate that, at 8-week and 12-
week infection there emerges a distinct pattern of protein abundance which suggests of 
certain specific mechanisms and impact of unknown molecules that contribute towards the 
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segregation of these disease groups into moderate and severe pathology in schistosomiasis 
disease (Figure 4.32).  
 
TABLE 4.5 Predictors of splenomegaly at time post-infection. 
Time post-
infection 
Predictors of 
splenomegaly 
r 
square 
Standardised 
 Coefficient 
p 
value 
8-week (n=10) Hydroxyproline 0.514 +0.717 0.020 
 Transferrin 0.497 -0.705 0.023 
12-week (n=10) Hydroxyproline 0.825 +0.908 0.000 
20-week (n=10) Hydroxyproline 0.834 +0.913 0.000 
 
TABLE 4.6 Predictors of hepatomegaly at time post-infection. 
Time post-
infection 
Predictors of 
hepatomegaly 
r 
square 
Standardised 
 Coefficient 
p value 
8-week (n=10) Transferrin 0.610 -0.772 0.001 
 Hydroxyproline 0.177 +0.484 0.006 
 Peroxiredoxin 6 0.145 +0.442 0.012 
12-week (n=10) Hydroxyproline 0.822 +0.878 0.000 
 Sm-PEPCK 0.081 0.287 0.046 
20-week (n=10) Hydroxyproline 0.463 +0.714 0.000 
 Peroxiredoxin 6 0.308 -0.556 0.018 
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FIGURE 4.32 Specific mechanisms contribute towards segregation of the mice at 8-week 
and 12-week infections either towards moderate (MSS) or severe (HSS) disease 
progression. 
 
4.3 Discussion 
The %SBW comparison between the five study groups (Figure 4.2) suggests aggravated 
splenomegaly is a marked feature of the severe schistosomiasis as previously indicated 
(Henderson et al., 1993) and similar to the findings in Chapter 3. The significant increase 
in hepatomegaly in the five study groups (Figure 4.3). These results were similar to the 
findings in hepatomegaly associated with ethanol consumption (Roede et al., 2008). The 
linear regression analysis between percent liver to body weight ratio and %SBW showed 
the important role of the liver during the schistosomiasis. These findings are unique to this 
study and suggest an interplay between liver and spleen during pathogenesis of 
schistosomiasis as the disease progresses towards severity (Figure 4.4).  
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4.3.1 Liver protein abundance at time post infection  
Liver total protein comparison between the five study groups showed decreased 
abundance when compared to control mice (Figure 4.5). These results support the findings 
from S. mansoni infected mice studies which demonstrated a significant decrease in liver 
total protein abundance at 8 week infection (Aly and Aly, 2006) suggesting that during 
schistosomiasis infection, the scarred liver is unable to synthesise proteins normally. 
 
The differential protein abundance among the six study groups gave a total of 44 protein 
spots (Figure 4.6, Table 4.1). Importantly, the data suggests that transferrin isoforms, 
retinol binding protein1, MUP isoforms, peroxiredoxin 6, keratin D isoforms, epoxide 
hydrolase isoforms, MHC Class 1 H2Q4 like protein and Sm-PEPCK play a role in 
disease progression. While most differences for comparison with control mice were for 
128 protein spots in 12-week infected mice we found greatest difference in level of change 
for 76 protein spots in HSS mice indicating greatest changes for 12-week infected mice 
but greatest magnitude of changes for 20-week infected mice.  
 
Interestingly, the protein spot abundance data for 12-week infection reflects the extent of 
liver dysfunction and the severity of liver damage due to schistosome worms and eggs 
(Table 4.1 and 4.2, Figure 4.7). In particular, proteins related to amino acid metabolism 
(homogentisate 1, 2-dioxygenase), fatty acid metabolism (acetyl-Coenzyme A 
acetyltransferase 2), xenobiotic metabolism (catalase, carbonic anhydrase III, GST Pi), 
energy metabolism (aldolase 2, electron transfer flavoprotein beta-subunit, glutamate 
dehydrogenase, isocitrate dehydrogenase 2), urea cycle (argininosuccinate synthetase) 
were decreased significantly. Moreover, the data at 12-week infection showed increased 
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apoptotic and blood coagulation proteins (Figure 4.7). These results are supported by a 
human intestinal schistosomiasis study that demonstrated an important role of apoptosis in 
schistosomiasis (Carneiro-Santos et al., 2000) and another study which suggests an 
important role for blood coagulation in modulating the cytokine and antigenic mediated 
immune responses in hepatosplenic schistosomiasis (El-Bassiouni et al., 1998). 
Additionally, El-Meneza et al. demonstrated maximal hepatic fibrosis occurs at 12-week 
infection (El-Meneza et al., 1989) supporting the findings in our study whereby 
suggesting that the increased abundance of cytoskeletal and extracellular matrix proteins 
(structural proteins) are a marked feature of 12-week infection (Figure 4.7). Previous work 
has shown that spontaneous and prominent immunomodulation of chronic schistosomiasis 
pathology at 12-week infection (Pelley et al., 1976). The results in our study support the 
findings of Pelley et al. and suggest that immunomodulatory mechanisms contribute to the 
pathology at 12-week infection.  
 
The linear regression scatter plots for all the protein spots examined at 8-week and 12-
week infection (retinol binding protein 1, transferrin, keratin D, MHC class 1 H2Q4 like 
protein, interleukin 2, peroxiredoxin 6 and epoxide hydrolase) showed two spot volumes 
as outliers indicating that distinct changes occur at 12-week infection and even at 8-week 
infection. A study in 8-week S. mansoni infected mice analysed metabolic profiles and 
reported reduced levels of the tricarboxylic acid cycle intermediates, increased pyruvate 
levels, impairment in amino acid metabolism and fatty acid metabolism (Wang et al., 
2004) similar to the findings in our study. Moreover, another study also reported liver 
dysfunction at 8-week infection (Harvie et al., 2007). While these studies found 
significant differences at 8-week infection similar to our findings, our results suggest 
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profound differences at 12-week infection. Our report on liver proteins in CBA/J mice is 
exclusive as it compared the protein abundance at 6-week, 8-week, 12-week and 20-week 
infections and showed that the response is varied at different times post infection. 
Together the protein spot abundance data for 6-week, 8-week 12-week, MSS and HSS 
infections suggests that the liver dysfunction was elevated in 12-week infected CBA/J 
mice.  
 
4.3.2 Multivariate analysis 
The PCA plot successfully distinguished the study groups according to the disease pattern 
(Figure 4.8) and protein abundance for pI range 4-7 and these results were confirmed by 
HCA (Figure 4.10). In contrast, the multivariate analysis of the protein spots for pI range 
6-11 was unable to identify discrete clusters consistent with the separate groups. The 
possible reasons for the lack of discrete clusters may be the lower resolution of the gels in 
the 6-11 pI range. The HCA dendrogram and heat map for pI range 4-7 showed clustering 
of mice with similar %SBW. This provides evidence that mice with high %SBW ratio 
may follow the hepatosplenic disease path irrespective of the week of infection. Finally, 
PCA and HCA performed on the 44 protein spots (33 protein spots for pI range 4-7 and 11 
protein spots for pI range 6-11) showed that some mice at 8-week and 12-week infection 
cluster with the chronic (MSS and HSS) mice with similar protein abundance pattern 
suggesting that these time points post-infection harbour crucial events that separate the 
mice into MSS and HSS disease forms.  
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4.3.3 Linear regression correlations 
Chapter 3 discussed the acute phase proteins (transferrin isoforms, retinol binding protein 
1), structural proteins (collagen isoforms, keratin D) and immune response proteins (MHC 
Class 1 H2Q4 like protein) in relation to 20-week schistosome infection. In this chapter 
we have investigated the relation of protein abundance at 6-week, 8-week, 12-week 
infections with control mice and 20-week infections and especially with splenomegaly 
representative of the disease pathology. The average volume ratios between the study 
groups (Table 4.1) demonstrate the impact of the disease on the protein abundance or vice 
versa. The following sections discuss the proteins according to their Gene Ontology 
function and the reasons and mechanisms that may affect the abundance of some 
interesting proteins shown in Figure 4.6. Additionally, our study assessed the amino acid 
hydroxyproline, which is discussed in the structural proteins section.  
 
4.3.3.1 Acute phase proteins 
Retinol binding protein 1, a negative acute phase protein, levels for HSS mice showed 
increased abundance during severe disease while no significant association was found for 
8-week, 12-week and MSS infected mice (Figure 4.12). The linear regression analysis for 
retinol binding protein 1 at 20-week infection with %SBW showed r square=0.7284, 
p=0.0017 (Figure 4.13). These findings support the previous results for 20-week infection 
comparisons (Chapter 3) and previous studies have demonstrated increased levels of 
retinol binding protein 1 during myofibroblastic differentiation in rat fibrosis (Uchio et al., 
2002) and in human liver fibrosis and cirrhosis diseases during wound healing (Lepreux et 
al., 2004). As retinol binding protein 1 is mainly expressed in the liver, the increased 
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protein abundance in our study indicates a possible role for retinol binding protein 1 in 
hepatic tissue repair.  
 
We found increased transferrin abundance especially in HSS mice (Table 4.2, Figure 
4.14) these results not only support the findings form Chapter 3, but also implies a greater 
role of liver transferrin at 12-week infection (r square= 0.7538, p=0.0011, Figure 4.15) 
and 20-week infection (r square= 0.9230, p < 0.0001, Figure 4.15) during schistosomiasis 
pathology. Since transferrin is a iron containing protein it acts an important source of iron 
for the developing schistosomulae or schistosome worms (Clemens and Basch, 1989) 
indicating the reason for the increased abundance during 12-week and 20-week infection. 
Interestingly, the multiple regression analysis showed that transferrin abundance at 8-week 
infection was inversely proportional to the progressive pathology in schistosomiasis 
(Table 4.5, Table 4.6). In support of this finding, a previous study suggests that the 
decreased abundance of transferrin is temporary is due to reduced rate of synthesis during 
infectious and toxic diseases of the liver (Jarnum and Lassen, 1961). Together, these 
findings warrant further investigation with the fact that retinol binding protein 1 and 
transferrin are negative acute reactants and showed increased abundance during 
schistosomiasis disease. 
 
4.3.3.2 Structural proteins 
We found significantly increased abundance of keratin D in HSS mice compared to other 
study groups (Figure 4.16) similar to the findings in Chapter 3. The linear regression 
analysis showed significant correlations at 20-week infection. When all the keratin D spot 
volumes were assessed together the linear regression remained significant independent of 
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the time of infection (Figure 4.17). Increased abundance of keratin D has been reported in 
alcoholic liver fibrosis (Salmhofer et al., 1994) and chronic HCV infection (Strnad et al., 
2006) supporting the findings in our study and indicating that similar mechanisms may be 
involved in schistosomiasis fibrosis. Additionally, Salmhofer et al. demonstrated more 
acidic forms of keratin D during liver injury, possibly similar to the results shown in 
Figure 4.6 (spots 21, 22, 23) suggesting that spot 21 and 22 may be the acidic forms, 
although this requires further investigation. Zatloukal and co-workers demonstrated that 
alterations of the hepatocytic keratin cytoskeleton are due to increased oxidative stress and 
reactive oxygen species during liver disease. The authors indicate that keratin D is 
necessary for hepatocyte structural stability and is a modulator of toxic stress and 
apoptosis (Zatloukal et al., 2004). In schistosomiasis also, reactive oxygen species play an 
important role in granuloma formation and disease progression (Elsammak et al., 2008),  
thus our results indicate that keratin D may be involved in stress modulation in the scarred 
liver during schistosomiasis. Additionally, Bastos and co-workers have confirmed the role 
of keratin D in liver regeneration (Bastos et al., 1992). We believe that increased keratin D 
abundance in our study may indicate its hepatoprotective role during liver disease and 
definitely these results may possibly be useful in assessing liver pathology in 
schistosomiasis. 
 
Hydroxyproline is an amino acid found in collagen and formed by hydroxylation of 
proline in preformed collagen. Hydroxyproline makes up 10% of the weight of the 
collagen and therefore used as an as a measure of tissue collagen content. During collagen 
synthesis, free hydroxyproline or hydroxyproline containing peptides appear as by-
products or due to improper incorporation of the amino acid in the collagen protein 
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(Robertson, 1964). During fibrosis, accumulation of collagen due to imbalance in collagen 
synthesis and degradation (Takahashi et al., 1980) may lead to increased hydroxyproline. 
In Chapter 3 we found increased abundance of collagen isoforms during 20-week murine 
schistosomiasis and therefore we assessed liver hydroxyproline as it indicates the degree 
of fibrosis. We found increased abundance of liver hydroxyproline in HSS mice compared 
to 8-week, 12-week and MSS infected mice (Figure 4.18). Studies have demonstrated high 
liver hydroxyproline at 8-week S. mansoni infection (Cheever and Barral-Netto, 1985, 
Hoffmann et al., 2001), 12-week infection, 18-week infection (El-Meneza et al., 1989) 
and 20-week infection (Montesano et al., 2002) which is in line with the findings in our 
study (Figure 4.18). The linear regression correlations for liver hydroxyproline per g of 
liver tissue showed a strong role of hydroxyproline in the pathogenesis of splenomegaly, 
which is independent of the time of infection (Figure 4.19). The r square values for 8-
week, 12-week and 20-week infected mice showed the prominent effect of hydroxyproline 
(90%) on %SBW especially at 12-week infection supporting previous findings (El-
Meneza et al., 1989). Ours is the only study that compares together the liver 
hydroxyproline levels in CBA/J mouse model during schistosome-mediated liver 
pathology from 8-week, 12-week and 20-week infections together. Measuring the levels of 
this amino acid in murine and human sera will assess severe fibrosis in the disease and 
affect treatment strategies in humans. 
 
4.3.3.3 Immune related proteins 
The MHC Class 1 H2Q4 like protein mean spot volume for 12-week infected mice was 
3 times the value for HSS mice. The spot volume for MSS mice was half the value for 
HSS mice. The spot volume for 8-week infected mice was 3 times the value for MSS mice 
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(Table 4.2, Figure 4.24). These results suggest that the egg induced inflammation is 
ongoing in 8-week and 12-week infected mice while it is resolved in MSS mice. The 
values for 8-week and 12-week infections are indicative of active parasitism and increase 
in hepatomegaly and splenomegaly, proposing a definitive role of non-classical MHC 
Class 1 like molecules in schistosomiasis pathology. The linear regression correlation (r 
square=0.9785) for MSS (Figure 4.25) mice suggest the definitive role of immune 
responses in resolving the egg inflammation in MSS mice as is seen in intestinal 
schistosomiasis (Santos et al., 1992). In addition, the non-classical MHC class I molecules 
are also involved in non-immune functions like interactions with pheromone receptors 
(receptors involved with MUP like molecules) present on the cell surfaces of the mice 
vomeronasal organ (Ohtsuka et al., 2008), thus suggesting a complex role of this protein 
not only during disease but also in health.  
 
The liver interleukin 2 (IL-2) spot volume data showed increased abundance for 8-week, 
12-week, MSS and HSS infected mice (Table 4.2, Figure 4.26). When the all the spot 
volumes for IL-2 were analysed for linear regression the results independent of the time of 
infection indicate that IL-2 abundance correlated with 25% of splenomegaly during 
murine schistosomiasis (Figure 4.27). During schistosomiasis the Th1 cells secrete this 
cytokine as an immune response to the parasite eggs logged in the liver (Brunet et al., 
1998). Previous studies have shown decreased abundance of IL-2 mRNA in 
granulomatous livers (Henderson et al., 1991) in contrast to the findings in our study. 
Conversely some studies indicate increased abundance of IL-2 during granulomatous 
inflammation in murine schistosomiasis (Yamashita and Boros, 1992) and human 
hepatosplenic schistosomiasis (Talaat et al., 2007) consistent with the results in our study. 
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The present study in murine schistosomiasis showed increased abundance of MHC Class 1 
H2Q4 like protein and IL-2 during pathogenesis of the disease further studies are required 
to define the role of these proteins during human schistosomiasis disease. 
 
4.3.3.4 Xenobiotic metabolism proteins 
Peroxiredoxin 6 belongs to the family of the thiol specific antioxidant proteins. 
Peroxiredoxin 6 is a bifunctional 25 kDa protein with both glutathione peroxidase and 
phospholipase A2 activities and uses glutathione and ascorbate as electron donors. It is the 
only member of the peroxiredoxin family that has the ability to remove hydrogen peroxide 
and phospholipid hydroperoxide and therefore, able to reduce the accumulation of 
phospholipid hydroperoxides in plasma membranes. Our study showed decreased 
abundance of peroxiredoxin 6 for 6-week, 8-week, 12-week, MSS and HSS infected mice 
compared to control mice (Table 4.2, Figure 4.28) and consistent with the findings in 
alcoholic liver disease in mice that suggested excessive oxidation of the protein during 
liver injury (Roede et al., 2008). Our results thus indicate that schistosome-mediated liver 
disease may be involved in oxidation of peroxiredoxin 6. Alternatively, recent studies 
suggest that over oxidized peroxiredoxin after oxidative stress can be reduced back to the 
active form during recovery from stress-related to inflammation and disease and 
importantly there is very slow regeneration of peroxiredoxin 6 (Chevallet et al., 2003). We 
believe that the over oxidized peroxiredoxin 6 may be the reason for decreased protein 
abundance at 8-week and 12-week infection and possibly also the cause for slow 
regeneration of active form of peroxiredoxin 6 in HSS mice (spot volume 29.76) 
compared to MSS mice (spot volume 47.32) (Figure 4.28, Figure 4.29). The linear and 
multiple regression analysis for 20-week infected mice showed that peroxiredoxin 6 
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(Figure 4.29, Table 4.6) plays an important role in pathogenesis of hepatosplenomegaly 
during schistosomiasis. Oxidation of peroxiredoxin leads to acidic isoforms and 
disulphide bonded dimers. As low abundance of peroxiredoxin 6 was detected in our study, 
it is possible that this change reflects oxidation of peroxiredoxin 6 because of oxidative 
stress. 
 
Epoxide hydrolases are a group of enzymes that catalyse the conversion of epoxides to 
less toxic and readily excretable dihydrodiols, hence an important component of the 
peroxisomes. Epoxide hydrolases are found in all mammalian tissues with the highest 
levels in liver and kidney. During hepatocellular cancer there is increased epoxide 
hydrolase activity (Murray et al., 1993) and during mutagen and carcinogen-induced liver 
injury activity of  liver epoxide hydrolase mRNA increases by 3-fold (Pickett and Lu, 
1981) which is in contrast to the results in our study. Our results indicate decreased 
synthesis of this scavenging enzyme during schistosome infection (Table 4.2, Figure 4.32). 
The linear regression analysis showed that decreased abundance of epoxide hydrolase 
correlated with 77% of splenomegaly at 20-week infection (Figure 4.33). Taken together 
the results for the xenobiotic metabolising enzymes the decreased abundance can be a 
unique combination for assessing hepatosplenic disease. 
 
4.3.3.5 MUP and Sm-PEPCK 
MUP is a potent pheromone mouse protein synthesised in the liver. We found decreased 
abundance of MUP with disease progression indicating a strong impact of the 
hepatosplenic disease on the pathophysiology of the protein (Figure 4.20). MUP decreased 
by almost 7-fold in HSS mice and is a marked feature of our study (Table 4.2, Figure 4.20) 
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and similar to the previous findings discussed in Chapter 3. Studies have demonstrated 
multi-hormonal regulation of liver MUP in healthy mice (Knopf et al., 1983) which may 
be impaired during diseased conditions. In murine schistosomiasis whether MUP 
regulation is due to the host‟s response to parasitism and/or the impact of the parasite 
infection on the MUP metabolism merits investigation. Decreased abundance of MUP in 
hepatocellular carcinoma (Elchuri et al., 2007) is similar to the findings in our study. The 
linear regression analysis showed the impact of MUP on splenomegaly during 
schistosomiasis (Figure 4.21). The results from our study indicate that MUP may be 
involved in pro-cancerous mechanisms in schistosomiasis. The similarity of MUP protein 
to human epididymal-specific lipocalin-9 (Virtanen and Kinnunen, 2008) is promising 
because it may help assess the human hepatosplenic disease but whether lipocalin-9 has 
similar consequences in human schistosomiasis merits investigation.  
 
High abundance of parasite protein Sm-PEPCK at 12-week and HSS infections (Table 4.2, 
Figure 4.22) suggests increased gluconeogenesis for the energy needs of the parasite 
indicating the active infection during these time points post-infection. When all the Sm-
PEPCK spot volumes were combined, the linear regression analysis supported the role of 
the protein in schistosomiasis disease pathology irrespective of the time of infection 
(Figure 4.23). The linear regression analysis for 20-week infected mice showed that Sm-
PEPCK predicted 87% of splenomegaly (Figure 4.23). Furthermore, a recent study 
reported that during host-schistosome interactions,  glyceroneogenesis a 
phosphoenolpyruvate carboxykinase (PEPCK)-dependent pathway is active and uses 
glutamine as a precursor (Yang et al., 2009). Indeed this indicates that during murine-
schistosome interactions this pathway is active and acts as an alternative source of energy 
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for the parasite in the liver portal area. Another study demonstrated Sm-PEPCK as a novel 
egg antigen with a T-cell epitope (Asahi et al., 2000) this information, in combination 
with the results in our study suggest that Sm-PEPCK can possibly be an infection specific 
marker for  human schistosomiasis however merits elucidation and investigation. 
 
4.3.4 Multiple regression analysis 
A forward stepwise multiple regression analysis identified determinants of hepatomegaly 
and splenomegaly. Liver hydroxyproline proved to be the strongest predictor of 
splenomegaly using multiple regression analysis. MUP, keratin D and Sm-PEPCK 
together correlated with 78% splenomegaly while MUP inversely related to disease 
development. Similarly, the strongest predictor for hepatomegaly was liver 
hydroxyproline with a 46% effect. MUP and Sm-PEPCK together correlated with 53% 
hepatomegaly. The multivariate analysis at time post-infection revealed valuable 
information regarding the effect of hydroxyproline, transferrin, MUP, keratin D, 
peroxiredoxin 6 protein abundance on hepatomegaly and splenomegaly in schistosomiasis. 
These results are suggestive of the importance of these proteins during disease progress 
and may be useful as diagnostic markers. Also, if used in a battery of tests may assist in 
distinguishing human hepatosplenic schistosomiasis. Finally, together the protein 
abundance patterns identified using 2D-DIGE and predictors of splenomegaly determined 
using multiple regression analysis the results from our study warrant investigation in 
mouse and human sera that will help assess the intestinal and hepatosplenic disease in 
humans.  
 
 
     159 
4.4 Conclusion 
Proteomic analysis of the liver at different stages of the Schistosomiasis mansoni revealed 
complex and compact differences between the six study groups. The splenomegaly and 
hepatomegaly data reflect the gravity of the schistosome infection. The Gene Ontology 
protein function data showed that at 12-week infection with decreased protein 
functionality confirming the only pathological stage in disease progression with severe 
liver dysfunction as measured by number of changes, while HSS mice showed greatest 
magnitude of changes. The present data also supports the theory of segregation of 8-week 
and 12-week infected mice into MSS and HSS most probably due to some unknown 
molecular factors during disease progression. Liver and serum hydroxyproline levels 
related strongly with the severe pathology which is indicative of a liver candidate protein 
fibrosis marker. Nonetheless, the multiple regression analysis showed transferrin, MUP, 
keratin D and peroxiredoxin 6 are important in disease pathology demanding attention. 
Remarkably, two spots related to epoxide hydrolase activity had decreased abundance in 
HSS and 12-week infected mice which is contradictory to the findings of other studies, if 
thoroughly investigated could help assess severe hepatosplenic disease. High abundance 
of Sm-PEPCK through the progression of the disease not only indicates the potential of the 
protein as a candidate marker for schistosome infection but also signifying its strong 
relation to the severity of the disease. Finally, the estimation of these proteins in serum 
will be of great value in assessing hepatosplenic schistosomiasis. 
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CHAPTER 5:  SERUM ANALYSIS 
 
5.1 Introduction 
Serum analysis was performed to test the strength and efficacy of the candidate protein 
marker/s identified in the CBA/J mouse liver study. To test whether the differences in the 
mouse candidate liver protein markers are reflected in the mouse serum we performed the 
2D-DIGE serum analysis. Mouse sera were labelled with CyDyes, analysed for 
differential protein spot patterns and protein spots were identified using mass spectrometry. 
The experimental design 3 for the serum 2D-DIGE is listed in Appendix A. Using targeted 
assays the candidate liver protein markers were then verified in five sera each for control, 
MSS and HSS mice. The candidate liver protein markers assessed in the mouse liver and 
serum analysis were detected in human serum samples at the Division of Parasitic 
Diseases, Centers for Disease Control and Prevention, Atlanta, USA. Targeted 
biochemical assays were used to analyse 23 INT (intestinal schistosomiasis) sera, 14 HS 
(hepatosplenic schistosomiasis) sera and 13 normal human sera. Details for human sera 
are in the Table 5.2.  
 
The proteins that were tested as candidate liver markers were based on the results obtained 
from the liver and serum 2D-DIGE experiments and linear and multiple regression 
analyses. The following candidate liver markers were selected as putative diagnostic 
markers for human hepatosplenic schistosomiasis that include connective tissue growth 
factor (CTGF), transferrin, keratin D and hydroxyproline. The reasons for the selection of 
the putative diagnostic markers are discussed below.  
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CTGF plays a vital role in fibrogenesis by triggering collagen synthesis in fibrotic diseases 
(Kovalenko et al., 2009) and an important predictor for schistosomiasis fibrosis (Dessein 
et al., 2009). In Chapter 3, Figure 3.6 demonstrates an increased abundance of Collagen 
6a1 isoforms in animals with severe disease. Thus, CTGF was selected as one of the 
candidate liver protein markers. Transferrin and keratin D (Figure 4.15 and 4.17) were 
included in the study for detection in human serum samples due to the results obtained in 
the mouse liver and serum 2D-DIGE data that suggested an association with severe 
pathology (Chapter 4). Hydroxyproline is a biochemical indicator of collagen synthesis 
and a measure of fibrosis in schistosomiasis (Cheever and Barral-Netto, 1985) and high 
serum hydroxyproline levels have been demonstrated in hepatic fibrosis (George and 
Chandrakasan, 2000). Hydroxyproline was selected as the candidate liver protein marker 
due to the increased abundance of hydroxyproline in the liver (Chapter 4, Figure 4.19). 
 
Proteins like major urinary protein (MUP) and Sm-PEPCK were possible candidate 
protein markers, but MUP is a male pheromone, hence only useful for infected males. Sm-
PEPCK is a parasite protein but at present has no available detection antibody. In addition, 
the protein is more indicative of schistosomiasis infection, rather than a marker of severe 
disease. As a result, these proteins were not included in the current mouse and human sera 
studies. Finally, to assess the status of liver function during schistosomiasis, we detected 
the serum total protein for mice and human sera. The detection of serum total protein 
reflects the changes in protein synthesis during disease. Serum total protein is a measure 
of the total protein in the serum and therefore detection of individual protein patterns 
using targeted assays is recommended.  
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5.2 Results  
5.2.1 Mouse serum 2D-DIGE analysis 
The DeCyder software analysed the differences between the control, MSS and HSS mouse 
sera for the pI range 3-10. A total of 60 protein spots changed with infection, of which 21 
protein spots showed 2-fold change in the average volume ratio with 1-ANOVA p ≤ 0.01 
in the pI range 3-10. Eighteen of these were identified using MALDI-TOF mass 
spectrometry and are listed in Table 5.1 (Figure 5.1). The aim of the mouse serum 2D-
DIGE was to explore the basic differences in the MSS and HSS sera and therefore the 
FDR feature was not applied to the analysis. Depletion of highly abundant proteins like 
albumin, transferrin, haptoglobin and immunoglobulins that represent >90% of all serum 
proteins improves the detection sensitivity of protein spots in the 2D-DIGE analysis. 
However, serum depletion of highly abundant proteins was not performed to understand 
the genuine protein patterns for all protein isoforms associated with MSS and HSS sera. 
Additional information of the identified protein spots is listed in Appendix C. 
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FIGURE 5.1 Pseudocolour 2D-DIGE map for 10 g protein per serum sample for control 
and HSS mice. Serum from control/uninfected mice (pooled sera, n=5) was labelled with 
Cy5 (green), serum from 20-week infected HSS mice (pooled sera, n=5) was labelled with 
Cy3 (red) and a pooled internal standard of sera from all mice in the study (n=15) was 
labelled with Cy2 (blue; not shown). Isoelectric focusing was performed on 7 cm IPG 
strips pI 3-10, and proteins were separated using SDS-PAGE. MUP (green) and transferrin 
(yellow) are shown. The image overlays of Cy5- and Cy3-labeled proteins appear yellow.  
 
The mouse serum 2D-DIGE showed some apparent immune-related differences related to 
immunoglobulin light and heavy chains in the MSS and HSS mice. There was decreased 
abundance in the haemoglobin chains (spot 4-8, Figure 5.1, Table 5.1), and increased 
abundance in complement C3 (spot 3) and decreased abundance in transthyretin (spot 18) 
indicating the effect of schistosome infection.   
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The serum MUP and the transferrin spots were not statistically significant using the 
criteria of 2-fold change, 1-ANOVA p ≤ 0.01 (Table 5.2). Therefore, to detect whether 
MUP and transferrin showed the same differential pattern as in the liver 2D-DIGE 
analysis, we extracted the spot volume data from serum 2D-DIGE maps for serum MUP 
and transferrin spots (Figure 5.1). There was a significant difference between control, 
MSS and HSS mouse serum MUP and transferrin (Figure 5.2). These results support the 
liver lysate 2D-DIGE (Chapter 3 and Chapter 4) and western blot (Chapter 4) data. Finally, 
our mouse serum 2D-DIGE study has revealed that the isoforms for highly abundant 
proteins (immunoglobulins, transferrin) showed specific differential patterns distinct for 
MSS and HSS mice.   
TABLE 5.1 Experimental design 3: Identified protein spot comparisons for control, MSS 
and HSS sera for the pI range 3-10, 2-fold change, 1-ANOVA p ≤ 0.01. 
Spot 
No. 
Protein Name 
AVR 
H/C1 
AVR 
M/C1 
AVR 
H/M1 
gi 
number 
pI1 
Mw1 
(kDa) 
Fun.2 Ref. 1 
1 
Chain L; Crystal 
Structure Of The 
Fab Fragment 
(Light Chain) 
+10.4 +5.97 +1.74 18655521 5.8 15.87 IMM 
(Pearce and 
MacDonald, 2002) 
2 Light Chain +7.31 +3.52 +2.08 18655521 5.8 15.87 IMM 
(Pearce and 
MacDonald, 2002) 
3 
Complement 
component 3 
+2.72 +2.67 +1.02 28175786 6.3 188.0 IMM 
(La Flamme et al., 
2003a) 
4 
Haemoglobin 
beta-1 chain 
-7.28 -2.92 -2.49 1183932 7.1 15.94 OXT 
(Brindley et al., 
1997, Nagi et al., 
1999) 
5 
Haemoglobin 
beta-1 chain 
-9.59 -2.60 -3.69 1183932 7.1 15.94 OXT 
(Brindley et al., 
1997, Nagi et al., 
1999) 
6 
Haemoglobin 
beta-1 chain 
-14.1 -5.81 -2.42 1183932 7.1 15.94 OXT 
(Brindley et al., 
1997, Nagi et al., 
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1999) 
7 
Haemoglobin 
beta-1 chain 
-19.4 -7.59 -2.55 1183932 7.1 15.94 OXT 
(Brindley et al., 
1997, Nagi et al., 
1999) 
8 
Haemoglobin 
beta-1 chain 
-9.24 -6.03 -1.53 1183932 7.1 15.94 OXT 
(Brindley et al., 
1997, Nagi et al., 
1999) 
9 
Immunoglobulin 
heavy chain 
+13.3 +8.92 +1.49 13097381 6.6 51.67 IMM 
(Pearce and 
MacDonald, 2002) 
10 
Immunoglobulin 
gamma1 heavy 
chain (IGHC) 
+23.3 +20.1 +1.16 21304450 6.0 56.08 IMM 
(Pearce and 
MacDonald, 2002) 
11 IGHC +21.8 +17.7 +1.23 21304450 6.0 56.08 IMM 
(Pearce and 
MacDonald, 2002) 
12 IGHC +23.0 +15.9 +1.44 21304450 6.0 56.08 IMM 
(Pearce and 
MacDonald, 2002) 
13 IGHC +17.2 +12.3 +1.39 21304450 6.0 56.08 IMM 
(Pearce and 
MacDonald, 2002) 
14 
Immunoglobulin 
kappa chain (IKC) 
+6.90 +1.90 +1.65 20269237 8.0 24.43 IMM 
(Pearce and 
MacDonald, 2002) 
15 IKC +3.95 +4.06 +1.99 20269237 8.0 24.43 IMM 
(Pearce and 
MacDonald, 2002) 
16 IKC +8.07 +3.71 +1.86 20269237 8.0 24.43 IMM 
(Pearce and 
MacDonald, 2002) 
17 IKC +8.32 +2.34 +1.70 20269237 8.0 24.43 IMM 
(Pearce and 
MacDonald, 2002) 
18 Transthyretin -2.60 -2.23 -1.15 19354093 5.8 15.87 TRT 
(Camacho-Lobato 
and Borges, 1998, 
Strauss, 2002) 
 
1
AVR: average volume ratio between study groups (C, control; M, MSS; and H, HSS); pI: 
isoelectric pH; Mw: molecular weight; Ref: references refer to association of protein with 
various diseases. 
2
Func.: Function  (IMM, immune response; OXT, oxygen transporter; 
TRT, thyroxine retinol tranporter). 
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TABLE 5.2 Serum MUP and transferrin average volume ratio (AVR) comparison 
between control (C), MSS (M) and HSS (H) mice sera for pI range 3-10. 
Protein 
name 
AVR 
H/C 
AVR 
M/C 
AVR 
H/M  
gi Number 1-ANOVA 
MUP -7.94 -2.51 -3.17 13276755 0.013 
Transferrin +1.95 -1.11 +2.17 62027488 0.019 
 
 
a)  b)  
FIGURE 5.2 Mouse serum (a) MUP and (b) transferrin spot volume data from serum 2D-
DIGE maps, 1-ANOVA p  0.01 for all spot volumes. *** p ≤ 0.001 HSS mice compared 
to control mice, # p ≤ 0.001 HSS mice compared to MSS mice, **p ≤ 0.01 MSS mice 
compared to control mice, 
@p ≤ 0.05 HSS mice compared to MSS mice by Newman-
Keuls Multiple Comparison Test.  
 
5.2.2 Mouse serum analysis using targeted assays 
We tested the candidate liver protein markers in mouse sera to verify the changes seen in 
mouse liver and serum 2D-DIGE analysis. Estimation of the mouse serum for total protein 
     167 
(BCA assay, Chapter 2, section 2.15), hydroxyproline (Hydroxyproline assay, Chapter 2, 
section 2.12), keratin D (Western Blot, Chapter 2, section 2.10), CTGF (CTGF ELISA, 
Chapter 2, section 2.11) and transferrin (Transferrin ELISA, Chapter 2, section 2.15) 
revealed interesting results and are summarised in Table 5.3.  
 
  TABLE 5.3 Summary of results for mouse serum analysis. Shown are mean  SEM. 
No. Mouse serum test Control MSS HSS 
1. Total protein (mg/mL)
@
 29.0  1.2 29.2 1.9 27.8 1.4 
2. Hydroxyproline (g/mL) @ 5.3  1.3 9.2  2.6 19.4  3.9* 
3. Keratin D (Band volume) 
6.8 ×10
6
  
0.5 ×10
6
 
6.2 ×10
6
  
0.3 ×10
6
 
10.8×10
6
  
0.5 ×10
6
 *** 
4. CTGF (ng/mL)
 @
 20.1  0.4 37.2  7.9 108.1  23.7 ** 
5. Transferrin (Band volume) 
1.0×10
6
  
0.1 ×10
6
 
0.9×10
6
  
0.1 ×10
6
 
1.8×10
6
   
0.2 ×10
6
* 
 
***p  0.001, **p  0.01, *p  0.05 when HSS mice compared to control and MSS mice 
@
Unit indicates level per mL of serum. 
 
Serum total protein is a commonly used liver function test and measures the total amount 
of protein in the serum. The mouse serum total protein concentration was similar among 
the study groups (control, 8-week, 12-week, MSS and HSS mice, Figure 5.3). The mouse 
serum total protein results were in contrast to the results obtained for mouse liver total 
protein that showed decreased liver total protein for diseased (6-week, 8-week, 12-week 
and 20-week infected) mice (Figure 4.5, Chapter 4). The serum results indicate that 
measurement of specific proteins like immunoglobulin patterns, as seen in serum 2D-
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DIGE analysis (Table 5.1), may help to identify changes and differentiate between the two 
disease syndromes. 
 
 
FIGURE 5.3 Mouse serum total protein. The mean concentrations ± SEM were similar 
among the study groups (control, n=5; 8-week, n=10; 12-week, n=10; MSS, n=5; HSS, 
n=5). 
 
Hydroxyproline is an amino acid found in collagen and therefore a measure of imbalance 
in collagen synthesis and degradation. We found that serum hydroxyproline levels for 
mice with HSS disease were significantly higher than MSS and control mice (Figure 5.4). 
The increased levels of serum hydroxyproline probably reflect the leakage of the amino 
acid into the circulatory system from the damaged and fibrotic liver during severe disease. 
In line with the findings of liver hydroxyproline in Chapter 3, this amino acid has been for 
the first time studied in schistosomiasis sera and definitely be worth investigating in 
human hepatosplenic disease.  
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FIGURE 5.4 Mouse serum hydroxyproline levels were higher in HSS mice compared to 
control and MSS mice. Shown are the means ± SEM (control, n=5; MSS, n=5; HSS, n=5), 
1-ANOVA p  0.05 for all, *p  0.05 when HSS compared to control or MSS mouse 
groups by Newman-Keuls Multiple Comparison Test.  
 
Keratin D is an intermediate filament protein and increased abundance in HSS mice 
compared to MSS and control mice was demonstrated in Chapter 3 and Chapter 4. The 
levels of mouse serum keratin D detected by western blot results were higher in animals 
with HSS compared to serum from animals with MSS and control mice (Figure 5.5). 
These results support the mouse liver 2D-DIGE data and emphasise the importance of this 
protein as a good candidate liver protein marker for hepatosplenic schistosomiasis.  
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FIGURE 5.5 Western blot analysis of mouse serum keratin D, means ± SEM (control, 
n=5; MSS, n=5; HSS, n=5), with an overall 1-ANOVA p  0.01, ***p  0.001 when HSS 
mice were compared to control and MSS mice by Newman-Keuls Multiple Comparison 
Test. Mouse serum keratin D western blot images are in Appendix G. 
 
CTGF represents the increased collagen synthesis during fibrosis and therefore assessment 
of this protein was important. The detection of mouse serum CTGF using ELISA 
demonstrated significantly increased levels in HSS mice compared to MSS and control 
mice (Figure 5.6). The serum CTGF results were in line with the increased collagen 
isoforms observed in Chapter 3 and if assessed in human sera can be used as an indicator 
of liver fibrosis in human schistosomiasis.  
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FIGURE 5.6 Mouse serum CTGF was analysed by ELISA, means ± SEM (control, n=5; 
MSS, n=5; HSS, n=5), 1-ANOVA p  0.01, **p  0.01 when HSS mice were compared to 
MSS and control mice by Newman-Keuls Multiple Comparison Test. (The serum control 
CTGF values are referred to from Cheng et al. (Cheng et al., 2006)). 
 
The mouse serum transferrin band volume fluorescence intensity analysed using western 
blot for each control mice and 8-week, 12-week, MSS and HSS infected mice showed 
HSS mice had significantly higher transferrin abundance compared to other study groups 
(Figure 5.7). These findings are in line with the results for liver transferrin abundance 
(Chapter 3) and serum transferrin 2D-DIGE data (Figure 5.2b) that indicated HSS mice 
had increased transferrin abundance. The transferrin results in our study contrast its 
function of “negative acute phase protein” and therefore estimation of transferrin in 
human sera will possibly help reflect more on mechanisms of action of this acute phase 
protein during schistosomiasis. 
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FIGURE 5.7 Mouse serum transferrin western blot analysis for control (C; n=5), 8-week 
infected (n=10), 12-week infected (n=10) and MSS (n=5), and HSS (n=5) groups. The 
means ± SEM of protein band fluorescence intensity are shown. Levels of HSS mice were 
significantly higher (* p   0.05 by Newman-Keuls Multiple Comparison Test) than those 
in control mice, 8-week, 12-week and MSS infected mice. 
 
5.2.3 Human serum analysis using targeted assays  
The human serum analysis was planned to extend the mouse serum experiments and detect 
whether similar changes occur in human sera. The candidate liver protein markers: total 
protein (BCA assay, Chapter 2, section 2.15), hydroxyproline (Hydroxyproline assay, 
Chapter 2, section 2.12), keratin D (Western Blot, Chapter 2, section 2.10), CTGF (CTGF 
ELISA, Chapter 2, section 2.11) and transferrin (Transferrin ELISA, Chapter 2, section 
2.15) were tested in human sera to determine their specificity for any of the INT and HS 
disease forms. The effect of possible confounding factors like HIV-1 infection status and 
ultrasound detected fibrosis were also tested. The human serum data was compared in four 
ways: normal, INT and HS groups, HIV-1 co-infection serostatus among INT and HS 
patients, then based on image patterns IPA, IPC and IPD/E and finally HIV-1 co-infection 
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serostatus among image patterns. Table 5.4 shows the characteristics for the human sera, 
analysed in our study. The INT and HS patients were male carwashers from Kisumu, 
Kenya and the normal human sera were from the Centers for Disease and Prevention, 
Atlanta, USA.  The results for normal, INT and HS human serum analysis are tabulated in 
Table 5.5. 
 
TABLE 5.4 Characteristics for human serum samples based on ultrasound image patterns 
and HIV-1 infection status. 
Subjects Normal INT
1
 HS
1
 
n (total) 13 23 14 
Ultrasound Image Pattern 
(IP) 
- IPA
1
 IPC
1
 IPD/E
1
 
n (according to image pattern) - 23 10 4 
HIV-1 infection status - -ve +ve -ve +ve -ve +ve 
n (according to HIV-1 status) - 11 12 6 4 4 - 
 
1
INT: intestinal schistosomiasis, HS: hepatosplenic schistosomiasis, IPA: image pattern 
“A”, IPC: image pattern “C”, IPD/E: image pattern “D/E”. n = number of subjects. 
 
TABLE 5.5 Summary of results for human serum analysis. Shown are mean  SEM. 
No. Human serum test Normal INT HS 
1. Total protein (mg/mL)
 @
 92.1
  2.4 159.7  1.7 *** 162.3   3.1*** 
2. Hydroxyproline (g/mL) @ 5.8
  1.1 16.7  2.6** 17.2  2.5** 
3. Keratin D (Band volume) 
8.5×10
6  
0.5 ×10
6
 
10.2×10
6  
0.7 ×10
6
 
15.8×10
6  
0.1 ×10
6 @ ##
 
4. CTGF (ng/mL)
 @
 5.6  0.7 13.4   2.7& 5.1  1.4 
5. Transferrin (mg/mL)
 @
 - 3.8 
  0.3 3.9   0.2 
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***p  0.001, **p  0.01 when INT and HS sera compared to normal human sera, @p  
0.05 when HS compared to normal human sera, ##p  0.01 when HS compared to INT 
sera, 
&
 p  0.05 when INT compared to HS and normal human sera 
@
Unit indicates level per mL of serum. 
 
The mean human serum total protein was significantly higher (p ≤ 0.001) in the INT and 
HS when compared to normal sera. The serum total protein results for INT and HS groups 
were in contrast to the mouse serum total protein data. Because the serum total protein is a 
gross measure of liver function, these results suggest excessive liver cell damage during 
human schistosomiasis cause leakage of the proteins into the circulation. Thus, human 
serum total protein assessed the extent of liver dysfunction in schistosomiasis. When 
serum total protein for INT and HS was categorised into HIV-1 seropositive and 
seronegative groups, no statistical difference was found.  
 
 
FIGURE 5.8 Human serum total protein, means ± SEM, 1-ANOVA p  0.01, ***p  
0.001 when compared to normal human sera by Newman-Keuls Multiple Comparison 
Test.  
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The serum hydroxyproline levels were higher in the HSS mice alone while the human sera 
analysis showed high levels in both chronic human disease forms. The mean serum 
hydroxyproline was high in persons with INT and HS disease forms than the mean values 
of sera from normal individuals (Figure 5.9). In human disease, the serum hydroxyproline 
levels may be due to the successive or continuous re-infections and therefore a constant 
initiation of collagen synthesis during schistosomiasis disease. When the serum 
hydroxyproline concentrations were analysed based on the HIV-1 serostatus, lower levels 
were found in HIV-1 seropositive patients than in HIV-1 seronegative patients, although 
this difference was not statistically significant. But HS HIV-1 seropositive patients had 
significantly (p  0.05) lower levels compared to HS HIV-1 seronegative patients (Figure 
5.10). Definitely, these results indicate that HIV-1 co-infection may lead to reduced 
fibrosis in schistosomiasis.  
 
 
FIGURE 5.9 Human serum hydroxyproline levels among study subjects. Shown are 
means ± SEM, 1-ANOVA p  0.01, **p  0.01 when INT and HS sera were compared to 
normal human sera by Newman-Keuls Multiple Comparison Test.  
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FIGURE 5.10 Human serum hydroxyproline comparison within INT and HS groups 
separated by HIV-1 co-infection status, means ± SEM. *p  0.05 when HS HIV-1 
seronegative patients were compared to HS HIV-1 seropositive individuals (n=4) by 
Newman-Keuls Multiple Comparison Test. 
 
The mouse serum keratin D (cytokeratin 18) western blot showed higher values in HSS 
mice compared to MSS and control mice. Consistent with the findings in mouse sera, the 
serum cytokeratin 18 was significantly higher in HS sera compared to INT and normal 
human sera (Figure 5.11). This relationship remained statistically significant (*p  0.05) 
even when INT and HS HIV-1 seronegative groups were compared (Figure 5.12) whereas 
INT and HS HIV-1 seropositive keratin D levels were similar. These results indicate that 
during severe disease there is a significant effect of the infection on the levels of 
cytokeratin 18 suggestive of a strong marker for hepatosplenic schistosomiasis.  
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FIGURE 5.11 Human serum cytokeratin 18 using western blot analysis, means ± SEM, 1-
ANOVA p  0.01, *p  0.05 when HS compared to normal human sera, #p  0.01 when 
HS compared to INT sera by Newman-Keuls Multiple Comparison Test.  Human serum 
western blot cytokeratin 18 images are in Appendix G. 
 
 
FIGURE 5.12 Human serum cytokeratin 18 levels within INT and HS groups separated 
by HIV-1 co-infection status. Shown are means ± SEM, 1-ANOVA p  0.01, *p  0.05 
when INT HIV-1 seronegative was compared with HS HIV-1 seronegative sera by 
Newman-Keuls Multiple Comparison Test.  
 
The human serum CTGF results contrasted with the mouse sera results that demonstrated 
higher values in sera from HSS mice than MSS animals. In the humans, INT sera showed 
significantly higher values compared to HS and normal human sera (Figure 5.13). When 
CTGF levels were categorised into HIV-1 seronegative and seropositive groups, patients 
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with HS irrespective of the HIV-1 serostatus had lower levels compared to INT patients 
irrespective of the HIV-1 serostatus (Figure 5.14). These results suggest that contrary to 
the findings in mouse studies, CTGF levels are positively associated with moderate not 
severe disease. Protein CTGF may still prove a valuable biomarker although its pathology 
is unclear. 
 
 
FIGURE 5.13 Human serum CTGF, means ± SEM, 1-ANOVA p  0.05, *p  0.05 when 
INT compared to HS and normal human sera by Newman-Keuls Multiple Comparison 
Test.  
 
 
FIGURE 5.14 Human serum CTGF levels within INT and HS groups separated by HIV-1 
co-infection status. Differences between the groups were not significant by Newman-
Keuls Multiple Comparison Test.  
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Based on the results from the mouse liver and serum analyses, transferrin was one of the 
best candidate markers that showed significantly high abundance in HSS mice compared 
to MSS and control mice. In contrast, the human serum transferrin quantified using ELISA 
demonstrated similar levels for INT and HS (Figure 5.15) both within the normal human 
sera reference range (3.0 to 5.2 mg/ml, Serum transferrin assay kit, Alpha Diagnostic Intl., 
Inc., USA). When INT and HS serum transferrin was tested for patient groups divided into 
HIV-1 seronegative and seropositive categories, the HIV-1 seropositive groups showed 
lower transferrin levels. However, only sera from the INT HIV-1 seropositive patient 
group had significantly (p  0.05) lower transferrin compared to its counterpart (Figure 
5.16). The results from the HIV-1 co-infection serostatus may relate to the decreased 
abundance of transferrin a negative acute phase protein during infection. 
 
 
FIGURE 5.15 Human serum transferrin ELISA results. Shown are the means ± SEM. 
Levels in INT and HS groups were similar (ns, not significant). 
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FIGURE 5.16 Human serum transferrin comparison within INT and HS groups separated 
by HIV-1 co-infection status, means ± SEM. *p  0.05 when INT HIV-1 negative 
compared to INT HIV-1 positive by Newman-Keuls Multiple Comparison Test. 
 
During schistosomiasis granuloma formation and the resulting pathology depends on and 
is mediated by CD4 cells. Therefore, the CD4 count was evaluated which showed that 
persons with severe hepatosplenic disease displayed strikingly reduced peripheral blood T 
cells. The CD4 count was lower in HS patients than INT patients, although the 
comparison was not statistically significant (Figure 5.17). When divided into HIV-1 
seronegative and seropositive categories, INT HIV-1 seropositive patients had 
significantly lower (p  0.01) CD4 counts than their INT seronegative counterparts. HS 
HIV-1 seronegative and HS HIV-1 seropositive groups had similar CD4 counts but were 
significantly lower (p  0.05) in comparison to INT HIV-1 seronegative patients (Figure 
5.18). These results suggest that severe disease with HIV-1 coinfection results in reduced 
CD4 counts and may aggravate the disease.   
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FIGURE 5.17 Human CD4 count comparison between INT and HS groups was not 
significant by Newman-Keuls Multiple Comparison Test.  
 
 
FIGURE 5.18 Human CD4 count comparison within INT and HS groups separated by 
HIV-1 co-infection status. The means ± SEM differed by 1-ANOVA  0.01 for all groups. 
*p  0.05 when HS HIV-1 seronegative and HS HIV-1 seropositive were compared to 
INT HIV-1 seronegative, ** p  0.01 when INT HIV-1 seropositive was compared to INT 
HIV-1 seronegative by Newman-Keuls Multiple Comparison Test.  
 
When all the candidate protein markers were reviewed according to the image patterns as 
described by Mwinzi et al. (Mwinzi et al., 2004) and the HIV-1 infection status none of 
the protein levels were statistically significant among the: IPA, IPC and IPD/E groups 
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except for serum hydroxyproline and CD4 counts. There were no HIV-1 seropositive 
patients in the IPD/E group.  
 
Serum hydroxyproline was significantly higher in the IPD/E group than IPA and IPC. This 
correlates with the higher degree of fibrosis detected by ultrasound that is associated with 
the severe form of hepatosplenic disease (Figure 5.19). Categorising the serum 
hydroxyproline image patterns according to the HIV-1 seronegative and seropositive 
groups showed no statistical significance, however the hydroxyproline levels were lower 
in HIV-1 seropositive patients than the HIV-1 seronegative patients (Figure 5.20).  
 
FIGURE 5.19 Human serum hydroxyproline compared according to ultrasound image 
patterns (fibrosis in IPA<IPC< IP/E). The means ± SEM differed in 1-ANOVA  0.05 for 
all groups, *p  0.05 when IPD/E was compared to IPA and IPC by Newman-Keuls 
Multiple Comparison Test.  
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FIGURE 5.20 Human serum hydroxyproline levels according to ultrasound image 
patterns (fibrosis in IPA<IPC< IP/E) separated by HIV co-infection status, shown are the 
mean ± SEM, the group comparison was not statistically significant.  
 
When the CD4 counts were evaluated according to the image patterns the differences were 
not statistically significant although IPD/E patients had low counts when compared to IPA 
and IPC (Figure 5.21). However, the HIV-1 co-infection status in the CD4 count subjects 
showed that HIV-1 seropositive patients had lower CD4 counts moreover severe 
hepatosplenic disease patients (IPD/E) had much lower CD4 counts when compared to 
moderate disease (IPA) and hepatosplenic (IPC) patients (Figure 5.22). Thus, interplay of 
the T cells between schistosomiasis and HIV-1 infection may possibly lead to the 
depletion of these cells and ultimately decreased immunity making the subject vulnerable 
to more infections.   
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FIGURE 5.21 Human CD4 count according to ultrasound image patterns (fibrosis in 
IPA<IPC< IP/E), shown are the mean ± SEM, the group comparisons were not 
statistically significant.  
 
 
FIGURE 5.22 Human CD4 count comparison according to ultrasound image patterns 
(fibrosis in IPA<IPC< IP/E) separated by HIV co-infection status. The means ± SEM 
differed by 1-ANOVA  0.01 for all groups. ** p  0.01 when IPA HIV-1 seronegative 
were compared with IPA HIV-1 seropositive, *p  0.05 when IPA HIV-1 seronegative 
was compared with IPC HIV-1 seropositive and IPD/E HIV-1 seronegative by Newman-
Keuls Multiple Comparison Test.  
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5.2.4 Multiple regression analysis 
The candidate protein markers were normalised logarithmically (loge) and entered into 
stepwise multivariate regression analysis to generate strong determinants of ultrasound 
detected fibrosis in human schistosomiasis. When all the ultrasound image patterns were 
combined together, cytokeratin 18 with r square=0.142, standardised =0.377, p=0.031 
was the only predictor of fibrosis in humans irrespective of the grading of the image 
pattern. These results indicate a possible role of this protein in the pathogenesis of human 
schistosomiasis and therefore might be a useful biomarker for the disease. 
 
5.3 Discussion 
5.3.1 Mouse serum analysis using 2D-DIGE  
The results from the mouse serum 2D-DIGE experiments showed changes in many 
immune related proteins, consistent with previous findings (Jassim et al., 1987, Pearce and 
MacDonald, 2002). The mouse serum 2D-DIGE analysis identified protein spots 
corresponding to light immunoglobulin chains (Figure 5.1, spots 1, 2, 14-17, Table 5.1) 
and heavy immunoglobulin chains (Figure 5.1, spots 9-13,Table 5.1). There was 
increased abundance of different isoforms of light and heavy immunoglobulins for MSS 
and HSS mice compared to control mice. In particular, the abundance of immunoglobulin 
gamma 1 heavy chain increased by almost 85-fold for HSS mice and 66-fold for MSS 
mice. The abundance of immunoglobulin kappa chain increased by almost 27-fold for 
HSS mice and 12-fold for MSS mice. 
 
Complement C3 is a positive acute phase protein and it enhances Th2 responses during S. 
mansoni infection (La Flamme et al., 2003a) and this may be a possible reason for the 
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increased abundance by 2-fold in MSS and HSS mice, thereby providing protection during 
parasitic infections.  
 
We found five haemoglobin spots (Figure 5.1, spots 4-8, Table 5.1) decreased by 7 to 19 
fold for HSS mice and 2 to 7 fold for MSS mice. The prevalence of anaemia is almost 
66% in schistosome-infected women (Ajanga et al., 2006) and highly prevalent in 
schistosome-infected children (Sturrock et al., 1996). Studies ascribe the consumption of 
red blood cells by adult schistosomes as a possibility for the cause of anaemia. The reason 
that the adult S. mansoni pairs reside in the host blood vessels for lifetime and derive iron 
from haemoglobin from red blood cells required for their growth, development and 
reproduction (Brindley et al., 1997) supporting the findings in our study and indicating 
severe anaemia in diseased mice.  
 
We found transthyretin abundance decreased by 2-fold in MSS and HSS mice compared 
to control mice. Tansthyretin is a negative acute phase protein and serum and 
cerebrospinal fluid carrier of the thyroid hormone thyroxine and retinol. Decreased levels 
of transthyretin in human hepatosplenic schistosomiasis have been reported previously 
(Camacho-Lobato and Borges, 1998, Strauss, 2002) indicating liver dysfunction.  
 
Importantly, the spot volume for serum MUP showed decreased abundance and serum 
transferrin spot volume showed increased abundance in HSS mice compared to MSS and 
control mice (Figure 5.2). These results were consistent with findings for the liver lysate 
2D-DIGE and western blot analysis in Chapter 3. Estimation of these proteins in human 
sera may possibly generate biomarkers for hepatosplenic disease. Additionally, future 
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work will utilise methods to delete the high abundance proteins (albumin, 
immunoglobulins, haptoglobin and transferrin) as they represent >90% of all the serum 
proteins. This approach will allow a better analysis of the low abundance proteins that 
have significant changes during infection. 
 
5.3.2 Mouse and human serum analysis using targeted assays 
Comparison of proteomic patterns in livers and sera of mice with MSS and HSS led to the 
discovery of the candidate proteins as pathology markers in mouse and human sera. The 
candidates we identified for further analysis include the amino acid hydroxyproline, serum 
keratin D (cytokeratin 18), serum connective tissue growth factor and serum transferrin 
are discussed sequentially in relation to schistosomiasis pathology. To measure the 
changes in protein synthesis during schistosomiasis we assessed serum total protein. 
 
The serum total protein was assessed to determine whether liver inflammation during 
disease is reflected in the circulating blood. Although serum total protein is a measure of 
protein turnover during disease state especially with nutritional problems, kidney disease 
or liver disease and assesses liver function, the mouse serum total protein profile in our 
study was similar between the five study groups (Figure 5.3). Our results in mice sera are 
consistent with the studies in Schistosomiasis mansoni mice (Rutkowski and Bruce, 1971),  
in schistosomiasis patients (Mousa et al., 1976) and in Egyptian children with 
schistosomiasis, hepatitis B and C virus-related liver diseases which demonstrated similar 
serum total protein levels (Mahdy et al., 2007). However, human schistosomiasis-HCV 
co-infection studies showed a 33% reduction in serum total protein concentrations (Fahim 
et al., 2000). In contrast, a previous study demonstrated that mice with progressive S. 
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mansoni infection showed increase in serum total proteins (Evans and Stirewalt, 1957), 
similar to a serological study in rhesus monkeys infected with S. mansoni (Smithers and 
Walker, 1961). These studies support the results in our human sera study (Figure 5.8) 
where both INT and HS patients had increased protein. Further studies of specific proteins 
separately would be advantageous to assess the disease pathology. 
 
Changes in mouse liver hydroxyproline levels were reflected in serum analysis. Mouse 
serum hydroxyproline was higher in HSS mice compared to MSS and control mice 
(Figure 5.4) consistent with the high results for liver hydroxyproline in HSS mice 
(Chapter 3). Our results are similar to the findings in toxicity induced hepatic fibrosis 
(George and Chandrakasan, 2000) and in Schistosomiasis mansoni at 10-week infection 
(Dunn et al., 1977). The serum hydroxyproline levels in INT and HS patients were similar 
and higher than normal human sera (Figure 5.9). The results from the human sera support 
the findings from gingival fibroblasts (Heng et al., 2006) and in patients with liver fibrosis 
(Attallah et al., 2007). Our human sera data differed from the mouse serum data in that it 
failed to differentiate between the moderate and severe disease. However, when serum 
hydroxyproline levels were analysed according to the ultrasound image pattern categories 
(Figure 5.19), patients with IPD/E had significantly higher levels than person with IPA 
and IPC, consistent with the findings in ultrasound detected fibrosis (Mwinzi et al., 2004) 
suggesting that serum hydroxyproline levels reflect the degree of fibrosis in human 
schistosomiasis. Additionally, sera from persons with HIV-1 seropositive category 
showed lower hydroxyproline levels than HIV-1 seronegative category, although this was 
only statistically significant (p  0.05) among groups with the HS disease form (Figure 
5.10). Serum hydroxyproline in other viral infection studies showed increased levels of the 
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protein due to increased collagen synthesis and degradation (Attallah et al., 2007, Kucharz, 
1984) indicating altered collagen synthesis and degradation in schistosomiasis and HIV-1 
co-infections. Previous HIV-1 infection studies show similar ultrasound detectable fibrosis 
in HIV-1 seronegative and HIV-1 seropositive patients with schistosome infection (Secor, 
2006). The results in our study indicate that HIV-1 co-infection during schistosomiasis 
reduces the fibrosis or the HIV-1 infection in itself creates immune deficiency that 
alleviates the impact of schistosome infection on the liver (Figure 5.20), thus indicating 
the limitations of ultrasound for detection of fibrosis in schistosomiasis and the 
importance of serum hydroxyproline detection in these subjects.  In addition, if the IPD/E 
patients were HIV-1 seropositive, this could mean that these patients may have decreased 
fibrosis or if the HIV-1 co-infection is severe it may lead to death.  
 
The serum keratin D (cytokeratin 18) western blot confirmed the liver 2D-DIGE results 
and showed a strong relationship between HSS mice and serum keratin D levels (Figure 
5.5). Supporting the mouse serum data, the human serum western blot showed 
significantly increased keratin D levels in HS patients when compared to INT and normal 
subjects (Figure 5.11). Studies in non-alcoholic liver disease have recorded high levels of 
serum keratin D similar to our study (Aoyama and Tanaka, 2009, Vos et al., 2008). 
Keratin D is similar to human cytokeratin 18 and acidic forms of this protein have been 
demonstrated in alcoholic hepatitis and hepatic steatosis (Salmhofer et al., 1994). 
Furthermore, analysis of the modification pattern of keratin D associated with 
schistosomiasis might identify a specific pattern, which relates to the severity of disease. 
HIV-1 co-infection showed there was no significant difference between seronegative and 
seropositive patients, but the INT seronegative patients had lower keratin D levels 
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compared to HS seronegative patients (Figure 5.12). Together, the data suggests that HIV-
1 co-infection does not affect keratin D levels. Additionally, keratin D emerged as a 
possible predictor of ultrasound detected fibrosis in human schistosomiasis supporting the 
findings in chronic HCV infection associated fibrosis (Strnad et al., 2006). Our study 
showed increased levels of keratin D in mouse and human serum studies, verifying these 
results on a larger number of human serum samples may generate a clearer picture of the 
relevance of this protein to the disease state.  
 
Connective tissue growth factor is triggered by TGF- during hepatic fibrosis and is 
highly expressed in fibrotic tissues. As a result, CTGF can be used as a measure of 
collagen synthesis. In our study, CTGF levels were significantly elevated in HSS 
compared to control and MSS mice, reflecting extensive fibrosis in the severe form of the 
disease (Figure 5.6). A study in transgenic livers in vivo demonstrated elevated levels of 
CTGF mRNA and CTGF protein (Tong et al., 2009). Another study  showed high serum 
CTGF levels are a useful non-invasive biomarker for assessment of liver fibrosis 
(Kovalenko et al., 2009). These studies are in line with our findings and support CTGF as 
a candidate marker for human hepatosplenic schistosomiasis. However, in our study, 
human serum CTGF levels were higher in INT patients than in individuals with HS 
patients (p  0.01, Figure 5.13). This contrasts a recent study conducted in schistosome-
infected Chinese, Sudanese, and Brazilians subjects that reported two single nucleotide 
polymorphisms (rs9402373 and rs12526196) located close to the CTGF gene as valuable 
markers for disease progression in schistosomiasis hepatic fibrosis (Dessein et al., 2009). 
The HS CTGF levels were lower than the INT patients irrespective of the HIV-1 
serostatus, the comparisons were not statistically significant (Figure 5.14). Our results 
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indicate that CTGF is potential marker for INT although further investigation using larger 
sample size as well as other co-infected (other helminth) serum samples may help in the 
validation.  
 
The results for mouse serum transferrin western blot data showed high abundance in 
HSS mice (Figure 5.7) comparable to data from 8-week S. mansoni infections in C57BL/6 
mice (Harvie et al., 2007) and in Nigerian woman with urinary schistosomiasis (Salawu 
and Arinola, 2004). In contrast, previously it has been reported that reduced serum 
transferrin levels are a manifestation of hepatosplenomegaly in Egyptian schistosomiasis 
patients (Saif et al., 1977), analogous to the study in S. mansoni 8-week infected mice (El-
Rigel and Hetta, 2006). The human serum transferrin analysis in our study showed similar 
levels in INT and HS patients (Figure 5.15) which were in the normal reference range for 
humans (3.0 - 5.2 mg/mL). HIV-1 co-infection resulted in decreased levels of transferrin 
compared to seronegative subjects; this difference was statistically significant within the 
INT patient groups (p  0.05, Figure 5.16). The decreased levels of serum transferrin in 
HIV-1 co-infection reflect the role of transferrin as an acute phase protein that decreases 
with inflammation during HIV-infection.  
 
The CD4 count showed results consistent with previous observations that persons with 
severe hepatosplenic disease present with reduced amounts of blood T cells (Figure 5.17). 
The CD4 counts in INT and HS seronegative and seropositive patients were discussed 
previously (Mwinzi et al., 2004) and showed reduced CD4 counts in HIV-1 seropositive 
individuals (Figure 5.18). In addition, the authors found an effect of ultrasound-detectable 
fibrosis leading to lower CD4 counts in IPD/E patients compared to IPA and IPC (Figure 
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5.21). HIV-1 co-infection status showed seronegative schistosomiasis patients had high 
CD4 count than seropositive patients (Figure 5.22) (Mwinzi et al., 2004).  
 
5.4 Conclusion 
The serum 2D-DIGE maps showed distinctive serum protein patterns between MSS and 
HSS mice, in particular the heavy and light immunoglobulin protein spot patterns were 
also distinct and different. MUP and transferrin emerged as protein markers for HSS mice 
and complement component 3, transthyretin being infection specific. Importantly, the 
serum CyDye labelling saturated the high abundant proteins with the CyDyes and reduced 
the sensitivity for low abundant proteins. Therefore, selective immunodepletion of serum 
for high abundant proteins (albumin, immunoglobulins, transferrin, and haptoglobin) may 
allow detection of the serum for low abundant proteins that will aid in detecting diagnostic 
markers for schistosome-mediated liver disease. The present investigation demonstrated a 
strong correlation between the mouse serum data and the mouse liver data. However, the 
human serum data did not produce the same results for all the candidate protein markers. 
In particular, human serum total protein, CTGF and transferrin results were not consistent 
with the findings in the mouse serum data. Human CTGF levels were high in INT patients. 
The human serum hydroxyproline and keratin D had comparable results to the mouse 
serum data. Human hydroxyproline and keratin D proved to be useful for assessing severe 
schistosomiasis. However, future studies should include MUP and Sm-PEPCK as markers 
for pathology in human schistosomiasis. Because some of the serum samples came from 
HIV-1 seropositive subjects, we tested what effect this co-infection may have on the 
serum results. Only hydroxyproline and transferrin were affected by HIV-1 co-infections, 
with both markers being decreased in seropositive patients. Further studies with larger 
     193 
patient populations would help to validate the candidate protein markers as predictors of 
schistosomiasis pathology. Taken together the results indicate the importance of 
hydroxyproline, keratin D and CTGF as promising candidates for elaborate sero-
epidemiological studies, which may help in differentiating the intestinal and hepatosplenic 
schistosomiasis. 
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CHAPTER 6:  DISCUSSION 
 
6.1 Summary of this research 
The primary aim of this project was to identify candidate liver protein markers in mice, 
which could serve as diagnostic markers for human hepatosplenic schistosomiasis. A 
secondary aim was to assess differential protein abundance during moderate splenomegaly 
and hypersplenomegaly syndromes in CBA/J mice, to understand the underlying 
pathological mechanisms that direct the development of these 2 disease forms found in 
human schistosomiasis. Using a proteomic approach to compare the liver and serum 
protein profiles, the global impact of schistosome infection on the liver could be 
determined at various times post infection. Together these experiments using the mouse 
model identified several candidate markers including transferrin, MUP, keratin D, CTGF, 
and hydroxyproline. However, analysis of the serum samples from infected subjects 
revealed that of these candidates only keratin D and hydroxyproline served as robust 
markers of HS. Overall, these studies have identified and validated unique candidate 
markers for future development and have revealed distinct and specific changes in liver 
protein expression during infection that may help elucidate the molecular mechanisms of 
disease pathology during schistosomiasis. 
 
6.1.1 Candidate markers of fibrosis 
The two marked pathological features of chronic schistosomiasis, granulomatous lesions 
(Stadecker, 1999) and fibrosis (Boros, 1989), differ among the intestinal and 
hepatosplenic forms. Our study identified and examined the expression of extracellular 
matrix associated proteins that are essential to these two processes including collagen, 
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hydroxyproline, and connective tissue growth factor (CTGF). Collagen isoforms 6a1 and 
IVX were the major collagen isoforms identified and have been previously associated with 
fibrotic transformation in alcoholic liver (Stickel et al., 2001). While collagen isoforms 
did not reach significance in our time point experiment, two collagen-associated 
proteins/products, hydroxyproline and CTGF were significantly correlated with 
hepatosplenic disease. Hydroxyproline, an amino acid found in collagen, increased in 
severe disease in mice and human sera and reflected fibrosis in severe hepatosplenic 
disease. Our study is the first to measure hydroxyproline in the serum of subjects with 
schistosomiasis and to demonstrate a significant correlation between serum levels and 
fibrosis. 
 
CTGF induces collagen synthesis during liver fibrogenesis (Paradis et al., 1999) but its 
role in schistosome-mediated liver fibrosis is unknown. CTGF may also induce collagen 
synthesis and fibrosis in schistosome infection, or alternatively, the fibrosis  may result 
from impaired collagen degradation and be independent of CTGF. Indeed, a study by 
Andrade et al. demonstrated that collagen synthesis and degradation occur at the same 
time (Andrade, 1992). Our results showed that while mouse serum CTGF levels were high 
in HSS mice, the human serum CTGF levels were specifically increased in INT patients. 
These contradictory results suggest that there is differential regulation of the fibrotic 
process in our experimental model and in human schistosomiasis. However, CTGF may 
still prove a useful inverse correlate of fibrosis in human schistosomiasis, and further 
studies into the involvement of CTFG in human schistosomiasis are merited. 
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6.1.2 Candidate markers of inflammation 
The 2D-DIGE study revealed that the negative acute phase proteins: transferrin, albumin, 
group specific component and retinol binding protein increased during severe disease, 
which is in contrast to their expected function during inflammation. This association of 
negative acute phase reactants with schistosome infection is unique to our study. Increased 
transferrin has been described by (Potter et al., 1985) in alcoholic liver disease and 
increased retinol binding protein has been described by (Uchio et al., 2002) in hepatic 
fibrogenesis similar to the findings in our study indicating that evaluation of these protein 
in mouse and human sera may be useful. However, evaluation of transferrin levels in 
human subjects indicated that the levels were  within the normal range. Whether this lack 
of correlation to disease is due to fundamental differences between human disease and our 
mouse model or some unknown confounding disease interaction is unclear. Nevertheless, 
these results indicate that transferrin, despite its promising results, is not a useful 
biomarker  
 
Xenobiotic metabolising proteins, which should increase in parasitic infections for 
removal of reactive oxygen species and toxic products generated due to infection, were 
decreased in abundance at 8-weeks, 12-weeks, and 20-weeks post infection, which is 
another major finding from our study. Most significantly, three spots with epoxide 
hydrolase activity were decreased with severe schistosome infection contradictory to the 
report by Murray et al. (1993) and one spot with peroxiredoxin 6 activity decreased in 
abundance in HSS mice similar to the study by Roede et al. (2008). While these proteins 
were not assessed in the serum by targeted assays, given their strong and unique 
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associations with disease, they have potential as markers and thus warrant further 
investigation. 
 
6.1.3 Other candidate markers 
Two novel proteins that were identified as potential markers of diagnostic value were 
MUP and Sm-PEPCK. MUP, a pheromone protein with similarity to human epididymal-
specific lipocalin-9, decreased in HSS mice when compared to 6-week, 8-week, and 12-
week and MSS infected mice. The decreased abundance of MUP was confirmed by 
western blot technique in liver and serum and consistent with the report in murine 
hepatocarcinogenesis (Dragani et al., 1989) suggesting that assessment of this protein in 
human sera may help identify hepatosplenic schistosomiasis. One drawback to the use of 
this protein is that it is considered to be male-specific, thus the usefullness as a disease 
form biomarker for all schistosomiasis patients is unclear. 
 
Sm-PEPCK a parasite protein showed increased abundance in MSS and HSS mice. 
Although using Western blot we found that murine PEPCK was also increased in the 
livers of MSS and HSS mice, we confirmed that the PEPCK identified by 2D-DIGE was 
parasite-derived by soluble egg antigen electrophoresis and mass spectrometry. We 
believe that Sm-PEPCK may be useful as an infection specific marker or possibly a 
therapeutic target. A previous study has described it as a novel egg antigen for 
schistosome infection (Asahi et al., 2000) and indicated the role for this protein in the 
pathogenesis of schistosomiasis.  
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6.1.4 Disease kinetics 
The 2D-DIGE map comparison for 6-week, 8-week, 12-week, 20-week infection with 
control CBA/J mice identified 34 protein spots that showed increased abundance and 94 
protein spots that showed decreased abundance during 12-week infection alone, verifying 
the fact that 12-week mice have severe liver dysfunction compared to any other study 
groups. In particular, at 12-week infection proteins associated with amino acid metabolism, 
fatty acid metabolism, one carbon metabolism, redox reactions and xenobiotic metabolism 
were decreased and specifically there was decreased abundance of basic proteins (pI range 
6-11) at 12-week infection. Although, 12-week infected mice showed profound changes in 
greatest number of protein spots, 8-week infected mice also showed significant changes 
and 20-week infected mice showed greatest magnitude of changes indicating that all the 
three time points post-infection are critical during the pathogenesis of schistosomiasis. 
 
6.1.5 Statistical analyses for identification of candidates 
The multivariate cluster analysis using PCA and HCA, aided in confirming the 
differentially expressed protein patterns distinct for HSS and MSS mice and 8-week and 
12-week infected mice with especially high %SBW. These results indicate that certain 
mechanisms or molecules in mice and/or the parasite contribute towards the segregation of 
these infected groups into MSS and HSS mice. Multiple regression analysis of the various 
proteins related to disease progression identified liver hydroxyproline, a measure of 
collagen synthesis and damage, as the strongest predictor of splenomegaly and 
hepatomegaly. Once hydroxyproline was removed, the next strongest indicator of 
splenomegaly was keratin D. Moreover, our analysis of mouse and human serum samples 
for hydroxyproline and keratin D, confirmed these results. Finally, our multiple regression 
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analysis identified MUP, Sm-PEPCK, transferrin and peroxiredoxin 6 as liver proteins that 
appear to act synergistically during the pathogenesis of murine schistosomiasis. Together 
these analyses have revealed not only potential biomarkers for hepatosplenomegaly but 
also possible molecular interactions that may be involved in the pathogenesis of severe 
disease. 
 
6.1.6 Validation of candidate protein markers 
Using targeted assays, we investigated the usefulness of the candidates identified from the 
mouse liver and serum 2D-DIGE studies. Contrary to our expectations, the human serum 
analysis showed diverse results compared to mouse serum data. The human CTGF was 
significantly high in INT patients than HS patients. The keratin D results were similar to 
the mouse serum analysis and showed significantly higher levels in HS patients than INT 
patients. Human serum hydroxyproline were similar in INT and HS patients although 
higher than normal subjects. However, when stratified for ultrasound-assessed fibrosis, 
hydroxyproline did correlate with severe fibrosis suggesting that it may only serve as a 
late and not an early marker of fibrosis. Ultimately, our study was successful in 
identifying candidate liver protein markers for human hepatosplenic schistosomiasis. We 
believe that keratin D may serve as a marker for HS and CTGF as a marker for INT 
patients, while serum hydroxyproline may reflect late stage fibrosis.  
 
6.2 Future directions 
CBA/J mouse model is an excellent model for future experiments related to 
schistosomiasis disease forms and hepatic fibrosis. Using the CBA/J mouse model at early 
infections, as early as 1, 2, 3, 4, 5, 6 week and applying the 2D-DIGE approach and 
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depletion of highly abundant proteins, low abundance proteins can be targeted. The 
present study was successful in identifying candidate liver protein markers; however, 2D-
DIGE experiments using narrow range IPG Dry strips might be useful in targeting proteins 
that have co-migrated due to similar pI or molecular weight. One important fact that 
cannot be ignored is that disease in the mice is a result of the single exposure to the 
parasite while in the human disease is a consequence of successive re-infections and 
therefore it would be worth investigating the protein abundance in mouse re-infections. 
This approach will identify proteins expressed during re-infections. 
 
Using high-throughput mass spectrometry like tandem mass spectrometry and liquid 
chromatography-mass spectrometry (LC/MS/MS) systems may identify post-translational 
modifications (e.g. glycosylation, phosphorylation, hydroxylation) of proteins that are 
unique during schistosomiasis disease. Although, two-dimensional electrophoresis 
coupled to mass spectrometry is the most versatile technique in proteomic analysis 
(Penque, 2009), a review by (Lambert et al., 2005) enumerates the importance of gel-free 
techniques coupled with Surface-Enhanced Laser Desorption/Ionization Time-of-Flight 
Mass Spectrometry (SELDI-TOF MS), liquid chromatography (LC/MS) and Capillary 
Electrophoresis (CE)-MS to identify novel biomarkers. The above techniques together 
with multiple reaction monitoring assays could help separate and identify individual liver 
derived protein and peptide constituents in plasma (McKay et al., 2007), from either host 
or parasite with potentials of a biomarker. Furthermore, quantitative differences among 
control and diseased samples can be analysed using label based methods such as ICAT 
(isotype-coded affinity tag) or 
16
O/
18
O labelling or iTRAQ (isobaric tag for relative and 
absolute quantification) (Shen et al., 2006). Label free methods such as mass spectral peak 
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intensities of peptide ions (ratios of ion intensities for peptides) and spectral counting 
(number of spectra per protein) (Old et al., 2005) are promising methods to measure 
differential changes in protein abundance during disease. Using these approaches will 
solve certain problems in 2D-DIGE techniques like streaky protein migration and 
inconsistent resolving of protein spots on the gel, which makes biomarker discovery 
difficult. 
 
Immunohistochemical localisation of identified proteins related to disease in non-infected 
and infected liver tissue using confocal microscopy can explain the possible reasons for 
the increased or decreased abundance of proteins during the progression of the disease. 
This experiment could also help understand whether the proteins are increased as a result 
of immune cell activity of liver granuloma or hepatocyte interactions with the liver 
granuloma. Conversely, immunoprecipitation can be used to validate the identified protein 
spots by using targeted antibodies. 
 
Two important proteins identified by this study were MUP and Sm-PEPCK as predictors 
of splenomegaly. MUP has similarity to human epididymal-specific lipocalin-9 and Sm-
PEPCK is a parasitic protein makes further research more interesting. Detection antibody 
is available for human epididymal-specific lipocalin-9 and could be used to monitor the 
protein pattern in early and late stages of human schistosomiasis. Sm-PEPCK antibody 
engineering and designing is a complex process, therefore alternatively, high-throughput 
mass spectrometry coupled with information from schistosome database (Berriman et al., 
2009) could help quantify the Sm-PEPCK protein in mouse serum, liver and human serum 
samples as well as detect whether the protein is post-translationally modified during 
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schistosome infection. This strategy might identify a potential drug target for treatment of 
schistosomiasis disease. The peculiar abundance pattern of peroxiredoxin6 in MSS and 
HSS mice requires more in-depth study to determine whether this pattern is due to over 
oxidation of the protein or decreased synthesis of the protein during schistosome infection. 
 
Because 2D-DIGE requires very small sample volume, using the finger prick method to 
collect human serum samples, and a similar experiment based on the mouse serum 2D-
DIGE in our study with depletion techniques can allow identification of low abundant 
protein patterns in human intestinal and hepatosplenic schistosomiasis. Moreover, human 
serological studies require large number of serum samples for candidate protein markers 
to be established as “biomarkers” (Schulz and Grimes, 2005) therefore detection of the 
candidate protein markers: CTGF, hydroxyproline and keratin D in a large sample size can 
help establish a reference range for these proteins.  
 
Finally, because schistosome infection does not occur in isolation, studying how the 
expression of our candidate protein markers is altered during other parasitic infections that 
invade the liver like Fasciola hepatica and P. falciparum would determine the specificity 
of the protein candidates for S. mansoni infections. Additionally, examination of the 
candidate protein markers in human serum samples from liver fibrosis, liver cirrhosis, 
hepatocellular carcinoma, hepatitis, alcoholic liver disease and non-alcoholic liver disease 
will confirm or refute whether the disease-specific protein abundance patterns we 
observed in our candidates are unique to schistosomiasis-induced fibrosis or reflect a more 
general inflammation-mediated fibrotic process.  
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APPENDICES 
APPENDIX A 
 
EXPERIMENTAL DESIGN 1: 8 gels for pI 4-7 and 8 gels for pI 6-11 
(Samples labelled with CyDyes were randomised across the gels.) 
Gel No. 
Cy2 Internal 
Standard 
Cy3 
Sample 
Cy5 
Sample 
1 10 g pooled sample
1
 10 g sample 1C2 10 g sample 1M2 
2 10 g pooled sample
1
 10 g sample 2H2 10 g sample 2C2 
3 10 g pooled sample
1
 10 g sample 3C2 10 g sample 3M2 
4 10 g pooled sample
1
 10 g sample 4H2 10 g sample 4C2 
5 10 g pooled sample
1
 10 g sample 5C2 10 g sample 5M2 
6 10 g pooled sample
1
 10 g sample 2M2 10 g sample 3H2 
7 10 g pooled sample
1
 10 g sample 4M2 10 g sample 1H2 
8 10 g pooled sample
1
 10 g sample 5H2 10 g sample 1C2 
 
1
10 g protein each of the liver lysates from 5 C, 5 M and 5 H 
 2
C, control (uninfected /normal); M, MSS; H, HSS 
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EXPERIMENTAL DESIGN 2: 23 gels for pI 4-7 and 23 gels for pI 6-11 
(Samples labelled with CyDyes were randomised across the gels.) 
Gel 
No. 
Cy2 Internal 
Standard 
Cy3 
Sample 
Cy5  
Sample 
1 10 g pooled sample
1
 10 g sample 1C2 10 g sample 1M2 
2 10 g pooled sample
1
 10 g sample 2H2 10 g sample 2C2 
3 10 g pooled sample
1
 10 g sample 3C2 10 g sample 3M2 
4 10 g pooled sample
1
 10 g sample 4H2 10 g sample 4C2 
5 10 g pooled sample
1
 10 g sample 5C2 10 g sample 5M2 
6 10 g pooled sample
1
 10 g sample 2M2 10 g sample 3H2 
7 10 g pooled sample
1
 10 g sample 4M2 10 g sample 1H2 
8 10 g pooled sample
1
 10 g sample 5H2 10 g sample 1C2 
9 10 g pooled sample
1
 10 g sample 6-week-01 10 g sample 8-week-02 
10 10 g pooled sample
1
 10 g sample 8-week-03 10 g sample 6-week-02 
11 10 g pooled sample
1
 10 g sample 6-week-03 10 g sample 8-week-06 
12 10 g pooled sample
1
 10 g sample 12-week-09 10 g sample 6-week-04 
13 10 g pooled sample
1
 10 g sample 6-week-05 10 g sample 12-week-10 
14 10 g pooled sample
1
 10 g sample 8-week-09 10 g sample 6-week-06 
15 10 g pooled sample
1
 10 g sample 6-week-07 10 g sample 12-week-02 
16 10 g pooled sample
1
 10 g sample 12-week-05 10 g sample 6-week-08 
17 10 g pooled sample
1
 10 g sample 6-week-09 10 g sample 8-week-08 
18 10 g pooled sample
1
 10 g sample 12-week-01 10 g sample 6-week-10 
19 10 g pooled sample
1
 10 g sample 8-week-01 10 g sample 12-week-08 
20 10 g pooled sample
1
 10 g sample 12-week-03 10 g sample 8-week-04 
21 10 g pooled sample
1
 10 g sample 8-week-05 10 g sample 12-week-06 
22 10 g pooled sample
1
 10 g sample 12-week-04 10 g sample 8-week-07 
23 10 g pooled sample
1
 10 g sample 8-week-10 10 g sample 12-week-07 
 
1
10 g protein each of the liver lysates from 5 C, 5 M and 5 H 
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2
(C, control (uninfected /normal); M, MSS; H, HSS) 
6-week, 6-week infected liver lysate (10 samples); 8-week, 8-week infected liver lysate 
(10 samples); 12-week, 12-week infected liver lysate (10 samples). 
 
EXPERIMENTAL DESIGN 3: 3 gels for pI 3-10. 
(Samples labelled with CyDyes were randomised across the gels.) 
Gel 
No. 
Cy2 
Internal Standard  
Cy3  
Sample 
Cy5  
Sample 
1 Pool of 15 serum samples
1
 Pooled C serum
2
 Pooled M serum
3
 
2 Pool of 15 serum samples
1
 Pooled H serum
4
 Pooled C serum
2
 
3 Pool of 15 serum samples
1
 Pooled M serum
3
 Pooled H serum
4
 
 
1
Pool of (5C +5M + 5H) sera, 10 g protein each;  
2 
Pool of 5 C sera; 
3
 Pool of 5 M sera; 
4
 Pool of 5 H sera  
(C, control (uninfected /normal); M, MSS; H, HSS). 
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APPENDIX B 
2D-DIGE GEL IMAGE ANALYSIS USING DECYDER SOFTWARE 6.5 
In the DeCyder Software 6.5 control panel, load gel images using “Image Loader”. Load 
Cy2, Cy3, Cy5 images one at a time. 
Using “Batch Processor” for the Differential In-gel Analysis and Biological Variation 
Analysis for all the gel images together will create Workspaces respectively. 
In the “Spot Table” Biological Variation Analysis (BVA) module segregate the gel images 
according to the experimental groups and name them accordingly. 
In the “Match Table” BVA module match the protein spots using the “Internal Standard”.  
The “Protein Table” BVA module allows the viewing of the differential pattern analysis. It 
allows selecting and comparing the experimental groups. It calculates the average fold 
ratio between groups with the choice for “False Discovery Rate” selection criteria. 
The BVA saved data can be used in the Extended Data Analysis (EDA) module to analyse 
the Differential Expression Analysis (DEA), Principle Component Analysis (PCA), 
Hierarchical Cluster Analysis (HCA) and Discriminant Analysis for Marker Selection 
(DAMS). The EDA is a module for multivariate analysis. 
The DEA graphically illustrates the increase and decrease in protein spots in the 
experimental groups with ANOVA, Student T-Test and Multiple Comparison Tests. 
PCA is supervised clustering which reduces the multidimensionality of the huge data sets 
and makes comparison between data sets (protein spots and DIGE proteomic images) 
easier. 
HCA is unsupervised clustering making compassion between protein spots on gel images, 
experimental groups and protein spot volumes feasible. The dendrogram and heat map 
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together give a lot of information about the similarities in functional groups in protein 
spots and similarities between study groups. 
Based on the resolution of the gel images and protein spots the DAMS feature allows the 
protein spot data to be analysed for biomarker selection. 
Shown below is the sequential analysis for pI 4-7 for Experimental Design 1 and 2 with 
illustrations form the DeCyder software.  
 
FIGURE B1 
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FIGURE B2 
 
 
FIGURE B3 
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FIGURE B4 
 
 
FIGURE B5 
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FIGURE B6 Analysis for Experiment Design 1 
 
 
FIGURE B7 
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FIGURE B8 
 
 
FIGURE B9 
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FIGURE B10 Analysis for Experiment Design 2 
HSS/Control, ANOVA 0.01, 2-fold, with FDR 
 
 
FIGURE B11 HSS/Control, ANOVA 0.01, 2-fold, with FDR 
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FIGURE B12 Extended Data Analysis 
 
 
FIGURE B13 
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FIGURE B14 
 
 
FIGURE B15 
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FIGURE B16 
 
 
 
FIGURE B17 Differential Expression Analysis (DEA) 
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FIGURE B18 Principle Component Analysis (PCA) 
 
 
FIGURE B19 Hierarchical Cluster Analysis (HCA) 
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FIGURE B20 Discriminant Analysis for Marker Selection (DAMS) 
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APPENDIX C 
Protein spot identifications using preparative gel  
 
 
FIGURE C1 Preparative gel pI 3-10 with 75 g protein from HSS serum. Numbers 1 to 
33 are proteins identified by peptide mass finger printing using MALDI-TOF mass 
spectrometry. Below is the list of proteins. 
 
TABLE C1 List of protein spots for Figure C1. 
Spot 
No. 
Expectation Protein Description 
Seq. 
Cov.% 
pI kDa 
Peptides  
matched 
1 3.7×10-11 
gi|19353306|gb|AAH24643.1|  
Albumin 1 [Mus musculus] 
47 5.8 70.73 27 
2 8.2×10-3 
gi|31982171|ref|NP_032671.2|  
murinoglobulin 1 [Mus musculus] 
17 6.0 166.71 17 
3 8.8×10-3 
gi|16741103|gb|AAH16407.1|  Serine 
(or cysteine) proteinase inhibitor, 
clade A, member 3K [Mus musculus] 
33 5.0 47.05 10 
4 7.5×10-5 
gi|28916693|ref|NP_666232.2|  
gelsolin [Mus musculus] 
19 5.8 86.32 13 
5 2.6×10-5 
gi|31982113|ref|NP_032903.2|  
plasminogen [Mus musculus] 
19 6.2 93.50 18 
6 6.3×10-4 
gi|70049|pir||MHMSM  Ig mu chain 
C region, membrane-bound form - 
mouse 
20 5.9 53.27 11 
7 3.0×10-3 
gi|60359986|dbj|BAD90212.1|  
mKIAA4106 protein [Mus musculus] 
22 6.5 87.85 10 
8 4.0×10-3 
gi|23956086|ref|NP_059067.1|  
hemopexin [Mus musculus] 
28 8.4 52.06 11 
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9 8.9×10-4 
gi|72679472|gb|AAI00598.1|  
Unknown (protein for MGC:118711) 
(afamin)[Mus musculus] 
29 5.5 71.33 20 
10 6.0×10-6 
gi|63694077|ref|XP_622665.1|  
PREDICTED: similar to HMW 
kininogen-I variant [Mus musculus] 
44 5.0 54.27 25 
11 8.6×10-3 
gi|6650539|gb|AAF21895.1|  epsilon-
sarcoglycan [Mus musculus] 
19 6.4 50.86 7 
12 4.7×10-4 
gi|51172612|ref|NP_032122.1|  group 
specific component (vitamin D-
binding protein)[Mus musculus] 
40 5.4 55.18 11 
13 4.5×10-4 
gi|122120|sp|P01898|HA10_MOUSE  
H-2 class I histocompatibility antigen, 
Q10 alpha chain precursor 
25 5.2 37.18 7 
14 2.5×10-3 
gi|21304450|emb|CAD32498.1|  
immunoglobulin gamma1 heavy 
chain [Mus musculus] 
6 6.0 56.08 9 
15 6.7×10-3 
gi|26665404|dbj|BAC44885.1|  
immunoglobulin gamma-1 heavy 
chain [Mus musculus] 
10 6.8 52.09 5 
16 7.3 ×10-3 
gi|13097381|gb|AAH03435.1|  Igh-4 
protein [Mus musculus] 
6 6.6 51.67 6 
17 8.0×10-3 
gi|387437|gb|AAA39549.1|  MHC 
factor B 
29 9.1 54.56 16 
18 7.4×10-6 
gi|34785996|gb|AAH57983.1|  Pzp 
protein [Mus musculus] (Alpha-2-
macroglobulin precursor (Pregnancy 
zone protein)) or Sm 20.8 (S. 
mansoni) 
10 6.2 167.23 19 
19 4.3×10-3 
gi|28175786|gb|AAH43338.1|  
Complement component 3 [Mus 
musculus] 
10 6.3 188.01 14 
20 8.3 ×10-3 
gi|16741595|gb|AAH16602.1|  
Galactokinase 1 [Mus musculus] 
16 5.2 42.68 5 
21 8.2×10-3 
gi|13096928|gb|AAH03261.1|  
Aurora kinase B (protein kinase)[Mus 
musculus] 
26 9.6 39.53 5 
22 3.8×10-3 
gi|13276755|emb|CAC34259.1|  
Major Urinary Protein [Mus 
musculus] 
36 4.9 20.93 9 
23 1.2 ×10-3 
gi|63561993|ref|XP_112440.3|  
PREDICTED: heparan sulfate D-
glucosaminyl 3-O-sulfotransferase 2 
[Mus musculus] 
18 
10.
0 
38.06 5 
24 9.1×10-3 
gi|1183932|emb|CAA32224.1|  
haemoglobin beta-1 chain [Mus 
56 7.1 15.94 9 
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musculus] 
25 3.9×10-5 
gi|19354093|gb|AAH24702.1|  
Transthyretin [Mus musculus] 
61 5.8 15.87 8 
26 4.8×10-3 
gi|18655521|pdb|1IQW|L  Chain L, 
Crystal Structure Of The Fab 
Fragment Of The Mouse Anti- 
Human Fas Antibody Hfe7a 
36 5.0 24.16 6 
27 7.7×10-5 
gi|34785996|gb|AAH57983.1|  Pzp 
protein [Mus musculus] (Alpha-2-
macroglobulin precursor (Pregnancy 
zone protein)) 
9 6.2 167.23 16 
28 2.3×10-3 
gi|7024437|emb|CAB75889.1|  
immunoglobulin light chain [Mus 
musculus] 
20 5.4 24.27 6 
29 8.4×10-3 
gi|20269237|dbj|BAB90990.1|  
immunoglobulin kappa chain [Mus 
musculus] 
40 8.0 24.43 8 
31 1.0×10-3 
gi|23956086|ref|NP_059067.1|  
hemopexin [Mus musculus] 
26 8.4 52.06 11 
32 5.5×10-4 
gi|28175786|gb|AAH43338.1|  
Complement component 3 [Mus 
musculus] or Glutathione 
Peroxidase(S. mansoni) 
10 6.3 188.01 23 
33 1.4×10-9 
gi|2145139|gb|AAB58426.1|  
apolipoprotein A-I [Mus musculus] 
51 5.5 30.35 18 
34 2.4×10-5 
gi|62027488|gb|AAH92046.1|  
Transferrin [Mus musculus] 
36 7.0 78.87 21 
35 3.8×10-3 
gi|41946979|gb|AAH66092.1|  
Complement component factor h 
[Mus musculus]  
9 6.7 143.80 12 
36 2.1×10-5 
gi|28172876 protein 4.1G [Mus 
musculus] 
 
15 
6.2 77.24 11 
37 5.4×10-3 
gi|18381134|gb|AAH22129.1|  C8b 
protein [Mus musculus] (Complement 
component 8 subunit beta) 
24 6.5 57.06 10 
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FIGURE C2: Preparative gel pI 4-7 with 400 g protein from HSS liver lysate. Numbers 
1 to 14 are proteins identified by peptide mass finger printing using MALDI-TOF mass 
spectrometry. Below is the list of proteins. 
 
TABLE C2 List of protein spots for Figure C2. 
Spot 
No. 
Expectation  Protein Description 
Seq. 
Cov.
% 
pI kDa 
Peptides  
matched 
1 4.4×10-4 
gi|27817830|dbj|BAC55524.2|  
connectin/titin N2A-PEVK [Mus 
musculus]  
8 5.6 130.71 20 
3  8.4×10-3 
gi|62027488|gb|AAH92046.1|  
Transferrin [Mus musculus] 
20 7.0 78.87 19 
4  6.7×10-3 
gi|62027488|gb|AAH92046.1|  
Transferrin [Mus musculus] 
11 7.0 78.87 16 
5 1.1×10-3 
gi|31981722|ref|NP_071705.2|  heat 
shock 70kD protein 5 (glucose-regulated 
protein) [Mus musculus] 
34 5.0 72.52 19 
6  6.0×10-5 
gi|26341396|dbj|BAC34360.1|  unnamed 
protein product [Mus musculus] 
(Albumin 1) 
28 5.5 67.04 14 
7  5.3×10-5 
gi|26341396|dbj|BAC34360.1|  Albumin 
[Mus musculus]  
31 5.5 67.04 14 
8  9.6×10-3 
gi|2612795|emb|CAA05364.1|  annexin 
VIII [Mus musculus] 
25 5.6 37.05 14 
9  3.6×10-3 
gi|38173925|gb|AAH61000.1|  Brain and 
reproductive organ-expressed protein 
[Mus musculus]  
14 5.7 43.95 9 
10 9.8×10-3 
gi|59889574|ref|NP_038943.3|  zinc 
finger protein 238 isoform 2 [Mus 
musculus] 
14 5.4 59.45 9 
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11  5.5×10-4 
gi|1504135|gb|AAB39209.1|  
interleukin-2 [Mus musculus]  
19 4.9 18.68 5 
12  6.8×10-3 
gi|31981722|ref|NP_071705.2|  heat 
shock 70kD protein 5 (glucose-regulated 
protein) [Mus musculus] 
31 5.0 72.52 16 
13  5.1×10-3 
gi|47117852|sp|P46718|PDCD2_MOUS
E  Programmed cell death protein 2 
(Zinc finger protein Rp-8)  
10 5.2 39.41 7 
14  6.9×10-4 
gi|13278412|gb|AAH04017.1|  Eno1 
protein [Mus musculus]  
31 5.6 38.62 12 
15 6.8×10-4 
gi|6680117|ref|NP_032206.1|  glutathione 
synthetase [Mus musculus] 
31 5.6 52.46 15 
 
 
a)
1 2
3
4
5
6
7
8
9
10
11
1213
14
15
47
46
48 45
39
44
42
40
41
38
 b)
16 17
18
19
20
21 22
23 24
25 26
27
28
29
30
31
32
33
34
35
36
37
43
49
50
 
FIGURE C3 a) Preparative gel pI 4-7 with 400 g protein from MSS liver lysate. b) 
Preparative gel pI 4-7with 75 g protein from HSS liver lysate. Numbers 1 to 50 are 
proteins identified by peptide mass finger printing using MALDI-TOF mass spectrometry. 
Below is the list of proteins. 
 
TABLE C3 List of protein spots for Figure C3 (a, b). 
Spot 
No. 
Expectation  Protein Description 
Seq. 
Cov.% 
pI kDa 
Peptides  
matched 
 1  9.1×10-3 
gi|12805443|gb|AAH02194.1|  Col6a1 protein 
[Mus musculus]  
19 5.8 44.76 9 
2 7.7×10-3 
gi|12805443|gb|AAH02194.1|  Col6a1 protein 
[Mus musculus]  
19 5.8 44.76 9 
3 1.3×10-4 
gi|14714615|gb|AAH10445.1|  Tumor 
rejection antigen gp96 [Mus musculus] 
15 4.7 92.76 9 
4 9.9×10-4 gi|285016|pir||S27878  selenium-binding 21 6.0 52.90 12 
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protein, hepatic - mouse 
5 1.8×10-4 
gi|19353306|gb|AAH24643.1|  Albumin 1 
[Mus musculus] 
26 5.8 70.73 13 
6 6.6×10-3 
gi|13384778|ref|NP_079672.1|  6-
phosphogluconolactonase [Mus musculus] 
32 5.6 27.46 20 
7 7.4×10-3 
gi|9910128|ref|NP_064377.1|  aldehyde 
dehydrogenase 9, subfamily A1 [Mus 
musculus] 
29 6.6 54.47 13 
9 7.4×10-3 
gi|63517253|ref|XP_144057.3|  PREDICTED: 
similar to elastase 3B, pancreatic [Mus 
musculus]  
9 6.4 38.02 6 
10 5.9×10-3 
gi|20380027|gb|AAH28817.1|  Fthfd protein 
[Mus musculus] 
10 5.6 99.55 10 
 - 
gi|23271467|gb|AAH24055.1|  Fthfd protein 
[Mus musculus]  
10 5.7 99.57 10 
11 8.8×10-4 
gi|56800495|emb|CAI35365.1|  expressed in 
non-metastatic cells 1 protein [Mus musculus]  
45 9.1 14.13 7 
12 3.4×10-4 
gi|5834643|emb|CAB55352.1|  N-
acetylgalactosaminyltransferase T-6 [Mus 
musculus]  
7 9.5 72.23 5 
13 3.5×10-7 
gi|7106255|ref|NP_031508.1|  arginase 1, 
liver [Mus musculus] 
64 6.5 34.96 20 
14 3.4×10-3 
gi|26986064|emb|CAC81903.1|  albumin 
[Mus musculus]  
37 5.5 24.23 18 
15 9.8×10-3 
gi|59889574|ref|NP_038943.3|  zinc finger 
protein 238 isoform 2 [Mus musculus] 
14 5.4 59.45 11 
16  9.2×10-3 
gi|30420885|gb|AAO64442.1|  collagen type 
XIV [Mus musculus] 
11 5.0 194.30 6 
17 4.8×10-3 
gi|30420885|gb|AAO64442.1|  collagen type 
XIV [Mus musculus] 
18 5.0 194.30 8 
18 5.2×10-6 
gi|62027488|gb|AAH92046.1|  Transferrin 
[Mus musculus] 
23 7.0 78.87 19 
19 9.2×10-7 
gi|62027488|gb|AAH92046.1|  Transferrin 
[Mus musculus] 
30 7.0 78.87 20 
20 7.0×10-6 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial precursor (Carbamoyl-
phosphate synthetase I) (CPSase I)  
20 6.5 165.80 24 
21 8.1×10-3 
gi|12805443|gb|AAH02194.1|  Col6a1 protein 
[Mus musculus]  
24 5.8 44.76 11 
22 8.6×10-3 
gi|12805443|gb|AAH02194.1|  Col6a1 protein 
[Mus musculus]  
14 5.8 44.76 8 
23 3.9×10-7 
gi|14714615|gb|AAH10445.1|  Tumor 
rejection antigen gp96 [Mus musculus] 
24 4.7 92.76 12 
24 9.6×10-4 gi|20380027|gb|AAH28817.1|  Fthfd protein 22 5.6 99.55 18 
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[Mus musculus] 
25 4.9×10-3 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial precursor (CPSase I)  
25 6.5 165.80 22 
26  5.0×10-4 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial precursor (CPSase I)  
25 6.5 165.80 22 
27 1.9×10-3 
gi|31981679|ref|NP_034607.2|  heat shock 
protein 1 (chaperonin) [Mus musculus] 
28 5.7 61.11 15 
29, 
30  
4.4×10
-3 
gi|28913521|gb|AAH48688.1|  Similar to zinc 
finger protein (C2H2 type) 276 [Mus 
musculus]  
36 5.7 11.62 5 
31  4.4×10-4 
gi|13277612|gb|AAH03716.1|  Anxa5 protein 
[Mus musculus]  
45 4.8 35.78 19 
32  8.3×10-3 
gi|6677739|ref|NP_033086.1|  regucalcin 
[Mus musculus] 
25 5.2 33.90 17 
34 4.4×10-4 
gi|27753960|ref|NP_083907.2|  hypothetical 
protein LOC76491 [Mus musculus] 
(alpha/beta hydrolase domain containing 14b) 
16 5.8 22.55 7 
36  4.1×10-4 
gi|26353794|dbj|BAC40527.1|  unnamed 
protein product [Mus musculus] (protein 
disulfide-isomerase (EC 5.3.4.1) ERp61) 
38 5.8 57.12 12 
37 9.2×10-4 
gi|26338069|dbj|BAC32720.1|  unnamed 
protein product [Mus musculus]  
28 4.2 12.43 3 
38 7.0×10-3 
gi|26326751|dbj|BAC27119.1|  unnamed 
protein product [Mus musculus] (valosin 
containing protein) 
22 5.1 90.04 7 
39 3.8×10-4 
gi|226471|prf||1513495A  Cu/Zn superoxide 
dismutase  
45 6.0 15.91 7 
40 8.2×10-5 
gi|7106255|ref|NP_031508.1|  arginase 1, 
liver [Mus musculus] 
58 6.5 34.96 15 
 42  1.8×10-4 
gi|13542782|gb|AAH05595.1|  Anxa6 protein 
[Mus musculus]  
8 5.3 75.70 6 
43 4.0×10-3 
gi|12849189|dbj|BAB28242.1|  unnamed 
protein product [Mus musculus](Ubiquitin B) 
25 6.9 34.38 10 
44 8.5×10-3 
gi|51172612|ref|NP_032122.1|  group specific 
component [Mus musculus] 
15 5.4 55.18 7 
48 6.4×10-4 
gi|13385584|ref|NP_080361.1|  MAWD 
binding protein homolog 2 [Mus musculus] 
47 5.2 32.19 14 
50 8.6×10-3 
gi|31980726|ref|NP_082408.2|  
phosphoglucomutase 2 [Mus musculus] 
32 6.3 61.78 15 
 
 
  
251 
a) 
1
36
1
1
12
13
1415
17
19
24
29
30
31
IPG Strip No. 09924 (4-7)-HSS-
14c
2
4
5
7
8
9
1
0
16
18
20 21
22 23
25
26
27
28
32
 b) 
 
IPG Strip No. 17861 (6-11)-HSS-17c 
33 34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 53 
54 
55 
56 
57 
58 
59 
60 
61 62  
FIGURE C4 a) Preparative gel pI 4-7 with 60 g protein from HSS liver lysate. b) 
Preparative gel pI 6-11 with 60 g protein from HSS liver lysate. Numbers 1 to 62 are 
proteins identified by peptide mass finger printing using MALDI-TOF mass spectrometry.  
 
TABLE C4 List of protein spots for FigureC4 (a,b). 
Spot 
No. 
Expectation  Protein Description 
Seq. 
Cov.
% 
pI kDa 
Peptides  
matched 
1 4.4×10-3 
gi|28373538|pdb|1LB3|A  Chain A, 
Structure Of Recombinant Mouse L Chain 
Ferritin At 1.2 A Resolution 
38 5.6 20.68 11 
3 5.9×10-4 
gi|23272966|gb|AAH37127.1|  Atp5b 
protein [Mus musculus]  
27 5.2 56.65 24 
4 4.5×10-4 
gi|12805443|gb|AAH02194.1|  Col6a1 
protein [Mus musculus]  
20 5.8 44.76 9 
5  2.1×10-2 
gi|49868|emb|CAA27396.1|  put. beta-actin 
(aa 27-375) [Mus musculus] 
21 5.8 39.45 8 
10  4.4×10-5 
gi|74191500 unnamed protein product 
[Mus musculus] Protein Disulfide 
Isomerase (PDIb) family proteins 
28 4.8 57.42 15 
11  6.9×10-5 
gi|33416530|gb|AAH55871.1|  Annexin A4 
[Mus musculus]  
37 5.4 36.20 16 
12  7.7×10-4 
gi|388921|gb|AAC37635.1|  purine 
nucleoside phosphorylase  
36 5.9 32.54 9 
13  8.5×10-4 
gi|63712196|ref|XP_354652.3|  
PREDICTED: 3-hydroxyanthranilate 3,4-
dioxygenase [Mus musculus]  
33 6.3 25.61 10 
18  5.3×10-4 
gi|56206786|emb|CAI24278.1|  prohibitin 
[Mus musculus]  
34 6.0 23.04 11 
19  8.9×10-3 gi|63660253|ref|XP_619203.1|  37 9.6 20.73 8 
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PREDICTED: hypothetical protein 
XP_619203 [Mus musculus]  
22  7.1×10-5 
gi|12844989|dbj|BAB26576.1|  unnamed 
protein product [Mus musculus] 
(phosphoglycerate mutase 1) 
55 6.7 28.80 14 
23  6.3×10-3 
gi|51830637|ref|XP_141626.3|  
PREDICTED: hypothetical protein 
XP_141626 [Mus musculus]  
(PREDICTED: similar to Ubiquitin-
conjugating enzyme E2Q (putative) 2 [Mus 
musculus]) 
11 4.5 43.56 7 
24 1.7×10-3 
gi|26338652|dbj|BAC32997.1|  unnamed 
protein product [Mus musculus]  
19 6.8 19.39 7 
25  1.6×10-3 
gi|28373538|pdb|1LB3|A  Chain A, 
Structure Of Recombinant Mouse L Chain 
Ferritin At 1.2 A Resolution 
38 5.6 20.68 9 
26  5.2×10-4 
gi|12846314|dbj|BAB27120.1|  unnamed 
protein product [Mus musculus] 
(Peroxiredoxin 1) 
31 8.6 22.45 11 
27  2.6×10-3 
gi|13385268|ref|NP_080073.1|  
cytochrome b-5 [Mus musculus] 
49 4.9 15.22 6 
28  1.6 ×10-4 
gi|33585469|gb|AAH55479.1|  Pik4ca 
protein [Mus musculus] / unknown 
[Schistosoma japonicum] 
17 6.2 35.86 8 
29  3.9×10-3 
gi|46401561|dbj|BAD16627.1|  
peptidylarginine deiminase, type IV [Mus 
musculus]/ ubiquitin [Schistosoma 
mansoni]  
13 6.6 74.97 14 
30 8.5×10-5 
gi|51859026|gb|AAH81432.1|  Glyoxalase 
1 [Mus musculus] 
27 5.2 20.96 11 
31  8.7×10-3 
gi|50510361|dbj|BAD32166.1|  
nonselenium glutathione peroxidase [Mus 
musculus] (peroxiredoxin 6) 
28 6.0 25.05 7 
32  6.3×10-7 
gi|56206644|emb|CAI24411.1|  malate 
dehydrogenase, soluble [Mus musculus] 
15 6.2 36.66 8 
33 3.8×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus]  
8 7.3 71.74 5 
34 2.9×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus]  
16 7.3 71.74 7 
35 1.4 ×10-3 
gi|56753812 SJCHGC06900 protein 
[Schistosoma japonicum](gi|74828716 S. 
mansoni-Phosphoenolpyruvate 
carboxykinase (Sm-PEPCK)) 
16 6.4 71.33 6 
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36 2.2×10-6 
gi|62027488|gb|AAH92046.1|  Transferrin 
[Mus musculus] 
24 7.0 78.87 16 
37 4.6×10-4 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial precursor (Carbamoyl-
phosphate synthetase I) (CPSase I)  
9 6.5 165.8 8 
38 2.5×10-3 
gi|15004258|gb|AAK73774.1|  mutant 
catalase [Mus musculus]  
18 7.8 60.01 14 
39 4.7×10-3 
gi|63575386|ref|XP_620669.1|  
PREDICTED: similar to Nucleoside 
diphosphate kinase B (NDK B) (NDP 
kinase B) (P18) [Mus musculus]  
22 10.4 14.98 6 
40 5.8×10-4 
gi|8569275|pdb|1QCO|B  Chain B, Crystal 
Structure Of Fumarylacetoacetate 
Hydrolase Complexed With Fumarate And 
Acetoacetate 
30 7.0 46.72 15 
41 9.4×10-4 
gi|202423|gb|AAA70267.1|  
phosphoglycerate kinase 
27 7.7 44.92 14 
42 5.2×10-3 
gi|26339842|dbj|BAC33584.1|  unnamed 
protein product [Mus musculus] 
(Sulfatase) 
11 9.5 70.61 19 
43 8.1×10-3 
gi|7106255|ref|NP_031508.1|  arginase 1, 
liver [Mus musculus] 
37 6.5 34.96 14 
44 3.4×10-3 
gi|6679184|ref|NP_032795.1|  ornithine 
transcarbamylase [Mus musculus] 
30 8.9 39.86 10 
47 2.9×10-4 
gi|21450291|ref|NP_659152.1|  aldolase 2, 
B isoform [Mus musculus] 
27 9.0 39.95 12 
48 8.9×10-5 
gi|6678509|ref|NP_033500.1|  urate 
oxidase [Mus musculus] 
45 8.7 35.25 19 
49 8.4×10-6 
gi|2690302|gb|AAB91426.1|  aspartate 
aminotransferase precursor [Mus 
musculus]  
26 9.3 47.79 9 
50 2.2×10-3 
gi|12846591|dbj|BAB27227.1|  
Cytochrome b5 reductase [Mus musculus]  
37 9.3 33.78 17 
52 5.9×10-3 
gi|193690|gb|AAA37748.1|  glutathione 
transferase (EC 2.5.1.18)  
40 7.8 24.82 11 
53  5.4×10-3 
gi|10197496|gb|AAG14901.1|  CD5.1 
[Mus musculus]  
9 9.6 55.14 14 
54 3.6×10-4 
gi|2624496|pdb|1BAY|B  Chain B, 
Glutathione S-Transferase Yfyf Cys 47-
Carboxymethylated Class Pi, Free Enzyme 
41 8.3 23.52 9 
55 9.4 ×10-3 
gi|56752803 Schistosoma japonicum short 
chain dehydrogenase 
23 9.9 24.19 11 
56 2.4 ×10-3 
gi|55716028  Rpl13 protein [Mus 
musculus] (Ribosomal Protein L 13) 
17 9.9 24.64 10 
57 4.0×10-3 gi|40786428|ref|NP_955398.1|  galactose- 24 8.5 47.12 14 
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3-O-sulfotransferase 2 [Mus musculus] 
58  1.1×10-3 
gi|54607171|ref|NP_032502.3|  keratin 
complex 2, basic, gene 6a [Mus musculus] 
22 8.3 59.66 16 
60  3.7×10-3 
gi|18044023|gb|AAH19638.1|  
4632417K18Rik protein [Mus musculus]  
10 5.9 45.82 10 
61  6.3×10-3 
gi|56237900|emb|CAI25914.1|  zinc finger 
protein 287 [Mus musculus]  
11 8.8 87.58 19 
62  2.7×10-3 
gi|45219726|gb|AAH66798.1|  RIKEN 
cDNA 3000003F02 [Mus musculus]  
11 8.6 79.91 15 
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FIGURE C5 a) Preparative gel pI 4-7 with 75 g protein from HSS liver lysate. b) 
Preparative gel pI 6-11 with 75 g protein from HSS liver lysate. Numbers 1 to 157 are 
proteins identified by peptide mass finger printing using MALDI-TOF mass spectrometry.  
 
TABLE C5 List of protein spots for Figure C5 (a, b).  
Spot 
No. 
Expectation  Protein Description 
Seq. 
Cov.% 
pI kDa 
Peptides  
matched 
1  8.2×10-3 
gi|53271|emb|CAA27227.1|  MUP [Mus 
musculus] 
70 4.8 17.71 8 
2  8.3×10-3 
gi|53271|emb|CAA27227.1|  MUP [Mus 
musculus] 
70 4.8 17.71 8 
3 5.5×10-4  
gi|115615 Calpain (Calcium-activated 
neutral proteinase) (CANP) 
14 5.3 87.56 5 
4 7.6×10-3 
gi|1841387|dbj|BAA11751.1|  14-3-3 zeta 
[Mus musculus]  
31 4.7 27.88 12 
5 2.8×10-4 
gi|56206786|emb|CAI24278.1|  prohibitin 
[Mus musculus]  
29 6.0 23.04 11 
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 6 8.1×10-4 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
25 8.4 45.46 16 
7 3.5×10-3 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
33 8.4 45.46 14 
8  9.5×10-3 
gi|6166177|sp|P15105|GLNA_MOUSE  
Glutamine synthetase (Glutamate--
ammonia ligase) (GS)  
21 6.5 42.81 13 
9  1.8×10-4 
gi|12584974|ref|NP_075022.1|  betaine-
homocysteine methyltransferase 2 [Mus 
musculus] 
26 6.0 40.28 15 
10  2.7×10-3 
gi|63471580|ref|XP_619602.1|  
PREDICTED: similar to S-
adenosylhomocysteine hydrolase [Mus 
musculus]  
28 6.1 48.08 14 
11  1.0×10-3 
gi|63471580|ref|XP_619602.1|  
PREDICTED: similar to S-
adenosylhomocysteine hydrolase [Mus 
musculus]  
24 6.1 48.08 13 
12  5.2 ×10-4 
gi|7549763|ref|NP_038575.1|  
homogentisate 1, 2-dioxygenase [Mus 
musculus] 
24 6.9 50.77 11 
13 5.5×10-4 
gi|29244162 hypothetical protein 
LOC237029 [Mus musculus] 
19 5.1 54.68 10 
16  9.6×10-3 
gi|285016|pir||S27878  selenium-binding 
protein, hepatic - mouse 
35 6.0 52.90 17 
17  4.0×10-5 
gi|18848341|gb|AAH24106.1|  Selenium 
binding protein 2 [Mus musculus]  
31 5.8 53.16 12 
18  2.3×10-3 
gi|18848341|gb|AAH24106.1|  Selenium 
binding protein 2 [Mus musculus]  
21 5.8 53.16 10 
21  2.7×10-3 
gi|50510861|dbj|BAD32416.1|  
mKIAA1258 protein (guanine 
deaminase)[Mus musculus]  
27 5.4 55.11 14 
22 4.9×10-3 
gi|809561|emb|CAA31455.1|  gamma-
actin [Mus musculus]  
21 5.6 41.34 7 
23 3.7×10-4 
gi|23272966|gb|AAH37127.1|  Atp5b 
protein [Mus musculus]  
25 5.2 56.65 23 
24 4.4×10-5   
gi|74203945 Protein Disulfide Isomerase 
[Mus musculus] 
19 4.8 56.97 11 
25 5.0×10-10 
gi|74203945 prolyl 4-hydroxylase, beta 
polypeptide [Mus musculus] 
36 4.8 56.97 18 
27 2.7×10-3 
gi|45219865|gb|AAH66857.1| protein 
disulfide isomerase associated 4 [Mus 
musculus] 
26 5.9 65.41 13 
29 2.9×10-3 gi|183396771|ref|NP_034607.3|   heat 22 5.7 61.11 12 
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shock protein 1 (chaperonin) [Mus 
musculus] 
 30 8.3×10-3 
gi|18252784|ref|NP_543121.1|  
formiminotransferase cyclodeaminase 
[Mus musculus] 
36 5.8 59.55 16 
31  9.8×10-4 
gi|15929294|gb|AAH15087.1|  Epoxide 
hydrolase 2, cytoplasmic [Mus musculus] 
14 5.9 63.07 11 
33  2.9×10-3 
gi|15929294|gb|AAH15087.1|  Epoxide 
hydrolase 2, cytoplasmic [Mus musculus] 
10 5.9 63.07 8 
38 3.2×10-7 
gi|3851614|gb|AAC72373.1|  succinate 
dehydrogenase Fp subunit [Mus 
musculus]  
27 6.2 59.27 15 
 39 6.5×10-3 
gi|3851614|gb|AAC72373.1|  succinate 
dehydrogenase Fp subunit [Mus 
musculus]  
17 6.2 59.27 12 
40 3.6×10-3 
gi|26329893|dbj|BAC28685.1|  glycerol 
phosphate dehydrogenase 2, 
mitochondrial [Mus musculus]  
24 6.2 81.38 16 
41 5.2×10-3 
gi|21704020|ref|NP_663493.1|  NADH 
dehydrogenase (ubiquinone) Fe-S protein 
1 [Mus musculus] 
25 5.5 80.76 13 
42  4.3×10-4 
gi|19879234|gb|AAK27416.1|  
mitochondrial assembly regulatory factor 
[Mus musculus]  
17 6.4 86.85 9 
50  4.1×10-5 
gi|51705066|ref|XP_129769.5|  
PREDICTED: carbamoyl-phosphate 
synthetase 1 [Mus musculus]  
14 6.4 166.9 20 
51  5.0×10-4 
gi|59808083|gb|AAH89599.1|  
Dimethylglycine dehydrogenase, 
precursor [Mus musculus]  
18 7.8 97.44 11 
52  5.3×10-4 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial precursor 
(Carbamoyl-phosphate synthetase I) 
(CPSase I)  
20 6.5 165.8 23 
53 8.6×10-3 
gi|73918911|sp|Q8C196|CPSM_MOUSE  
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial precursor 
(Carbamoyl-phosphate synthetase I) 
(CPSase I)  
14 6.5 165.8 20 
54  1.4×10-3 
gi|33563270|ref|NP_035086.1|  
oxoglutarate dehydrogenase (lipoamide) 
[Mus musculus] 
12 6.5 117.4 19 
55 1.4×10-5 
gi|26352359|dbj|BAC39816.1|  Sarcosine 
Dehydrogenase [Mus musculus]  
37 6.4 57.84 17 
57  1.1×10-4 
gi|20380027|gb|AAH28817.1|  Fthfd 
protein [Mus musculus] 
34 5.6 99.55 20 
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58 3.6×10-4 
gi|23271467|gb|AAH24055.1|  Fthfd 
protein [Mus musculus]  
33 5.7 99.57 19 
61  7.4×10-3 
gi|200246|gb|AAA39897.1|  pyruvate 
carboxylase  
13 6.1 103.1 18 
62 8.4×10-3 
gi|26346581|dbj|BAC36939.1|  pyruvate 
decarboxylase [Mus musculus]  
30 5.8 91.42 25 
63  2.5×10-3 
gi|200246|gb|AAA39897.1|  pyruvate 
carboxylase  
16 6.1 103.8 22 
 64 4.3×10-4 
gi|48976025|ref|NP_598665.1|  acetyl-
Coenzyme A carboxylase beta [Mus 
musculus] 
14 5.9 278.1 25 
65 2.4×10-3 
gi|31542333|ref|NP_067370.2|  hypoxia 
up-regulated 1 [Mus musculus] 
21 5.2 111.4 20 
68 4.8×10-3 
gi|30420885|gb|AAO64442.1|  collagen 
type XIV [Mus musculus] 
18 5.0 194.3 7 
69 9.2×10-3 
gi|30420885|gb|AAO64442.1|  collagen 
type XIV [Mus musculus] 
11 5.0 194.3 6 
71 1.0×10-5 
gi|57013837|sp|O08795|GLU2B_MOUS
E  Glucosidase II beta subunit precursor 
(Protein kinase C substrate, 60.1 kDa 
protein, heavy chain) (PKCSH) (80K-H 
protein) 
13 4.4 59.74 9 
72 1.3×10-3 
gi|57013837|sp|O08795|GLU2B_MOUS
E  Glucosidase II beta subunit precursor 
(Protein kinase C substrate, 60.1 kDa 
protein, heavy chain) (PKCSH) (80K-H 
protein) 
15 4.4 59.74 10 
74  4.6×10-6 
gi|27369605|ref|NP_766039.1|  UDP-N-
acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 [Mus 
musculus] 
13 9.2 72.25 16 
83 3.9×10-3 
gi|27464957|gb|AAN64234.1|  DNA 
polymerase theta short isoform [Mus 
musculus]  
9 7.2 252.4 21 
84 3.8×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus]  
8 7.3 71.74 5 
85 2.9×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus]  
16 7.3 71.74 7 
86  1.7×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus]  
10 7.3 71.74 6 
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88 1.3 ×10-3 
gi|56753812 SJCHGC06900 protein 
[Schistosoma japonicum]( 
Phosphoenolpyruvate carboxykinase 
(PEPCK)) 
16 6.5 71.33 6 
91  6.2×10-4 
gi|18079339|ref|NP_542364.1|  aconitase 
2, mitochondrial [Mus musculus] 
22 8.4 86.19 13 
96 1.3×10-6 
gi|54887356|gb|AAH37009.1|  
Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit 
[Mus musculus]  
32 9.5 83.31 18 
97  7.0×10-3 
gi|1213008|emb|CAA62015.1|  17beta-
hydroxysteroid dehydrogenase IV [Mus 
musculus] 
16 9.0 80.02 14 
98  1.3×10-3 
gi|16741519|gb|AAH16571.1|  Slc25a13 
protein (solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator))[Mus musculus]  
39 9.5 44.55 15 
99  5.3×10-3 
gi|54887356|gb|AAH37009.1|  
Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit 
[Mus musculus]  
13 9.5 83.31 11 
100  4.4×10-4 
gi|6753514|ref|NP_034079.1|  carnitine 
palmitoyltransferase 2 [Mus musculus] 
15 8.8 74.54 12 
102  7.6×10-3 
gi|26350301|dbj|BAC38790.1|  
trifunctional enzyme, thiolase [Mus 
musculus]  
39 9.6 51.77 13 
103 1.2×10-6 
gi|2690302|gb|AAB91426.1|  aspartate 
aminotransferase precursor [Mus 
musculus]  
35 9.3 47.79 11 
104  8.2×10-3 
gi|26344475|dbj|BAC35888.1|  electron 
transferring flavoprotein, dehydrogenase 
[Mus musculus]  
22 7.4 69.06 9 
105  7.9×10-3 
gi|34328415|ref|NP_780647.2|  aldehyde 
dehydrogenase 4 family, member A1 
[Mus musculus] 
23 8.9 62.25 10 
106 3.1×10-4 
gi|45476581|ref|NP_035457.1|  sterol 
carrier protein 2, liver [Mus musculus] 
17 7.2 59.74 10 
107  7.6×10-6 
gi|26344712|dbj|BAC36005.1|  mutant 
catalase [Mus musculus]  
30 7.8 60.10 14 
108  8.6×10-3 
gi|18848352|gb|AAH24133.1|  aldehyde 
dehydrogenase 4 family, member A1 
protein [Mus musculus]  
19 8.6 60.78 14 
112 6.2×10-3  gi|6680748 ATP synthase, H+ 30 9.2 59.83 16 
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transporting, mitochondrial F1 complex, 
alpha subunit, isoform 1 [Mus musculus] 
113 8.7×10-3 
gi|74146998 ATP synthase, H+ 
transporting, mitochondrial F1 complex, 
alpha subunit, isoform 1 [Mus musculus] 
28 9.3 56.03 15 
114 7.1×10-5 
gi|74146998 ATP synthase, H+ 
transporting, mitochondrial F1 complex, 
alpha subunit, isoform 1 [Mus musculus] 
29 9.3 56.03 15 
115 7.9×10-3   
gi|74211977 ATP synthase, H+ 
transporting, mitochondrial F1 complex, 
alpha subunit, isoform 1 [Mus musculus] 
30 9.3 59.86 16 
116  3.6×10-3 
gi|37542157|gb|AAK72480.1|  core 2 
beta-1,6-N-acetylglucosaminyltransferase 
II [Mus musculus]  
20 9.0 51.41 11 
117  2.3×10-3 
gi|26354278|dbj|BAC40767.1|  glutamate 
dehydrogenase [Mus musculus]  
25 8.6 61.60 11 
118  2.2×10-3 
gi|26344712|dbj|BAC36005.1|  mutant 
catalase [Mus musculus]  
26 7.8 60.10 13 
119 2.4×10-3 
gi|26354278|dbj|BAC40767.1|  glutamate 
dehydrogenase [Mus musculus]  
27 8.6 61.60 12 
120  6.5×10-4 
gi|23271115|gb|AAH33440.1|  Aldehyde 
dehydrogenase family 6, subfamily A1 
[Mus musculus]  
35 8.6 58.46 15 
121  6.7×10-3 
gi|7549763|ref|NP_038575.1|  
homogentisate 1, 2-dioxygenase [Mus 
musculus] 
31 6.9 50.77 13 
122 8.6×10-5 
gi|20810027|gb|AAH28901.1|  Acetyl-
Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) [Mus musculus] 
42 8.8 42.30 21 
123  6.7×10-5 
gi|20810027|gb|AAH28901.1|  Acetyl-
Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) [Mus musculus] 
31 8.8 42.30 15 
124  5.4×10-3 
gi|12850542|dbj|BAB28763.1|  acetyl-
Coenzyme A acetyltransferase 2 [Mus 
musculus] 
16 7.2 38.64 9 
125  7.3×10-3 
gi|20810027|gb|AAH28901.1|  Acetyl-
Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) [Mus musculus] 
53 8.8 42.30 23 
126 2.1×10-4 
gi|6754156 hydroxyacid oxidase 1, liver 
[Mus musculus] 
21 7.6 41.26 11 
127  4.1×10-3 
gi|7709978|ref|NP_057911.1|  alanine-
glyoxylate aminotransferase [Mus 
musculus] 
27 8.9 46.20 19 
129  1.4×10-3 gi|42490808|gb|AAH66164.1|  11 9.1 57.01 9 
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interleukin 31RA protein [Mus musculus]  
130  8.1×10-3 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
39 8.4 45.46 10 
131  5.9×10-3 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
19 8.4 45.46 6 
133  3.6×10-3 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
19 8.4 45.46 13 
135  2.9 ×10-3 
gi|55669643|pdb|1R8Y|H  Chain H, 
Crystal Structure Of Mouse Glycine N-
Methyltransferase (Monoclinic Form) 
27 7.3 32.98 10 
137  2.5×10-3 
gi|226778|prf||1605130A  carbonic 
anhydrase III  
14 8.0 29.61 6 
138  9.7×10-4 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
28 8.4 45.46 15 
139  2.0×10-4 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
23 8.4 45.46 12 
140  6.2×10-3 
gi|226778|prf||1605130A  carbonic 
anhydrase III  
29 8.0 29.61 12 
141  8.9×10-3 
gi|1864018|gb|AAB48543.1|  
triosephosphate isomerase [Mus 
musculus]  
52 5.6 22.72 13 
 143 5.1×10-5 
gi|21759114|sp|Q9DCW4|ETFB_MOUS
E  Electron transfer flavoprotein beta-
subunit (Beta-ETF) 
43 8.9 27.52 16 
144  2.9×10-3 
gi|2624496|pdb|1BAY|B  Chain B, 
Glutathione S-Transferase Yfyf Cys 47-
Carboxymethylated Class Pi, Free 
Enzyme 
45 8.3 23.52 10 
145 2.9×10-4 
gi|6754084 glutathione S-transferase, mu 
1 [Mus musculus] 
41 7.7 26.06 11 
146  4.0×10-3 
gi|12846244|dbj|BAB27089.1|  
peptidylprolyl isomerase A [Mus 
musculus]  
57 8.7 18.14 12 
147  1.8×10-3 
gi|48474620|sp|Q99LB2|DHRS4_MOUS
E  Dehydrogenase/reductase SDR family 
member 4 (NADPH-dependent carbonyl 
reductase/NADP-retinol dehydrogenase) 
(CR) (PHCR)  
27 9.6 27.96 15 
149  2.8×10-3 
gi|4760594|dbj|BAA77357.1|  beta-2-
globin [Mus musculus]  
30 8.2 15.84 6 
150  5.5×10-3 
gi|4760590|dbj|BAA77355.1|  beta-1-
globin [Mus musculus]  
55 7.3 15.81 7 
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151  4.0×10-3 
gi|4760594|dbj|BAA77357.1|  beta-2-
globin [Mus musculus]  
64 8.2 15.84 8 
152  4.1×10-5 
gi|12846939|dbj|BAB27370.1|  
hemoglobin, beta adult major chain  [Mus 
musculus]  
28 9.3 15.30 5 
153  8.3×10-4 
gi|6678509|ref|NP_033500.1|  urate 
oxidase [Mus musculus] 
51 8.7 35.2 17 
154  3.7×10-3 
gi|21707669|gb|AAH34173.1|  Aldolase 
2, B isoform [Mus musculus]  
34 9.0 39.97 16 
155  8.1×10-3 
gi|6678509|ref|NP_033500.1|  urate 
oxidase [Mus musculus] 
40 8.7 35.25 12 
156  2.4×10-3 
gi|193703|gb|AAA37751.1|  glutathione 
transferase alpha 3 
30 8.8 25.40 7 
157  4.3×10-3 
gi|52139036|gb|AAH82563.1|  
Angiopoietin-like 1 [Mus musculus] 
22 9.1 56.76 10 
 
 
FIGURE C6 Preparative gel pI 4-7 and 6-11 with 75 g protein from HSS liver lysate. 
Numbers 1 to 72 were proteins identified by peptide mass finger printing using MALDI-
TOF mass spectrometry.  
 
TABLE C6 List of protein spots for Figure C6.  
Spot 
No. 
Expectation Protein Name 
Seq. 
Cov.% 
pI kDa 
Peptides  
matched 
2 6.6×10-4 
gi|26352359|dbj|BAC39816.1|  sarcosine 
dehydrogenase [Mus musculus] 
34 6.4 57.84 26 
3 3.6×10-3 
gi|26352359|dbj|BAC39816.1|  sarcosine 
dehydrogenase [Mus musculus] 
42 6.4 57.84 28 
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4 4.2×10-3 
gi|59808083|gb|AAH89599.1|  
Dimethylglycine dehydrogenase, precursor 
[Mus musculus] 
22 7.8 97.44 12 
5 4.3×10-3 
gi|59808083|gb|AAH89599.1|  
Dimethylglycine dehydrogenase, precursor 
[Mus musculus] 
36 7.8 97.44 18 
6 8.8×10-3 
gi|26341396|dbj|BAC34360.1|  unnamed 
protein product (Albumin 1) [Mus 
musculus] 
14 5.5 67.04 7 
7 3.0×10-3 
gi|26354755|dbj|BAC41004.1|  unnamed 
protein product (gelsolin) [Mus musculus] 
15 5.7 81.07 9 
8 1.8×10-6 
gi|6678329|ref|NP_033399.1|  
transglutaminase 2, C polypeptide [Mus 
musculus] 
35 5.0 78.18 19 
11 7.4×10-3 
gi|15030102|gb|AAH11301.1|  succinate 
dehydrogenase Fp subunit [Mus musculus] 
24 7.2 73.39 13 
15 4.8×10-4 
gi|15929294|gb|AAH15087.1|  Epoxide 
hydrolase 2, cytoplasmic [Mus musculus] 
44 5.9 63.07 16 
16 7.0×10-6 
gi|15929294|gb|AAH15087.1|  Epoxide 
hydrolase 2, cytoplasmic [Mus musculus] 
38 5.9 63.07 15 
18 2.5 ×10-4 IPI00310669 Dihydroxyacetone kinase 39 6.4 59.94 10 
19 5.6×10-3 
gi|60392921|sp|P11369|POL2_MOUSE  
Retrovirus-related Pol polyprotein LINE-1 
(Long interspersed element-1) (L1) 
[Contains: Reverse transcriptase ; 
Endonuclease] 
18 9.9 150.59 6 
22 2.2×10-3 
gi|904132|gb|AAA70378.1|  S-adenosyl-L-
homocysteine hydrolase 
30 6.0 48.17 15 
23 3.0×10-4 
gi|54114937|gb|AAH39179.1|  Eno1 protein 
[Mus musculus] 
40 7.8 50.18 15 
24 8.4×10-5 
gi|12836655|dbj|BAB23751.1|  isovaleryl 
coenzyme A dehydrogenase [Mus 
musculus] 
25 8.7 46.61 13 
27 8.6×10-3 gi|293682|gb|AAA39373.1|  keratin D 27 5.3 47.47 9 
28 2.1×10-4 gi|293682|gb|AAA39373.1|  keratin D 16 5.3 47.47 7 
29 3.4×10-3 
gi|309215|gb|AAA37551.1|  EndoA' 
cytokeratin (5' end put.); putative 
35 5.4 53.22 14 
33 2.9×10-3 
gi|21618806|gb|AAH31710.1|  Dhdh protein 
[Mus musculus] 
31 5.9 36.97 9 
34 2.0×10-6 IPI00228630 Fructose-1,6-bisphosphatase 1 51 6.2 37.30 14 
35 1.4×10-3 
gi|31982229|ref|NP_032465.2|  
ketohexokinase [Mus musculus] 
21 5.8 33.29 5 
36 1.2×10-4 
gi|13277612|gb|AAH03716.1|  Anxa5 
protein [Mus musculus] 
39 4.8 35.78 13 
37 5.5×10-3 gi|26341416|dbj|BAC34370.1|  unnamed 32 4.7 28.99 16 
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protein product (tropomyosin 3, gamma) 
[Mus musculus] 
38 3.0×10-3 
gi|50510361|dbj|BAD32166.1|  
mKIAA0106 protein (nonselenium 
glutathione peroxidise) (peroxiredoxin 6) 
[Mus musculus] 
22 6.0 25.17 6 
41 4.9×10-4 
gi|63545837|ref|XP_620353.1|  
PREDICTED: similar to tumor protein, 
translationally-controlled 1 [Mus musculus] 
17 6.1 82.14 6 
42 5.4×10-3 
gi|71051244|gb|AAH99597.1|  Major 
urinary protein 1 [Mus musculus] 
56 4.9 21.04 9 
43 6.4×10-3 
gi|13385268|ref|NP_080073.1|  cytochrome 
b-5 [Mus musculus] 
43 4.9 15.22 5 
45 3.1×10-3 
gi|21730472|pdb|1KGL|A  Chain A, 
Solution Structure Of Cellular Retinol 
Binding Protein Type- I In Complex With 
All-Trans-Retinol 
56 5.1 15.86 7 
49 9.5×10-4 
gi|226471|prf||1513495A  Cu/Zn superoxide 
dismutase 
52 6.0 15.91 8 
50 9.7×10-4 
gi|12846804|dbj|BAB27309.1|  unnamed 
protein product [Mus musculus] (60S 
ribosomal protein) 
25 11.6 23.83 7 
51 4.0×10-5 
gi|20330802|ref|NP_598738.1|  transferrin 
[Mus musculus] 
26 7.0 78.87 20 
52 1.4×10-5 
gi|62027488|gb|AAH92046.1|  Transferrin 
[Mus musculus] 
31 7.0 78.87 19 
53 5.1×10-3 
gi|18848352|gb|AAH24133.1|  Aldh4a1 
protein [Mus musculus] 
31 8.6 60.78 13 
54 5.1×10-8 
gi|442441|gb|AAA66054.1|  catalase [Mus 
musculus]  
42 8.3 60.00 23 
56 3.2×10-7 
gi|442441|gb|AAA66054.1|  catalase [Mus 
musculus]  
34 8.3 60.00 19 
57 9.9×10-3 
gi|6729934|pdb|1MAB|A  Chain A, Rat 
Liver F1-Atpase (ATP synthase, H+ 
transporting, mitochondrial F1 complex, 
alpha subunit, isoform 1) 
33 8.4 55.38 17 
58 1.9×10-4 
gi|62533211|gb|AAH93510.1|  Betaine-
homocysteine methyltransferase [Mus 
musculus] 
24 8.4 45.46 7 
60 9.0×10-3 
gi|51243036|ref|NP_001003717.1|  
oxysterol-binding protein-like protein 8 
isoform b [Mus musculus] 
23 7.3 97.53 7 
62 7.0×10-3 
gi|49257190|gb|AAH72658.1|  Enoyl 
Coenzyme A hydratase, short chain, 1, 
mitochondrial [Mus musculus] 
36 9.3 31.95 10 
64 7.8×10-3 gi|2624496|pdb|1BAY|B  Chain B, 46 8.3 23.52 9 
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Glutathione S-Transferase Yfyf Cys 47-
Carboxymethylated Class Pi, Free Enzyme 
65 9.6×10-3 
gi|2624496|pdb|1BAY|B  Chain B, 
Glutathione S-Transferase Yfyf Cys 47-
Carboxymethylated Class Pi, Free Enzyme 
37 8.3 23.52 7 
66 5.2×10-3 
gi|33468899|ref|NP_034489.1|  glutathione 
S-transferase, mu 3 [Mus musculus] 
50 7.8 25.91 8 
67 2.9×10-3 
gi|2624496|pdb|1BAY|B  Chain B, 
Glutathione S-Transferase Yfyf Cys 47-
Carboxymethylated Class Pi, Free Enzyme 
52 8.3 23.52 9 
69 1.7×10-4 
gi|4760590|dbj|BAA77355.1|  beta-1-globin 
[Mus musculus] 
37 7.3 15.81 5 
70 2.3×10-4 IPI00828873 Beta-2-globin 52 7.9 15.85 5 
72 3.5×10-3 
gi|51770518|ref|XP_489790.1|  
PREDICTED: similar to MHC class I 
histocompatibility antigen H-2 Q4 alpha 
chain precursor - mouse [Mus musculus] 
15 7.3 71.74 6 
 
 
FIGURE C7 Preparative gel pI range 4-7 and 6-11 for soluble egg antigen with 75 g 
protein. Numbers 1 to 49 are proteins identified by peptide mass finger printing using 
MALDI-TOF mass spectrometry.  
 
TABLE C7 List of protein spots for Figure C7. 
Spot 
No. 
Expectation  Protein Description 
Seq. 
Cov.% 
pI kDa 
Peptides  
matched 
1 8.4×10-4 
gi|320988|pir||A60608  paramyosin - fluke 
(Schistosoma mansoni) (fragment) 
43 5.1 51.19 14 
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2 3.9×10-3 
gi|56758882|gb|AAW27581.1|  unknown 
[Schistosoma japonicum] 
31 5.5 89.55 6 
3 5.3×10-3 
gi|320985|pir||A45529  heat shock protein 
86 - fluke (Schistosoma mansoni) 
(fragment) 
39 5.4 51.43 16 
4 8.8×10-4 
gi|320985|pir||A45529  heat shock protein 
86 - fluke (Schistosoma mansoni) 
(fragment) 
43 5.4 51.43 17 
5 4.0×10-3 
gi|2829289|gb|AAC00519.1|  HSP70 
[Schistosoma japonicum] 
26 5.1 71.64 15 
6 3.8×10-4 
gi|10168|emb|CAA28976.1|  70,000 mol wt 
antigen/hsp70 homologue (619 AA) 
[Schistosoma mansoni] 
12 5.4 68.36 12 
7 2.0×10-4 
gi|56753427|gb|AAW24917.1|  unknown 
[Schistosoma japonicum] 
23 6.3 71.45 13 
- - 
gi|2829291|gb|AAC00520.1|  HSP70 
[Schistosoma japonicum] 
23 5.4 56.05 - 
8 6.4×10-3 
gi|21634531|gb|AAM69406.1|  heat shock 
protein HSP60 [Schistosoma mansoni] 
38 5.3 58.76 17 
9 1.8×10-4 
gi|1314808|gb|AAA99815.1|  T-complex 
polypeptide 1 alpha subunit [Schistosoma 
mansoni] 
26 6.0 60.05 11 
10 8.7×10-3 
gi|313121|emb|CAA80521.1|  ER-luminal 
cysteine protease ER 60 [Schistosoma 
mansoni] 
37 6.3 54.80 18 
11 2.5×10-4 
gi|313121|emb|CAA80521.1|  ER-luminal 
cysteine protease ER 60 [Schistosoma 
mansoni] 
36 6.3 54.80 18 
12 7.0×10-3 
gi|29841421|gb|AAP06453.1|  similar to 
NM_019693 HLA-B associated transcript 1 
in Homo sapiens [Schistosoma japonicum] 
20 6.5 47.68 8 
13 1.1×10-3 
gi|3023710|sp|Q27877|ENO_SCHMA  
Enolase (2-phosphoglycerate dehydratase) 
(2-phospho-D-glycerate hydro-lyase) 
44 6.2 47.43 18 
14 1.7×10-4 
gi|3023710|sp|Q27877|ENO_SCHMA  
Enolase (2-phosphoglycerate dehydratase) 
(2-phospho-D-glycerate hydro-lyase) 
45 6.2 47.43 19 
15 9.8×10-5 
gi|312018|emb|CAA80520.1|  protein 
disulfide isomerase homologue 
[Schistosoma mansoni] 
48 4.9 54.48 20 
16 2.6×10-3 
gi|1345835|sp|Q06814|CRTC_SCHMA  
Calreticulin precursor (SM4 protein) 
33 4.7 45.55 15 
17 8.0×10-4 
gi|496495|emb|CAA55978.1|  alpha tubulin 
2 [Patella vulgata] 
32 4.9 50.88 13 
18 1.8×10-3 
gi|1345835|sp|Q06814|CRTC_SCHMA  
Calreticulin precursor (SM4 protein) 
45 4.7 45.55 18 
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19 2.1×10-3 
gi|1174756|sp|P42638|TPM2_SCHMA  
Tropomyosin 2 (TMII) 
68 4.5 32.68 21 
20 2.6×10-4 
gi|320989|pir||A60607  tropomyosin - fluke 
(Schistosoma mansoni) 
62 4.6 32.99 20 
21 1.2×10-3 
gi|189503078 |  actin [Schistosoma 
japonicum] 
28 5.4 41.71 7 
22 1.8×10-3 
gi|67625681|tpe|CAJ00225.1|  TPA: gag 
protein [Schistosoma mansoni] 
31 9.5 26.31 6 
23 5.4×10-4 
gi|76154879 SJCHGC07268 protein 
[Schistosoma japonicum] 
36 8.1 16.33 6 
24 1.9 ×10-3 
gi|627088|pir||A54521  40k egg antigen 
(clone 10F5) - fluke (Schistosoma mansoni) 
30 6.2 39.56 11 
25 7.5×10-3 
gi|6649234|gb|AAF21436.1|  14-3-3 epsilon 
[Schistosoma mansoni] 
38 4.9 28.85 9 
26 2.3×10-3 gi|790658|gb|AAC46983.1|  14-3-3 protein 58 4.7 28.47 17 
27 2.4×10-4 
gi|56757579|gb|AAW26951.1|  unknown 
[Schistosoma japonicum] 
42 4.8 22.74 13 
28 1.4×10-4 
gi|29841012 similar to NM_011967 
proteasome (prosome, macropain) subunit, 
alpha type 5 in Mus musculus [Schistosoma 
japonicum] 
45 5.2 27.47 11 
29 2.4×10-3 
gi|2529289|gb|AAB95297.1|  heat shock 
protein 70 [Biomphalaria glabrata] 
35 5.5 69.92 10 
30 1.4×10-3 
gi|10281261|gb|AAG15507.1|  thioredoxin 
peroxidase 1 [Schistosoma mansoni] 
48 6.1 21.31 9 
31 1.5×10-3 
gi|1711398|sp|Q07167|SM16_SCHMA  16 
kDa calcium-binding protein (Egg antigen 
SME16) 
44 5.0 16.83 6 
32 9.4×10-4 
gi|4581919|gb|AAD24794.1|  
phosphoenolpyruvate carboxykinase 
[Schistosoma mansoni] 
12 6.8 71.47 7 
33 8.6×10-3 
gi|4581919|gb|AAD24794.1|  
phosphoenolpyruvate carboxykinase 
[Schistosoma mansoni] 
16 6.8 71.47 6 
34 6.5 ×10-4 
gi|156118913 creatine kinase [Schistosoma 
mansoni] 
28 7.9 77.42 16 
35 6.0×10-3 
gi|56755541|gb|AAW25949.1|  unknown 
[Schistosoma japonicum] 
27 8.5 72.59 15 
36 1.8×10-3 
gi|4581919|gb|AAD24794.1|  
phosphoenolpyruvate carboxykinase 
[Schistosoma mansoni] 
30 6.8 71.47 14 
37 9.8×10-3 
gi|29841414 similar to GenBank Accession 
Number AB022159 chaperonin containing 
TCP-1 zeta-1 subunit in Mus musculus 
[Schistosoma japonicum] 
31 6.8 26.49 7 
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38 1.5×10-3 
gi|60601894|gb|AAX27404.1|  unknown 
[Schistosoma japonicum] 
44 6.4 31.41 12 
39 2.1×10-5 
gi|556413|gb|AAA93516.1|  
phosphoglycerate kinase 
36 6.8 44.89 13 
40 2.1×10-3 
gi|47551121|ref|NP_999743.1|  
mitochondrial ATP synthase alpha subunit 
precursor [Strongylocentrotus purpuratus] 
23 8.4 59.82 9 
41 5.0×10-3 
gi|627088|pir||A54521  40k egg antigen 
(clone 10F5) - fluke (Schistosoma mansoni) 
30 6.2 39.56 11 
42 9.5×10-3 
gi|84411|pir||JL0121  glyceraldehyde-3-
phosphate dehydrogenase (phosphorylating) 
(EC 1.2.1.12) - fluke (Schistosoma 
mansoni) 
51 8.4 36.64 20 
43 1.2×10-3 
gi|56758570|gb|AAW27425.1|  unknown 
[Schistosoma japonicum] 
22 9.3 36.91 10 
44 5.1×10-3 
gi|73535312|pdb|1U3I|A  Chain A, Crystal 
Structure Of Glutathione S-Tranferase 
From Schistosoma Mansoni 
34 6.6 23.89 9 
45 3.1×10-3 
gi|243794|gb|AAB21173.1|  glutathione S-
transferase, GST [Schistosoma mansoni, 
Peptide, 218 aa] 
56 7.8 25.51 12 
46 5.6×10-3 
gi|55670478|pdb|1VYG|A  Chain A, 
Schistosoma Mansoni Fatty Acid Binding 
Protein In Complex With Arachidonic Acid 
67 8.0 15.00 9 
47 5.5×10-3 
gi|10281261|gb|AAG15507.1|  thioredoxin 
peroxidase 1 [Schistosoma mansoni] 
37 6.1 21.31 9 
48 2.0×10-5 gi|267013 Superoxide dismutase [Cu-Zn] 50 6.1 15.89 6 
49 5.5×10-5 
gi|605647|gb|AAA57567.1|  fructose 1,6 
bisphosphate aldolase [Schistosoma 
mansoni] 
45 7.9 39.97 17 
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APPENDIX D 
Solutions and Reagents 
D.1 Standard Lysis Buffer, pH 8.4 (20 mL)  
(30 mM TrisHCl, 2 M Thiourea, 7 M Urea, 4% (w/v) CHAPS) 
0.4 mL 1.5M Tris-HCl pH 8.8 
3.04 g thiourea 
8.4 g urea 
0.8 g CHAPS {3-[(3-cholamidoproply) dimethyl ammonio]-1-propane-sulfonate}  
Dissolve in MilliQ and make volume to 20 mL. Make aliquots and store at -20 
o
C. 
 
D.2 Rehydration Buffer for IPG DryStrips pI 3-10 and 4-7 (25 mL) 
(2 M Thiourea, 7 M Urea, 2% IPG buffer 3-10, 2% DTT, 4% (w/v) CHAPS) 
3.8 g thiourea 
10.5 g urea 
0.5 mL IPG Buffer (3-10) 
0.5 g DTT (Dithiothreitol) 
1.0 g CHAPS 
60 L bromophenol blue (BPB-used as tracking dye) 
Dissolve and make up the volume to 25 mL with MilliQ. Make aliquots and store at -20 
o
C. 
NOTE: For the above rehydration buffer IPG buffer (4-7) can be used if buffer will be 
used only for IPG DryStrips 4-7.  
 
D.3 Rehydration Buffer for IPG DryStrips pI 6-11 (20 mL) 
(2 M Thiourea, 4 M Urea, 1% IPG Buffer 6-11, 2% (w/v) CHAPS, 10 % Isopropanol,   
5% Glycerol) 
3.04 g thiourea 
8.4 g urea 
0.2 mL IPG Buffer (6-11) 
0.4 g CHAPS 
2.0 mL isoproponal 
1.0 mL glycerol 
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60 L bromophenol blue (BPB-used as tracking dye) 
Dissolve and make up the volume to 20 mL with MilliQ. Make aliquots and store at -20 
o
C. Add 2.5 % DTT (For 1 mL rehydration buffer, add 0.025 g DTT) just before 
rehydration of strips. Add 3.0 % DTT (For 1 mL rehydration buffer, add 0.03 g DTT) for 
cathodic paper wick. 
 
D.4 Equilibration buffer (500 mL) 
(50 mM Tris, 6 M Urea, 30% Glycerol, 2% SDS) 
6.7 mL 1.5 M Tris-HCl pH 8.8 
72.0 g urea 
60.0 mL glycerol 
4.0 g SDS (sodium dodecyl sulphate) 
60 L bromophenol blue (BPB-used as tracking dye) 
Add 20 mL MilliQ to 250 mL measuring cylinder, and then add 60 mL glycerol. Add 20 
mL MilliQ, all above chemicals and stir constantly to dissolve. Add BPB and make 
volume to 200 mL. Store in bottle at room temperature. 
 
D.5 Fixer (1000 mL) 
(50% C2H5OH, 3% H3PO4) 
500 mL C2H5OH (ethanol)  
30 mL H3PO4 (phosphoric acid/orthophosphoric acid) 
470 mL MilliQ  
Store at room temperature. 
 
D.6  Colloidal staining solution (1000 mL)   
(17% (NH4)2SO4, 34% CH3OH, 3% H3PO4) 
170 g (NH4)2SO4 (ammonium sulphate) 
340 mL CH3OH (methanol) 
30 mL H3PO4 (phosphoric acid/orthophosphoric acid) 
Dissolve in MilliQ and make volume to 1000 mL. Store in bottle at room temperature. 
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D.7 0.06% Coomassie brilliant blue (100 mL)  
0.06 g Coomassie G-250 in 100 mL MilliQ. 
 
D.8 50% ACN 0.1% TFA (500 L) 
250 L ACN (Acetonitrile), 0.5 L TFA (trifluoroacetic Acid) and 250 L MilliQ. 
 
D.9 50 mM NH4HCO3 50% CH3OH (500 mL) 
2 g NH4HCO3 (Ammonium Bicarbonate)  
250 mL Methanol 
Make up the volume to 500 mL with MilliQ. 
 
D.10 Working CyDye  
STOCK: 1 mM (1 nmol/L) 
WORKING CyDye (80 pmol/L/10 g protein) 
Dimethylformamide (DMF) used for reconstitution should be of high quality and open for 
less than 3 months. DMF should be handled under the hood and a syringe should be used 
to draw 200 µL in 1.5 mL tube. 
1. Reconstitute the stock as directed on the kit (Add 5 L DMF to each vial of 5 g 
CyDye). Vortex vigorously for 30 s and centrifuge at 12000 rpm for 30 s. 
2. For 2 samples Add 0.16 L of each stock CyDye to 2 L DMF.  
 
D.11 10 mM Lysine (10 mL) 
Add 0.018 g L-Lysine (MW 182.6) to 10 mL MilliQ, mix and dissolve. Make aliquots and 
store at 4 
o
C. 
 
D.12 Running Buffer (5X Tris-Glycine-SDS Buffer) (1000 mL)  
15 g   Tris 
72 g   Glycine 
05 g   Sodium Dodecyl Sulphate (SDS) 
Dissolve in MilliQ and make volume to 1000 mL 
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D.13 Western transfer buffer (1000 mL) 
(192 mM Glycine, 25 mM Tris Base, 0.037% (w/v) SDS, 20% (v/v) Methanol) 
3.03 g   Tris 
14.4 g   Glycine 
3.75 ml 10% SDS 
200 mL  Methanol  
Dissolve in MilliQ and make volume to 1000 mL 
 
D.14 Tris Buffered Saline (10X TBS)  
(1X composition 0.5 M Tris, 1.5 M NaCl, pH 7.4)  
12.1 g   Tris 
40.0 g   NaCl 
12 mL   1M HCl 
Adjust the pH to 7.6 using concentrated HCl and make up the volume to 500 mL with 
MilliQ. 
 
D.15 TBST buffer 
995 mL  1X TBS Buffer 
5 mL   Tween-20 
 
D.16 Blocking Buffer 
5 g  Skimmed milk powder or 1 g casein 
100 mL T-TBS buffer 
 
D.17 Dovex/ Norit Mixture (Dry powder is stable for years at room temperature) 
1. Mix 40 g Dovex (Sigma Aldrich) and 20 g Norit (Activated chatcoal, Sigma Aldrich) 
in a large beaker, add 6 M HCl and mix well. 
2. Transfer the above mix to 800 mL Buchner funnel using #1 Whatman 9.0 cm filter 
paper and apply suction. 
3. Add more 6 M HCl, mix and suction, repeat 2/3 times. 
4. Add 95% ethanol, mix and suction, repeat step. 
5. Add 100% ethanol, mix and suction, repeat twice. 
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6. Dry the powder in large drying dish under hood for 48 hours.  
 
D.18 Citrate-Acetate Buffer 
57     g  NaAcetate.3H2O (Sigma Aldrich)  
37.5 g   Na3Citrate.2H2O (Sigma Aldrich) and  
5.5 g   H3Citrate.2H2O (Sigma Aldrich) 
385 mL  isopropanol (Sigma Aldrich)  
make volume to 1000 mL with MilliQ water. 
 
D.19 7% Chloramine-T 
7 g Chloramine-T (Sigma Aldrich)  
make 100 ml with MilliQ, store in dark bottle at 4 
o
C. 
 
D.20 Ehrlich’s Reagent 
25 g   p-dimethylaminobenzaldehyde (Sigma Aldrich), dissolve in  
37.5 mL  60% perchloric acid (Sigma Aldrich), store in dark bottle at 4 
o
C. 
 
D.21 Solution A (Oxidant Solution) (Always make fresh) (Mix 1 part 7% Chloramine-T 
with 4 parts Citrate-Acetate buffer) 
For 40 samples, add 2 mL 7% Chloramine-T with 8 mL Citrate-Acetate buffer. 
For half microplate, add 1 mL 7% Chloramine-T with 4 mL Citrate-Acetate buffer. 
 
D.22 Solution B (Always make fresh) (Mix 3 parts of Ehrlich’s Reagent with 13 parts 
isoproponal) 
For 32 samples, add 15 mL of Ehrlich’s Reagent with 65 mL isoproponal. 
For half microplate, add 1 mL of Ehrlich’s Reagent with 4.33 mL isoproponal. 
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APPENDIX E  
Control lysate haemoglobin spot fluorescence comparison  
The spot volume fluorescence intensity of haemoglobin spots from control/ uninfected 
2D-DIGE maps labelled with either Cy3 or Cy5 dyes was calculated for each experimental 
design (Table 1 and 2). The difference in spot volume fluorescence intensity showed 
haemoglobin concentration between the two experimental designs was similar (Table E1) 
suggesting that the sample set for control samples were similar in physiology. 
Additionally, indicating that there was no blood contamination during liver sample 
collection for both experimental designs. 
 
Expt. Design 1 
Sample Name 
with CyDye 
Spot Volume 
(Fluorescence 
Intensity) 
Expt. Design 2 
Sample Name 
with CyDye 
Spot Volume 
(Fluorescence 
Intensity) 
Cy3 C1 833909 Cy5 C2 910275 
Cy5 C1 4176331 Cy3 C3 1582513 
Cy5 C4 1598374 Cy5C4 3603526 
Cy3 C3 1202540 Cy3 C1 1740748 
Average 1952789 Average 1959266 
Difference between averages 6477 
 
TABLE E1 The difference between the haemoglobin spot volume fluorescence intensity 
for C=control/uninfected mice from experimental designs 1 and 2.  
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APPENDIX F 
Two-Dimensional Differential In Gel Electrophoresis (2D-DIGE) 
Introduction 
2D-DIGE is a technique used to study proteomic differences between cells/tissues in 
different functional states. This was first described by (Ünlü, Morgan et al. 1997) using 
cyanine dyes or CyDye DIGE fluors or CyDyes, now marketed solely by GE Healthcare 
Bio-Sciences AB, SE-751 84 Uppsala, Sweden. For experimental purposes three CyDyes 
are available: Cy2, Cy3 and Cy5, designed with similar charge and molecular weight, so 
that if a protein labelled with the CyDye, it will migrate to the same position on a 2-D gel. 
There is a specific excitation wavelength for each CyDye which generates a separate gel 
image for each CyDye labelled sample, superimposing these images allows the study of 
proteins that are expressed differentially and consistently. Commercially, two CyDye kits 
are available, CyDye DIGE Fluor minimal dyes and CyDye DIGE Fluor saturation dyes. 
The minimal labelling technique is used for multiplexing of 3 samples including the 
internal standard, as compared to saturation technique which allows multiplexing of 2 
samples only. 
 
DIGE chemistry  
CyDye DIGE Fluor minimal dyes (GE Healthcare) were used to label the liver and serum 
samples in this study. The NHS ester reactive group in minimal labelling CyDyes 
covalently binds to the lysine epsilon amino group of proteins through an amide linkage 
(Figure F1). The CyDyes label approximately 3 % of the protein sample. This type of 
labelling has been therefore called minimal labelling as it involves labelling of a single 
lysine residue per protein. At neutral or acidic pH, the lysine residue in proteins carries an 
intrinsic +1 charge. The labelling reaction is carried out on ice in dark with the 
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concentration of 80 pmol CyDye per 10 µg protein, during which the CyDye  with +1 
charge gets coupled to the lysine on the protein, replacing the lysine’s +1 charge with its 
own, without significantly altering the pI of the protein (Courtesy: GE Healthcare). 
 
 
FIGURE F1 Minimal labelling CyDye containing NHS ester active group covalently 
binds to lysine residue of protein via an amide linkage. (Courtesy: GE Healthcare). 
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APPENDIX G 
 
FIGURE G1 Western blot for Mouse liver PEPCK (Control=1N, 2N, 3N; MSS=7c, 8c, 
9c; HSS=10c, 12c, 17c) 
 
FIGURE G2 Western blot for Mouse liver MUP (Control=1N, 2N, 3N; MSS=7c, 8c, 9c; 
HSS=10c, 12c, 17c) 
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FIGURE G3 Western blot for Mouse liver Transferrin (Control=1N, 2N, 3N; MSS=7c, 
8c, 9c; HSS=10c, 12c, 17c; SEA=soluble egg antigen) 
 
 
 
FIGURE G4 Western blot showing actin as loading control (Control=1N, 2N, 3N; 
MSS=7c, 8c, 9c; HSS=10c, 12c, 17c; SEA= soluble egg antigen) 
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FIGURE G5-G7 Western blot for Mouse serum Transferrin (Control=1-5N; MSS=1-5M; 
HSS=1-5H; 8-week infected=801-810; 12-week infected= 1201-1210) 
FIGURE G5 (Control mice= 1C-5C) 
  
FIGURE G6 (MSS mice=1M-5M; HSS mice=1H-5H) 
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FIGURE G7 (8-week infected=801-810) 
  
FIGURE G8 (12-week infected=1201-1210) 
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FIGURE G9-G13 Keratin D (cytokeratin 18) western blot analysis for (bands in red box) 
for mouse and human sera. 
FIGURE G9 (INT=human intestinal schistosomiasis, samples INT1-12) 
 
 
FIGURE G10 (INT=human intestinal schistosomiasis, samples INT13-23; HS= human 
hepatosplenic schistosomiasis, HS1) 
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FIGURE G11 (HS= human hepatosplenic schistosomiasis, HS2-14) 
 
 
FIGURE G12 (mice control=C, 1-5; mice MSS=M, 1-5; mice HSS= H,1-5) 
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FIGURE G13 (INT=human intestinal schistosomiasis, INT12; HS= human hepatosplenic 
schistosomiasis, HS1) 
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